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Disease progression in rheumatoid arthritis (RA) is assessed by standard clinical, 
radiological and functional measures. Clinical disease activity in RA is graded as no 
disease (remission), low, moderate and high disease, based on validated criteria. 
Radiological progression in RA is monitored by serial x-rays of hands and feet, and 
by quantification of structural damage, using various scoring methods. This proves to 
be a valuable outcome measure in RA studies.   
 
RA patients with active disease usually develop progressive radiological damage. 
However, it has been shown that clinical disease activity may not correlate with 
radiological damage, particularly in early RA. Therefore, this thesis was mainly aimed 
to test the hypothesis that, „radiological damage can progress despite clinical disease 
inactivity or remission‟ and to investigate possible underlying mechanisms including 
disease heterogeneity, treatment effect and scoring methodology. Disease progression, 
outcomes and prognostic factors were analysed in an inception cohort of early RA 
(Early Rheumatoid Arthritis Study/ERAS) for this thesis.  
 
In this study of early RA patients, sustained remission was less frequent than remission 
at individual time points and baseline variables such as gender, duration of symptoms, 
disease activity (DAS) and health assessment questionnaire (HAQ) scores have shown 
predictive value for sustained remission. Structural damage on x-rays progressed 
despite clinical disease inactivity or remission in a subgroup of patients and disease 
heterogeneity was the most likely explanation for the disconnect between clinical 
disease activity and radiological damage in the ERAS cohort.  
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This study has also found that scoring methods as well as reading order of x-ray films 
could influence radiographic progression in early RA, particularly at individual level.  
Male sex, rheumatoid factor (RF) and radiographic damage at baseline showed 
prognostic value in predicting radiographic progression despite remission.  
 
Study patients with persistent clinical disease inactivity have shown better radiological, 
surgical, functional, and other outcomes compared to relapsing-remitting or persistent 
disease activity. There was no significant difference in functional and other outcomes 
between patients in remission with x-ray progression and those in remission without x-
ray progression.  
 
Therefore, x-rays of hands and feet at regular intervals are valuable in determining true 
disease progression in early RA, even during clinical disease inactivity. Scoring 
methodology in itself could have an influence on the type of radiographic progression 
in RA studies. Sustained disease inactivity in RA is more favourable than relapsing-





















First of all, I am grateful to my principal supervisor, Professor Adam Young, for his 
excellent support, supervision and guidance over the last few years in carrying out this 
research project and in writing up this thesis. 
I would like to thank my other supervisor, Dr David Wellsted and Sam Norton from 
the University of Hertfordshire, who have provided necessary advice as well as 
adequate supervision on data analysis and statistics throughout the study period. 
I am also grateful to Dr Csilla Solymossy from the ERAS and Dr Annelies Boonen 
and Dr Desiree van der Heijde from the University Hospital Maastricht, Maastricht, 
Netherlands who have trained and supervised me in the x-ray scoring techniques that 
are crucial for this thesis. 
I would like to thank Dr Josh Dixey, one of the ERAS members, for his valuable 
guidance and support throughout the study. I would also like to thank other ERAS 
members and metrologists, without whom ERAS and this thesis would not have been 
possible.  
I cannot thank enough, Cathy Mayes (ERAS coordinator) and Marie Hunt (Research 
coordinator), who fulfilled my ever-demanding tasks for this thesis in a very 
professional and efficient manner.  
 
Finally, a special thanks to my wife Chitra for her constant support and 
encouragement during this difficult period and to my little sons Roshan and Ritesh, 











Abstract ……………………………………………………………………. 2 
 
 
Acknowledgements ……………………………………………………….. 4 
 
 
List of Contents …………………………………………………………… 5 
 
 
List of Tables ……………………………………………………………… 10 
 
 
List of Figures …………………………………………………………….  13 
 
 
List of Abbreviations …………………………………………………….  15 
 
 
Chapter 1: Introduction 
 
 
1.1 Rheumatoid arthritis……………………………………..  19  
 
1.1.1 Background………………………………………   19  
1.1.2 Epidemiology…………………………………….  21   
1.1.3 Aetiology…………………………………………  22 
  a) Genetic factors…………………………..   22 
  b) Environmental factors…………………..   23 
1.1.4 Normal joint……………………………………...  24 
  a) Normal synovium……………………….  24 
  b) Synovial fluid……………………………  25 
  c) Articular cartilage……………………….  25 
  d) Subchondral bone……………………….  27 
1.1.5 Joint in RA……………………………………….  29 
  a) Extra-articular disease………………….... 32 
 
 6 
1.1.6 Impact of RA…………………………………….  32 
  a) Functional or work disability……………  33 
  b) Cost of RA……………………………….  33
    
 
1.2 Early rheumatoid arthritis……………………………….  35 
 
1.3 Disease presentation and progression……………………  36  
 
1.3.1 Clinical……………………………………………  36 
1.3.2 Radiological………………………………………  37 
1.3.3 Functional………………………………………...  40 
 
1.4 Assessment of disease activity……………………………   42 
  
1.4.1 Assessment of clinical disease activity………….  42 
a) Swollen and Tender joint counts……….  45 
b) Pain……………………………………..  46 
c) Global assessment of disease activity…..  46 
d) Acute phase reactants…………………..  46 
e) Disease activity scores and indices……..  47 
f) Criteria to assess disease activity………..   49 
g) Criteria to assess treatment response……  51 
  
1.4.2 Assessment of radiological progression………….  52 
a) Radiographic abnormalities……………..   53 
b) Joints to be included…………………….  54 
  c) Standard views of radiographs…………..  55 
  d) Scoring order of the films……………….  55 
  e) Scoring methods…………………………  56 
  f) Number of observers…………………….  63 
  g) Reliability……………………………….  63 
  h) Sensitivity to change…………………….  64 
  i) Presentation of radiographic results……..  65 
  j) Radiographic remission………………….  67 
  k) Radiographic healing……………………  67 
 7 
 
1.4.3 Assessment of function…………………………..   68 
 
1.5 Outcomes and prognostic factors………………………..   71 
 
1.5.1 Outcomes…………………………………………  71 
1.5.2 Outcome measures……………………………….  72 
a) Clinical………………………………….  72 
b) Radiological…………………………….  72 
c) Functional……………………………….  73 
 1.5.3 Prognostic factors………………………………..  73 
 
1.6 Clinical versus Radiological disease activity……………  75 
 
1.6.1 Relationship between clinical and                           
 radiological disease activity………………… 75  
1.6.2 Radiological progression despite                                    
clinical disease inactivity…………………………. 78 
 
 
1.7 Rationale for this thesis…………………………………. 84
  
  
   




Chapter 2: Patients, Materials and Methods 
 
  
 2.1 Early Rheumatoid Arthritis Study (ERAS)…………….  95 
   
2.1.1 Background of ERAS……………………………  95 
2.1.2 Patient recruitment……………………………….  95 
2.1.3 Data collection and storage………………………  96 
 a) Clinical……………………………….....  96 
 b) Laboratory………………………………  97 
 c) Radiological……………………………  98 
 8 
i) Scoring methodology                                       
for ERAS……………………….  98 
ii) Scoring methodology and                          
training for this thesis……………  98                                                                    
 d) Functional………………………………  100 
 e) Other outcomes…………………………  101 
2.1.4 Treatment profile………………………………..  101  
2.1.5 Statistics…………………………………………  102 
 
 
Chapter 3: Remission in early rheumatoid arthritis  
 
3.1 Background………………………………………..  105 
3.2 Objectives………………………………………….  106 
3.3 Patients and methods………………………………  106 
3.4 Results…………………………………………….  111 
3.5 Discussion…………………………………………  123 
 
Chapter 4: Radiographic disease progression in early rheumatoid 
arthritis 
 
4.1 Background………………………………………...  130 
4.2 Objectives………………………………………….  131 
4.3 Patients and methods………………………………  131 
4.4 Results………………………………………..........  134 
4.5 Discussion…………………………………………  152 
 
Chapter 5: Influence of scoring methodology on radiographic 
progression in rheumatoid arthritis 
  
5.1 Background………………………………………..  158 
5.2 Objectives…………………………………………  160 
5.3 Patients and methods……………………………...  160 
5.4 Results…………………………………………….  162 
5.5 Discussion…………………………………………  180 
 
 9 
Chapter 6: Progression of x-ray damage despite remission in early 
rheumatoid arthritis 
 
6.1 Background………………………………………..  185 
6.2 Objectives…………………………………………  186 
6.3 Patients and methods……………………………...  187 
6.4 Results…………………………………………….  190 
6.5 Discussion…………………………………………  201 
 
Chapter 7: Disease progression and outcomes in early rheumatoid 
arthritis  
 
7.1 Background…………………………………..........  207 
7.2 Objectives…………………………………………  209 
7.3 Patients and methods………………………………  210 
7.4 Results…………………………………………….  214 
7.5 Discussion…………………………………………  227 
 
 






 1. Critical appraisal …………………………………….  253 
 2. ERAS data forms…………………………………….  305 
 3. Paper and Abstracts from this thesis…………………  312 
 
 









Table 1.1  1987 revised ARA classification criteria for RA Page 20 
Table 1.2  Previous early RA studies on remission Page 85 
Table 1.3 Studies on radiological deterioration despite   Page 89                                   
clinical improvement or remission in RA 
Table 2.1 Clinical disease activity based on EULAR criteria  Page 97 
Table 3.1 Baseline disease characteristics Page 111 
Table 3.2 Predictive factors for DAS remission Page 114         
on univariate analysis 
Table 3.3 Predictive factors for sustained DAS  Page 114           
remission on multivariate analysis 
Table 3.4   Predictive factors for sustained DMARD-free remission  Page 116                         
on univariate analysis (Cox regression method)  
Table 3.5      Predictive factors for sustained DMARD-free remission Page 117                         
on multivariate analysis (Cox regression) 
Table 3.6 Outcomes at 3 and 5 years in the remission    Page 121                                          
and non-remission groups at same time points 
Table 4.1 Baseline disease characteristics of the study cohort  Page 134 
Table 4.2 Larsen score progression from year 1 to 5   Page 135 
Table 4.3 Radiographic progression between year 2 and 3   Page 138                                       
in comparison to other study points 
Table 4.4 Correlation between Larsen score and other    Page 143                                   
disease measures at baseline, year1, 2, 3 and 5 
 11 
Table 4.5 Baseline features compared to Larsen scores    Page 151                                                                     
at baseline and 5yrs 
Table 5.1 Baseline disease characteristics    Page 166 
Table 5.2 Radiographic progression using Larsen score:  Page 167                                               
random vs chronological  
Table 5.3 Baseline disease characteristics    Page 169 
Table 5.4 X-ray progression based on Larsen    Page 170                                                            
and SvdH methods  
Table 5.5 Baseline disease characteristics    Page 174 
Table 5.6 Radiographic progression      Page 174                                                                       
based on 3 different scoring methods 
Table 6.1 Baseline demographic of the study cohort   Page 190 
Table 6.2 Baseline disease characteristics in Group1                                      
(DAS remission without x-ray progression    Page 194                                         
& Group2 (DAS remission with x-ray progression) 
Table 6.3 Baseline predictive factors using univariate   Page 197                                            
and multivariate analyses 
Table 6.4 Outcomes at 3 years in Groups 1 & 2    Page 199                                                        
in relation to x-ray progression 
Table 7.1 Baseline demographics     Page 214 
Table 7.2 Clinical disease progression based on DAS   Page 216 
Table 7.3 Radiographic (Larsen) progression    Page 216                                                             
in relation to clinical disease activity 
Table 7.4 Functional (HAQ) progression in relation to     Page 218                                  
clinical disease activity 
 12 
Table 7.5 Outcomes in relation to cumulative    Page 221                                                   
clinical disease activity 
Table 7.6 Other outcomes in relation to cumulative   Page 221                                            
clinical disease activity 
Table 7.7 Baseline demographics      Page 224 








































LIST OF FIGURES 
 
 
3.1    Radiological (Larsen) progression between 1 and 5 years  Page 119 
3.2 Functional (HAQ) progression between 1 and 5 years page 120 
4.1 Larsen score progression from 1 to 5 years Page 136 
4.2 Progression of ESR over 5 years Page 140 
4.3 Progression of DAS over 5 years Page 140 
4.4 Progression of HAQ over 5 years Page 141 
4.5 Larsen score (mean) progression in 4 different   Page 146                                          
treatment groups  
4.6  Larsen score (median) progression in 4 different  Page 148                                       
treatment groups 
5.1 Larsen score – Inter observer reliability Page 163 
5.2  Larsen score – Intra observer reliability Page 163 
5.3 Erosion score Page 164 
5.4 Narrowing score Page 164 
5.5 Total score Page 165 
5.6 Larsen score progression based on random reading  Page 167                                 
(Observer CS) 
5.7 Larsen score progression based on chronological  Page 168                                     
(Observer KJ) 
5.8 Radiographic progression from 1 to 5 years (Larsen):  Page 168                                             
random vs chronological  
5.9 Total Larsen score      Page 170 
5.10 Erosion score        Page 171 
5.11 Narrowing score      Page 171 
 14 
5.12 Total SvdH score      Page 172 
5.13 Progression of SvdH erosion score     Page 175 
5.14 Progression of SvdH narrowing score    Page 175 
5.15 Progression of SvdH total score (Mean)    Page 176 
5.16 Progression of SvdH total score (Median)    Page 176 
5.17 Progression of SENS erosion score     Page 177 
5.18 Progression of SENS narrowing score    Page 177 
5.19 Progression of SENS total score (Mean)    Page 178 
5.20 Progression of SENS total score (Median)    Page 178 
5.21 Progression of Larsen score (Mean)     Page 179 
5.22 Progression of Larsen score (Median)    Page 179 
6.1 Radiological progression (Larsen)       Page 192                                                                         
in relation to clinical disease activity 
6.2 Scatter plots showing change in Larsen scores                                                  
from yr1 (lar1) to yr3 (lar3) in patients     Page 196                                                                  
in persistent DAS remission  
6.3 Functional (HAQ) progression in Groups 1 & 2   Page 200 
7.1 Larsen score progression between baseline and year 5   Page 217          
in all the groups 











LIST OF ABBREVIATIONS 
 
 
ACR  American college of Rheumatology 
ANA  Anti nuclear antibody 
APR  Acute phase reactants 
ARA  American Rheumatism association 
BMI  Body mass index 
CDAI  Clinical disease activity index 
COI  Cost of illness 
CRP  C-reactive protein 
CSF  Colony stimulating factor 
CTX  C-terminal telopeptide 
DAS  Disease activity score 
DAS28  Disease activity score with 28 joint count 
DMARDS Disease modifying anti rheumatic drugs 
EAC  Early Arthritis Cohort 
EGA  Evaluator global assessment 
EMS   Early morning stiffness 
ERAS  Early Rheumatoid Arthritis Study 
ESR  Erythrocyte sedimentation rate 
EULAR European League against Rheumatism 
FBC   Full blood count 
FG  Functional grade 
GH  Global health 
HAQ  Health assessment questionnaire 
HLA  Human leukocyte antigen 
 16 
HPA  Hypothalamo-pituitary-adrenal 
HPG  Hypothalamo-pituitary-gonadal 
ICAM  Intercellular adhesion molecules 
IFN  Interferon 
IGF  Insulin like growth factor 
IL  Interleukins 
ILAR  International League of Associations for Rheumatology 
IP  Interphalangeal 
JSN  Joint space narrowing 
MCP  Monocyte chemotactic protein 
MCP  Matacarpophalangeal 
MHC  Major histocompatibility complex 
MMP  Matrix metalloproteinases 
MTP  Metatarsophalangeal 
NTX  N-terminal telopeptide 
ODF  Osteoclast differentiation factor 
OMERACT Outcome Measures in Rheumatology Clinical Trials Conference 
OPG  Osteoprotegerin 
PGA  Physician global assessment 
PIP  Proximal interphalangeal 
QoL  Quality of life 
RA  Rheumatoid arthritis 
RAI  Ritchie articular index 
RANKL Receptor activator of nuclear factor κB ligand 
RF  Rheumatoid factor 
 17 
SDAI  Simplified disease activity index 
SE  Shared epitope 
SDC  Smallest detectable change 
SDD  Smallest detectable difference 
SENS  Simplified erosion narrowing scoring method 
SES  Short erosion scale 
SJC  Swollen joint count 
SRM  Standardised response mean 
SvdH  Sharp van der Heijde scoring method 
TGF  Transforming growth factor 
TIMP  Tissue inhibitors of metalloproteinases 
TJC  Tender joint count 
TNF  Tumour necrosis factor 
TRANCE TNF-related activation-induced cytokine 
US FDA United States Food and Drug Administration 
VAS  Visual analogue scale 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF  Vascular endothelial growth factor 
















































1.1 Rheumatoid arthritis 
1.1.1 Background 
Rheumatoid arthritis (RA) is a chronic systemic disease affecting joints as well as 
extra-articular structures and is the most common type of inflammatory arthritis 
worldwide. RA most commonly involves the small joints of hands and feet, often in a 
symmetrical distribution resulting in pain, stiffness and loss of function.  
RA has a wide clinical spectrum ranging from mild joint symptoms to severe 
inflammation and damage to joints. RA is diagnosed on clinical, serological and 
radiological grounds. The American Rheumatism Association (ARA) first proposed 
classification criteria for RA in 1956 and then revised them in1958 (1;2).  
Although, these criteria were widely used to diagnose RA for many years, they were 
heavily criticised for their lack of sensitivity and specificity. The ARA published 
revised classification criteria for RA in 1988, based on cross-sectional data from a 







Table 1.1 1987 Revised ARA Classification Criteria for RA 
Criterion Definition 
 
1 Morning stiffness Morning stiffness in and around the joints 
lasting at least 60 minutes before maximal 
improvement 
2 Arthritis of 3 or more joint 
areas 
Arthritis of 3 or more joint areas at the same 
time with swelling involving proximal 
interphalangeal (PIP), metacarpophalangeal         
( MCP), wrist, elbow, knee, ankle and 
metatarsophalangeal (MTP) joints  
3 Arthritis of hand joints At least one joint area swollen in PIP, MCP or 
wrist joints 
4 Symmetrical arthritis Simultaneous involvement of the same joint 
areas on both sides of the body 
5 Rheumatoid nodules Subcutaneous nodules over bony prominences 
or extensor surfaces or in periarticular regions 
6 Rheumatoid factor Presence of rheumatoid factor (RF) in the 
blood 
7 Radiographic changes Presence of erosions or juxta-articular 







For classification purposes, RA is diagnosed if a patient satisfies 4 out of 7 criteria 
from the above table and criteria 1 to 4 must be present for at least 6 weeks. However, 
these criteria were based on data from patients with established disease and it is 
widely recognised that some of these features may be absent during early stages of the 
disease.   
Disease course in RA can be unpredictable and in many cases, particularly in patients 
with active disease, it progresses to develop cartilage destruction, joint damage and 
deformity over a period of time (4-7). Clinical disease progression in RA is usually 
monitored by standard clinical, laboratory and functional indices, whereas serial x-
rays of hands and feet assess structural damage (4-7).  
It has been demonstrated that progression of structural damage on x-rays leads to 
more functional disability, increased requirement for orthopaedic surgery and 
negative impact on socioeconomic as well as other healthcare costs (8-12). Therefore, 
the ultimate goal of treatment in RA is to suppress disease activity as low as possible 
in order to induce and maintain clinical remission and to reduce joint damage and 
deformity and thus a more favourable long-term outcome. 
 
1.1.2 Epidemiology 
Prevalence of RA in the general population worldwide is estimated to be between 0.3 
to 1.5 % using different types of classification criteria. Epidemiological data have 
shown that Native American populations such as Pima Indians have a high prevalence 
of RA and it is low in countries like China, Japan and Africa compared to Caucasians 
(13) . Although RA can occur at any age, its incidence increases with age and may 
vary depending upon the type of classification criteria used and demographics of the 
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population studied (14). The peak age of onset has risen to 50 years or more and is 
more common in women than men with a ratio of 3:1 (9;12;15)   
 
1.1.3 Aetiology  
RA is an autoimmune disease of unknown cause and interaction between genetic and 
environmental factors play an important role in the development of disease in 
susceptible individuals.  
 
a) Genetic factors 
Family and twin studies indicate that first degree relatives of patients with RA have an 
increased frequency of developing this disease, particularly if the patients had severe 
disease or were seropositive for rheumatoid factor (16). Identical twins have higher 
concordance rates of the disease compared to non-identical twins supporting genetic 
susceptibility (16;17). However, RA is a polygenic and genetically heterogeneous 
disease and non-inherited factors are also of great importance. 
 
In RA, the causative role of different genes may vary between individual patients and 
various combinations of polymorphisms in a selection of different genes (genotype) 
may predispose to the clinical picture (phenotype). Some genes are responsible for 
severity of the disease rather than occurrence.  Only few genes have been consistently 
associated with RA. The major histocompatibility complex (MHC) is a large genetic 
region on the short arm of chromosome 6, which has been consistently linked to RA. 
A large part of the MHC comprises human leukocyte antigen (HLA) genes, which 
encode individual‟s tissue type and are divided into class I (HLA-A, HLA-B, HLA-C) 
and class II (HLA-DR, HLA-DQ, HLA-DP) genes. The encoded proteins are crucial 
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in determining the individual‟s immune response to antigenic stimuli. HLA class II 
genes, in particular HLA-DR4 and HLA-DRβ1, have been strongly linked to RA.  
Particular HLA-DRβ1 molecules in RA share a sequence that influences the peptides 
that are bound and viewed by the immune system. This core amino acid sequence is 
named the „shared epitope‟ and these epitopes have been linked with both 
predisposition to, and severity of RA (18-20). Other genes have also been implicated 
in the aetiology of RA, such as genes encoding tumour necrosis factor (TNF)-α and 
interleukins (IL). 
 
b) Environmental factors   
Population studies have shown that non-inherited factors such as environmental 
triggers, particularly smoking and infections play a major role in the aetiology of RA. 
Infectious agents, such as Epstein-Barr virus (EBV), Parvovirus B19, Mycobacterium 
tuberculosis, Escherichia coli and Proteus mirabilis have all been implicated as 
possible trigger factors for RA, but the results have been inconsistent (21-26).  
 
Environmental agents are considered as triggers rather than as being directly involved 
in the disease process and complex interplay between genetic and environmental 
factors are probably important for the initiation of the disease process in susceptible 
hosts. Certain viruses and bacterial agents contain identical peptide sequence to 
autoantigen and infection with these microbial agents can induce an immune response 
that cross-reacts with the autoantigen, termed „antigen mimicry‟. Antigen mimicry is 
one hypothesis to explain induction of autoimmunity by environmental triggers. 
Another concept proposes that a local immune response to any environmental agents 
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may release pro-inflammatory cytokines to up regulate antigen-presenting capacity 
resulting in an immune mediated inflammatory cascade (27). 
 
Hormonal factors may also play a possible role in the aetiology of the disease as 
suggested by increased female preponderance, high incidence during the pre-
menopausal or post-partum period and protective effect of oral contraceptive pills 
presumably due to its progesterone content (28).  
 
Diet and stress have also been considered to play a possible role in the disease 
expression (29;30).  Vitamin D and its metabolites may have an inverse relationship 
with disease activity in inflammatory polyarthritis or RA, due to their 
immunomodulatory effects (31). Studies have shown that higher consumption of olive 
oil, oil-rich fish, fruit, vegetables and beta-cryptoxanthin may have a protective effect 
on the development of RA, whereas lower consumption of foods rich in antioxidants, 
could be associated with an increased risk of RA, but the results were inconclusive 
(32). Also, high intake of red meat and low intake of vitamin C might play a role in 
the development of inflammatory polyarthritis (33;34).    
 
1.1.4 Normal joint 
a) Normal synovium 
The normal human body contains a number of synovial joints and each synovial joint 
is made up of two bones, linked by a fibrous capsule with a deeper synovium, which 
lines the joints except in the areas of articular cartilage. The normal synovium is 
characterised by lack of cellularity but it is a highly vascular connective tissue, bound 
by the fibrous joint capsule on one side and by the joint space on the other.  
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The synovial membrane has a thickness of one or a few cells and forms the surface 
layer of the synovial tissue. It comprises two layers, a superficial lining layer called 
intima and a deep sub-lining layer called sub-intima. The intima contains two major 
cell types on electron microscopy: type A synoviocytes, resembling macrophages, and 
type B synoviocytes with fibroblast characteristics. The intima does not have typical 
features of an epithelium and it lacks a basement membrane between synoviocytes. 
The matrix of the intima has abundant proteoglycans and glycosaminoglycans, 
particularly hyaluronic acid. The sub-intima is a vascular connective tissue stroma 
containing blood vessels, lymphatics and nerve endings within a matrix comprising 
varying proportions of lipid, collagen fibrils and more organized fibrous tissue. 
 
b) Synovial fluid 
The synovial membrane secretes this highly viscous and nourishing fluid with high 
concentration of hyaluronic acid, which acts as a lubricant and help to minimise joint 
damage. Other constituents of the synovial fluid include nutrients and solutes that 
diffuse from the blood vessels in the sub-intima. The exact mechanism of synovial 
fluid production is not known, but it appears that a balance of hydrostatic and osmotic 
forces regulates exchange of fluid between the circulation and the joint space.  
 
c) Articular cartilage 
Each articular surface is composed of hyaline cartilage, which strongly adheres to the 
underlying sub-chondral bone and the load bearing properties of the cartilage depend 
on the structure and matrix. The articular cartilage comprises chondrocytes embedded 
in a hydrated matrix composed of collagen, proteoglycans and other matrix proteins. 
The matrix contains more than 70 per cent water and chondrocytes occupy only 5-10 
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per cent of the normal cartilage by volume. However, chondrocytes are vital to 
maintain the integrity of the matrix as they synthesize collagen, proteoglycans and 
other components such as fibronectin (35). 
 
Collagens are a family of secreted matrix proteins that contain elements of a unique 
triple-helical peptide structure, which accounts for their tensile strength. These 
fibrillar proteins, together with proteoglycans, account for the biomechanical 
properties of articular cartilage. There are 14 different types of collagen but are 
divided into three major groups based on the structure and properties of triple-helical 
peptides (36;37). The differences between collagens relate to either the length of the 
triple helix, the presence of non-collagenous units within the molecule that impart 
extra flexibility, or the addition of non-collagenous side chains such as carbohydrates. 
The most common collagen in the body is the type I fibrillar collagen, which is the 
main structural element in bone, ligaments and tendons, often occurring together with 
the type III collagen. The major collagen in articular cartilage is type II, constituting 
80 to 90 per cent of the total content, with types IX and XI contributing most of the 
remainder.  
 
Proteoglycans are large, negatively charged macromolecules comprising a 
polypeptide core with glycosaminoglycan side-chains. The major proteoglycan of 
articular cartilage is aggrecan, which contain abundant chondroitin sulphate and 
keratin sulphate side-chains. The main function of the aggrecans relates to their 
anionic and water-trapping properties, which provide deformability and 
compressibility. The superficial layer of articular cartilage has a high ratio of collagen 
to aggrecan compared to the deep layer close to the subchondral bone. Therefore, the 
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surface layers have high tensile strength and resilience whereas the deep layers have 
higher deformability and compressibility. Proteoglycans in the cartilage matrix have a 
steady turn over maintained by a constant slow rate of aggrecan degradation and loss 
and its replacement by new synthesis. The tissue content of aggrecan is maintained at 
a constant level by a co-ordinated turn over between degradation and biosynthesis.  
 
The chondrocytes are responsible for controlling these events and appear to be 
sensitive to the aggrecan content of the matrix and some feedback mechanisms seem 
to co-regulate synthesis and degradation (38). Enzymes such as collagenase, 
gelatinase, stromelysin and aggrecanase mediate breakdown of collagen and the 
surrounding matrix. These enzymes are zinc-dependant matrix metalloproteinases 
(MMP) controlled by tissue inhibitors of metalloproteinases (TIMPs). In RA, release 
of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumour necrosis 
factor-alpha (TNF-α) reduce synthesis and increase catabolism of articular cartilage, 
resulting in rapid breakdown, as opposed to growth factors such as transforming 
growth factor-beta (TGF-β) and insulin-like growth factor-1 (IGF-1), which stimulate 
synthesis of cartilage components.  
 
d) Subchondral bone 
The basal layer of articular cartilage is calcified and is attached directly to 
subchondral bone. Major part of the bone matrix is composed of type I collagen and 
the remaining is made up of proteoglycans, glycoproteins, glycosaminoglycans such 
as hyaluronic acid, and proteins such as osteocalcin. Glycoproteins such as 
osteopontin, osteonectin and bone sialoproteins function as anchoring molecules, 
bridging matrix constituents to bone cells.  
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Bone contains three different cell types on histological sections: osteoblasts, 
multinucleated osteoclasts and osteocytes. Osteoblasts, derived from the 
mesenchymal stromal cell system, are critical for the synthesis of collagen and bone 
matrix as well as non-collagen proteins and they control bone mineralization. The 
factors that control bone formation are complex and not fully understood but they 
seem to largely work through osteoblasts. The other major cell type is osteoclasts, 
which are derived from precursors in the haemopoietic system and they break down 
bone via a combination of lysosomal enzymes and low pH. Calcitonin, and possibly 
oestrogens, exerts inhibitive effect on osteoclasts through specific receptors and the 
resorptive effects of thyroid and parathyroid hormones are probably mediated through 
the osteoclasts. The third cell type is osteocytes, which occupy lacunas within the 
mineralized bone and they probably have an important function in the detection of, 
and response to, mechanical forces within mineralized bone.  
 
The activities of bone cells are influenced by cytokines, which are peptides produced 
by cells such as lymphocytes (lymphokines) or monocytes (monokines) that act as 
autocrine, paracrine, or endocrine mediators. Examples of such cytokines that have 
effects on bone include ILs, TNFs, interferons (IFN), IGF, TGF and colony 
stimulating factors (CSFs). These cytokines have anabolic or catabolic effects on the 
bone mediated through their multiple actions with synergism or antagonism on 
osteoblasts or osteoclasts. This constant process of bone formation and resorption i.e. 
bone remodelling is essential to maintain bone strength and to optimize load-bearing 
capacity and it also plays an important role in metabolic homeostasis, in particular 
calcium and magnesium.  
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Various mechanical forces and endocrine factors such as parathyroid hormone (PTH), 
thyroid hormone, vitamin D, calcitonin and sex hormone influences bone 
remodelling. Bone formation and resorption is carefully balanced in young adults to 
maintain bone mass but in the older people, particularly in postmenopausal women, 
breakdown exceeds synthesis, leading to osteoporosis. Bone resorption is also 
accelerated by drugs such as corticosteroids and by active inflammation.  
 
1.1.5 Joint in RA   
The most pronounced and fundamental pathology in RA is destruction of articular 
cartilage and subchondral bone by ectopic and hyperplastic synovium. The 
involvement of synovial joints in RA is both of the synovial fluid and membrane. 
Synovial fluid volumes and cellularity are increased with predominance of 
polymorphs. T lymphocytes and macrophages are also seen in large numbers along 
with dendritic cells, plasma cells and B-lymphocytes in the synovial fluid and 
membrane. The lining layer of the synovial membrane, which is normally two cells 
thick, become much thickened with increased numbers of both type A (macrophage-
like) and type B (fibroblast-like) cells (39).  
 
In RA, the synovium becomes highly vascular with increased number of new blood 
vessel formation termed „angiogenesis‟.  The junction between synovial tissue, 
cartilage, and the bare area of bone within the joint capsule is prone to develop 
erosions early in RA. The synoviocytes proliferate as the disease progresses and 
invade the adjoining articular cartilage, where the secretion of cytokines, and cartilage 
and bone-degrading enzymes, results in characteristic destructive changes of RA. The 
invading, hyperplastic synovium is called pannus and the zone of invasion is called 
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cartilage-pannus junction. Synovial membrane that lines the tendons and bursae also 
develop similar proliferative changes leading to destruction and deformity (39-41).   
 
Rheumatoid synovium contains a number of pro and anti-inflammatory cytokines, 
which are mainly of T-cell and macrophage origin. Prominent pro-inflammatory 
cytokines are TNF-α, IL-1, IL-6, IL-8, IL-12, IL-15, IL-18 and interferon-gamma 
(IFN-γ), whereas the main anti-inflammatory cytokines are IL-4, IL-10, IL-11, IL-13, 
TGF-β, and cytokine neutralizing factors such as soluble TNF-α receptors and IL-1 
receptor antagonist (IL-1ra). An imbalance between pro and anti-inflammatory 
cytokines may be the main pathogenic mechanism in RA as pro-inflammatory 
mediators, in particular TNF-α and IL-1, appears to play a major role in the immune 
mediated inflammatory cascade leading to various articular and systemic 
manifestations (39;42-44). Other pro-inflammatory factors present within the RA 
synovium include nitric oxide, prostaglandins, leukotrienes, and free oxygen radicals.  
 
Rheumatoid synovium is characteristically highly vascular with angiogenesis and this 
is stimulated by various factors including hypoxia and soluble factors such as vascular 
endothelial growth factor (VEGF) and soluble vascular cell adhesion molecule-1 
(VCAM-1), which stimulate endothelial cell growth. There are other adhesion 
molecules that are abundantly present on the vascular endothelium such as E-selectin 
and intercellular adhesion molecules (ICAMs). Their expression is stimulated by pro-
inflammatory cytokines, particularly TNF-α and IL-1, resulting in the recruitment of 
inflammatory cells via specific receptors. Chemokines such as monocyte chemotactic 
protein-1 (MCP-1), IL-8 and MCP-2 are highly expressed in RA synovium and they 
stimulate progression of inflammatory cells into the joint (39;45;46).  
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Tissue hyperplasia and lymphocyte proliferation as a result of immune response is 
normally counteracted by programmed cell death or apoptosis to prevent over 
accumulation of cells. In rheumatoid joints, apoptosis is actively inhibited despite the 
presence of pro-apoptotic stimulants such as hypoxia and TNF-α in rheumatoid 
synovium. Impaired synoviocyte apoptosis may contribute to the pathogenesis of RA 
(39).  
 
The exact mechanism of cartilage and bone destruction in RA is not understood, but 
may be related to a variety of destructive enzymes secreted by pannus. The important 
ones are MMPs, which include collagenases, stromelysins and gelatinases, and serine 
and cysteine proteases such as cathepsins. These enzymes destroy the articular 
cartilage by acting upon collagen and proteoglycan matrix but are normally controlled 
by physiological inhibitors such as TIMPs. An impaired regulatory mechanism 
between these destructive enzymes and their inhibitors may partly be responsible for 
the destructive nature of the disease (39;47-49).  
Other destructive factors include the cytokines TNF-α and IL-1, which activate 
osteoclasts leading to bone resorption. Bone destruction may also be mediated by 
factors such as osteoclast differentiation factor (ODF) or TNF-related activation-
induced cytokine (TRANCE) and receptor activator of nuclear factor κB ligand 
(RANKL). ODF interacts with membrane RANK that is present on osteoclast 
precursors, resulting in their differentiation and activation and subsequent bone 
destruction. The combination of TNF-α, IL-1 and ODF probably contributes to peri-
articular as well as systemic osteoporosis in RA. There is also a soluble form of 
RANK called osteoprotegerin (OPG), which acts as a decoy receptor, inhibiting the 
effects of ODF on osteoclasts (39;50). 
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a) Extra-articular disease 
Apart from joints, RA also affects many other structures in the body causing various 
extra-articular or systemic manifestations. Rheumatoid nodules are the most common 
and others include vasculitis, serositis, interstitial lung disease and Felty‟s syndrome. 
The precise mechanism of extra-articular disease in RA is unknown and one of the 
hypotheses is that rheumatoid factor (RF) activate macrophages expressing Fc-γ 
receptors, which then produce pro-inflammatory cytokines and chemokines, leading 
to further influx of inflammatory cells. RF also activate complement pathway 
resulting in immune complex deposition in the perivascular tissues leading to 
inflammation and vasculitis. Severe disease and extra-articular features may be 
associated with a double dose of the shared epitope, particularly in DR4/DR14 (51). 
 
Neurological component may also possibly play a role in the pathogenesis of RA and 
is suggested by high levels of neuropeptides such as substance P, symmetry of the 
joints involved and sparing of paralysed limbs in patients with stroke. It has also been 
suggested that patients with RA have abnormalities in hypothalamo-pituitary-adrenal 
(HPA) and hypothalamo-pituitary-gonadal (HPG) axes, including a suppressed 
response to painful stimuli. 
 
 
1.1.6 Impact of RA 
RA, like many other chronic diseases, has a significant impact on patient‟s functional 
ability, job status and quality of life (QoL) and it represents a huge economic burden, 
not only for patients and their families, but also for the society as a whole (10;52-54).  
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a) Functional or work disability 
RA affects patients‟ ability to perform day-to-day activities due to various reasons 
such as, pain, fatigue, stiffness, swelling, deformity and damage. As the disease 
progresses, a significant proportion of patients develop functional disability with 
increased requirement for aids, appliances, home adaptations and orthopaedic surgery 
(9;12;55). Therefore, patients with RA may experience a number of problems in 
relation to their work such as inability to continue working, not able to work in the 
same occupation or not able to work same number of hours. This is termed work 
disability and it is one of the most important outcomes in the RA studies (9;12;55). 
Previous studies have reported rate of work disability varying between 22% and 85% 
and the length of follow-up in those studies ranged from 1 year up to a maximum of 
30 years (9;56;57).   
 
b) Cost of RA 
The overall costs and economic consequences of RA can be enormous with huge 
socioeconomic implications. Cost of illness (COI) due chronic, crippling disease like 
RA can be divided mainly into two components: direct costs and indirect costs. Direct 
costs relate to the treatment of RA, borne mainly by the health care sector, including 
hospitalizations, orthopaedic surgeries and social care. Indirect costs means costs 
incurred due to loss of productivity and there are two forms: morbidity and mortality 
costs. Morbidity costs include value of production losses due to work disability, 
whereas mortality costs are calculated as value of lost production due to disease 
related premature death.  
 
 34 
It was estimated that the direct and indirect costs of RA in England was £1.265 billion 
in 1992, of which 48% was due to direct medical costs and 58% due to loss of 
productivity (58). Hospital costs were the largest direct expenditure in this study and 
the indirect costs were probably underestimated, as mortality costs were not included 
in the analysis. Other population-based COI studies have estimated a direct cost of £ 
3680 to £3800 per RA patient per year and indirect costs were at least 3 times higher 
than direct costs in one study (59;60). Indirect medical costs appear to be the major 
financial burden as it can be as high as 85% of the total economic costs (61-63).   
 
Some recent studies have also confirmed that the economic burden due to RA could 
be enormous. In a French study, it has been estimated that direct costs per patient was 
€1812 – €11,792 annually and indirect costs €1260 – €37,994 per annum. 75% of the 
direct costs were associated with in-patient care and 20% for medications. Physician 
visits accounted for 20% of the direct costs. However, indirect costs were more 
expensive and were responsible for 80% of the excess cost related to RA (64).  
In another systematic review, the total average annual medical cost was estimated as 
ranging from $5720 (£3575) to $5822 (£3638). In this study, in-patient care 
constituted about 17 to 88% of total direct costs, whereas physician visits and 
medications accounted for 8 to 21% and 8 to 24% of total direct costs respectively 
(65).  
 
In a primary care based inception cohort of early inflammatory polyarthritis (Norfolk 
Arthritis register/NOAR), mean 6-month total cost was estimated to be £2800/person, 
of which 14% was due to direct costs and the remainder was due to non-health service 
or indirect costs (66). 
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1.2) Early Rheumatoid Arthritis 
Early RA was traditionally defined as disease duration of less than 5 years from onset 
of symptoms until 1990s. However, over the last two decades, disease duration of 24 
months or less has been considered as early RA with much emphasis placed on the 
first 6 to 12 months. The concept of early RA and early arthritis clinics was 
introduced to make an early diagnosis and to plan timely interventions. This is 
because, observational studies have shown that significant percentages of patients had 
already developed erosive disease within the first 3 years of disease onset and they 
continued to progress strikingly, particularly if left untreated, with poor long-term 
outcomes (67-71).  
 
Early RA patients with undiagnosed or untreated disease may develop persistent 
inflammation with progressive joint damage. It is essential to start treatment before 
patients develop irreversible damage or disability. Early intervention has been 
reported to reduce disease progression with better radiological and functional 
outcomes (72-75).  
 
Longitudinal studies, involving a large number of early RA patients with prolonged 
follow-up are vital in providing key information on the nature of disease progression, 
prognosis and long-term outcomes. The advantages of these observational studies are 
that patients with mild or inactive disease are also included with less stringent 
exclusion criteria and patients are managed in a „real life‟ setting, although high 
dropout rate may be a problem. On the other hand, clinical trials mainly recruit 
patients with active disease and have strict exclusion criteria with a limited follow-up 
period, but are more useful to assess treatment response. 
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1.3) Disease presentation and progression  
The natural history of RA is not fully known, although a number of studies have 
examined the course of conventionally treated RA over time. The characteristic 
features of RA include joint inflammation, destruction, deformity and disability, with 
very variable disease presentation and subsequent course. The three main components 
of disease progression are clinical, radiological and functional.  
 
1.3.1 Clinical   
RA characteristically involves the small joints of hands and feet in a symmetrical 
distribution, although it can affect any joint and manifest in various extra-articular 
sites as well. The main symptoms include joint pain, tenderness, swelling, stiffness 
and deformity, which sometimes are associated with constitutional symptoms such as 
malaise, fever, fatigue and weight loss (76). The usual mode of disease onset is either 
acute (abrupt) or insidious (gradual), with the latter being more common and some 
patients may also have episodic (palindromic) presentation (76-78).  
 
The pattern of joint involvement is usually polyarticular but it can also present with 
either oligoarticular (≤ 4 joints involved) or monoarticular involvement. In patients 
with recent-onset arthritis, other differential diagnoses such as, seronegative 
spondyloarthritides, connective tissue diseases, infections, post-viral and other types 
of inflammatory arthritis should be considered before making a definite diagnosis of 
„early RA‟.  
 
The natural course of RA can be unpredictable and usually patients tend to pursue one 
of the following clinical courses: 1. chronic and progressive; 2. relapsing and 
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remitting; and 3. non-recurrent or remission (6;70;76). The common course of disease 
process is chronic and progressive but it can vary or fluctuate depending upon the 
patients‟ and disease characteristics and treatment effect. The severity of clinical 
disease activity at a given time point or over a period of time is normally graded as, 
no disease (remission), low (mild) or minimal disease activity, moderate disease 
activity and high (severe) disease activity (79-81). Various criteria have been 
proposed and validated to assess the level of clinical disease activity using specific 
cut-off points and this helps to study the nature of disease progression, treatment 
response, prognosis and outcomes (79-85).    
 
It has been suggested recently that the „life cycle‟ of RA falls into four phases. Firstly, 
it is the period leading up to the onset of arthritis, and next period is the time during 
which disease persistence or remission is determined. Third phase is the evolution 
into a specific form of arthritis, and finally the outcome of arthritis (86). It was also 
suggested that the term „early rheumatoid arthritis‟ is not appropriate and patients 
either have established RA or an undifferentiated inflammatory arthritis (86).   
 
1.3.2 Radiological  
In RA, persistent inflammation in the affected joints cause damage to the articular 
cartilage and surrounding bone, resulting in loss of joint space, joint destruction and 
deformity. Historically, plain film radiography has been used to detect these changes 
and a variety of abnormalities including osteoporosis, cysts, erosions, joint space 
narrowing (JSN), subluxation, ankylosis, malalignment and sclerosis can be 
identified. Erosions and joint space narrowing are more common during the early 
stages of the disease with further progression as the disease advances, whereas 
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subluxations, malalignment and ankylosis are more apparent in the later stages of the 
disease (87).  
 
X-rays can be used to define structural damage at a given time point as well as 
damage progression over time. Early radiological changes of rheumatoid such as, 
erosions and JSN are more evident on the x-rays of hands, wrists and feet. A 
significant proportion of RA patients with early disease may have already developed 
erosions within 2 years of the disease onset and feet appear to develop erosions earlier 
than hands (88-91). Although erosions occur earlier and more frequently in the feet 
than in the hands, subsequent radiological damage progression seems to be fairly 
equal at both sites in patients with early RA (90;92). However, in a longitudinal study 
of patients with established RA, radiological damage was more evident in the wrists 
and feet initially and most of the subsequent progression occurred in the wrists, knees 
and MCP joints compared to the feet (93). 
 
Joints may differ in their susceptibility to develop erosions and JSN. For example, PIP 
joints show more erosive changes than JSN, whereas the wrists show JSN and 
erosions to be equal. It has been suggested that it may be due to the tendency of the 
rheumatoid hands to flex, which makes it difficult to assess and similar problems may 
be experienced at the MTP joints due to dorsal subluxation. Erosions at the wrist tend 
to be less discrete and more often of a surface type leading to underestimation. Also, 
compressive forces transmitted through the wrist may further damage the cartilage 
and compress the porotic bone, resulting in sclerosis and making erosive changes less 
apparent (90). The rate of progression of JSN and erosions may be variable as some 
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patients showed erosions progressing faster than JSN (88;90), whereas others showed 
JSN exceeding erosions (92).  
 
Ideally all synovial joints should be included to assess the radiographic progression, 
but this would be more time consuming and not practical. It has been shown that 
radiographic changes at the small joints of hands and feet correlate well with large 
joints, both for the extent of overall joint damage at a given time point and for the rate 
of progression over time (93-95). Therefore, x-rays of hands and feet have been used 
traditionally to assess radiological progression in RA (87;96;97).  
 
The rate of radiographic progression in RA may be unpredictable, as individual 
patients will have variable progression dependent on disease severity, response to 
therapy and other factors. Some patients show more rapid progression during the early 
stages of the disease with slowing down in the later years (98), whereas others show 
constant linear rate of progression over time (7;68;99).  
 
Different mathematical models of radiographic progression with time have also been 
proposed: 1) flat or non-progressive; 2) slow or moderate onset, but an increasing 
progression rate (linear); 3) moderate-to-fast onset and a stable progression rate 
(square-root type); 4) fast onset, but a later decreasing progression rate (first-order 
kinetics type); and 5) slow onset, then acceleration and later deceleration (sigmoid 
type) (100). Plant et al proposed 4 different models of radiographic progression in an 
8 year outcome study of early RA patients: 1) flat or nonerosive; 2) linear; 3) lag; and 
4) plateau (90). This study also showed that radiological progression was fast in the 
first 2 years of disease and thereafter it was highly variable.  
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Other imaging modalities such as, ultrasonography (US), magnetic resonance imaging 
(MRI) and computed tomography (CT) have also been used to study radiological 
damage at a given time point and progression over time (101;102). These newer 
techniques appear to be more sensitive in detecting erosions earlier than conventional 
radiography, and also correlate well with subsequent development of erosions on x-
rays (101-104). 
 
RA can also affect the cervical spine, which may lead to destructive changes close to 
the spinal column. Inflammation of the synovial membrane (synovitis) and pannus 
formation are seen in the odontoid-atlas joint, uncovertebral joint and facet joints in 
the cervical spine, ultimately leading to cervical spine instability, which can cause 
serious and life-threatening complications (76;105). X-rays of the cervical spine in 
flexion and extension views and MRI are commonly used to look for cervical spine 
involvement in RA and radiographically, atlantoaxial or C1-C2 subluxation is the 
common type of cervical spine instability in severe disease (76;105). There are other 
types of subluxations such as anterior and vertical subluxation. 
 
1.3.3 Functional  
RA can interfere with activities of daily living and cause significant impairment in 
physical function. Patients with active disease often develop progressive decline in 
their functional ability, which may be associated with increased rates of work 
disability and increased use of healthcare resources leading to high medical costs and 
poor socioeconomic outcomes (12;56;57;106;107).  
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Functional disability at the early stages of the disease appears to be mainly due to 
joint pain, swelling and stiffness secondary to active inflammation in the joints rather 
than structural damage, whereas at the later stages of the disease it correlates 
significantly with radiological damage (107;108).  
 
Functional status of an individual is an important determinant of his or her 
employment and it is a good predictor of future work disability (56;57;109). It has 
been shown that patients with RA are more likely to lose their jobs due to their 
functional limitation and prevalence of work disability can be much higher in RA 
compared to the general population (56;110). Work disability is strongly influenced 
by the nature of work as manual workers are more likely to stop working and there are 
also other contributory factors such as, work autonomy, job characteristics and level 
of formal education (6;56). Age of disease onset, education, disease severity and 
disability are important predictors of employment outcome (56;111). Women, older 
age at disease onset (≥ 60 years) and significant functional disability at disease 
presentation have been shown to be associated with worse functional outcomes 
(12;107;112). 
 
A significant proportion of patients with RA develop substantial functional disability 
over time and the extent of disability is partly a function of disease duration at the 
time of assessment (6). Although patients show individual variation in the progression 
of their functional disability, several studies have shown that disability increases with 
disease duration at a fairly constant rate (107). It has also been shown that functional 
decline can be more rapid during the early (12;113) and late stages of the disease 
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(12;114). Sometimes patients show an initial improvement in their functional ability 
followed by a progressive functional decline (55;107;115). 
 
In early RA, functional disability can be labile as it is mainly due to active 
inflammation in the joints rather than structural damage and so it can fluctuate in 
accordance with disease severity and can improve with effective treatment (107). 
Functional disability in patients with early RA may stabilise by 5 years and thereafter 
it often shows linear progression and strong correlation with radiological damage 
(107). Therefore, the ultimate goal of treatment in RA should be to control the 
inflammation as much as possible and to avoid structural damage in order to improve 
functional as well as socioeconomic outcomes.  
 
1.4) Assessment of Disease Activity 
In RA, measurement of disease activity at specific time points or at regular intervals 
helps to evaluate disease progression and it is vital to assess treatment response, 
outcomes and prognostic factors. Various methods have been introduced and 
validated to measure disease activity in RA over the last few decades. These methods 
have been designed and modified to evaluate three different but interrelated aspects of 
the disease progression: clinical, radiological and functional. 
 
1.4.1 Assessment of clinical disease activity 
Until 1980s, physicians used various terminologies such as active, inactive, mild, 
moderate or severe to describe the disease status based on their own observation and 
judgement without any consistency or standardization. Non-specific terms such as 
„entirely well‟, „no arthritis‟ and „symptom free‟ had been used to define disease 
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inactivity state or remission (116). In 1981, the American Rheumatism Association 
(ARA) developed preliminary clinical criteria for remission (117) and both the 
original and modified versions of these criteria were used in several studies (116-
118). 
 
Preliminary ARA remission criteria  
 
1. No joint pain 
2. No fatigue 
3. Early morning stiffness for <15 minutes 
4. No joint swelling or tendon sheath swelling 
5. No joint tenderness or pain on motion 
6. Normal ESR of <30 in women and <20 in men 
 
According to the above criteria, patients are classified as being in remission if they 
fulfil 5 out of 6 criteria at two time points i.e. on visits 0 and 2 months. This has been 
modified later by omitting fatigue and by making the assessment at one study point 
rather than two times, to make it more disease specific and more practical to use.  
 
Modified ARA remission criteria 
1.  No joint pain 
2. Early morning stiffness for <15 minutes 
3. No joint swelling or tendon sheath swelling 
4. No joint tenderness or pain on motion 
5. Normal ESR of <30 in women and <20 in men 
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Using the modified ARA criteria, with the exclusion of fatigue, either 4 out of 5 or all 
5 criteria have to be fulfilled to define remission (118).  
Clinical remission criteria excluding patient reported joint pain, fatigue and morning 
stiffness from the preliminary ARA criteria have also been used (119). 
 
Clinical remission criteria  
1. No joint tenderness or pain on motion 
2. No swollen joints 
3. Normal ESR of <30 in women and <20 in men 
 
Patients have to fulfil all the above 3 criteria at a given time point to qualify for 
remission using the clinical remission criteria. However, all the above criteria are 
based on categorical rather than continuous measures and so it is not useful to assess 
different levels of disease activity.  
 
In the early 1990s, core sets of disease activity measures have been proposed by the 
American College of Rheumatology (ACR, formerly ARA), European League 
Against Rheumatism (EULAR) and World Health Organization (WHO) / 
International League of Associations for Rheumatology (ILR), to standardize disease 
activity assessments in the clinical trials involving RA patients (120-123). These 
measures included swollen joint count (SJC), tender joint count (TJC), patient 
assessment of pain, global assessment of disease activity by the patient (PGA) and by 
the evaluator (EGA) and acute phase reactants such as erythrocyte sedimentation rate 
(ESR) and c-reactive protein (CRP). The core set also included structural damage on 
radiographs and functional status and these measures were identified on the basis of 
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available evidence, consensus by expert committees and most importantly because of 
their ability to predict outcome (123;124). These measures are also very useful and 
crucial to assess disease activity and treatment response in day-to-day clinical 
practice. 
 
a) Swollen and tender joint counts 
Joint involvement or inflammation in RA has traditionally been assessed using 
swollen (soft tissue swelling and effusion) and tender joint counts (tenderness on 
pressure or motion). Methods, to include deformed joints in the assessment have also 
been suggested but not used routinely (125;126). A number of different joint indices 
and counts have been developed over the years and they vary by the number of joints 
assessed or by the way several joints are aggregated to represent joint regions (124). 
Some of these methods weight joints by surface area (weighted joint counts), whereas 
others weight joints by severity of swelling and tenderness (graded joint counts) 
(124).  
 
The joint indices that were introduced earlier involved extensive number of joint 
counts and grading of swelling and tenderness, which were time consuming and led to 
inter-observer disagreement (127-131). Ritchie et al, introduced a graded tender joint 
count, assessing 26 joint areas with grades ranging between 0 to 3 depending upon the 
severity of joint tenderness (130). Hart and colleagues modified this later to exclude 
grading by severity, which was the main reason for disagreement between observers 
(128). Further modifications of the joint indices and simplifications of the extensive 
joint counts were carried out by other groups over the years, reducing the number of 
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joints assessed (132-134). These simplified joint counts have been validated and are 
reliable and easy to use in clinical practice (135-137).  
 
b) Pain 
Pain is the main symptom for majority of patients with RA and it is usually measured 
on a 100-mm visual analogue scale (VAS), evaluating symptom for one week before 
the study point. Horizontal VAS is more commonly used than vertical scales and there 
are also other reliable methods of pain assessment such as, arthritis impact 
measurement scale (AIMS) and McGill pain questionnaire (124).  
 
c) Global assessment of disease activity 
Both patients and evaluators assess overall disease activity on a 100-mm VAS. Patient 
global assessment of disease activity (PGA) is a subjective measure and it is different 
from the patient assessment of global health (GH) as in the latter, all possible domains 
of health outcomes, including those that are directly or indirectly related to the disease 
process are included. On the other hand, evaluator global assessment of disease 
activity (EGA) is usually based on subjective and objective measures that is available 
to the evaluator (124). 
 
d) Acute phase reactants 
ESR and CRP are the most commonly used acute phase reactants (APRs) in RA to 
assess disease activity and progression. These inflammatory markers usually rise in 
direct proportion to the severity of disease activity and they correlate well with 
clinical and radiographic disease progression and also outcomes (138-140). There are 
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also other biomarkers of disease activity such as ILs, TNF-α, MMPs and RANKL, 
which are expensive and complex and so are mainly used as research tools. 
 
e) Disease activity scores and indices   
Using these disease activity measures individually to evaluate disease activity may 
not give reliable identification of disease activity as they assess different aspects of 
the disease and it may lead to methodological problems. Composite disease activity 
scores have been developed over the years to overcome these problems and these 
scores use special formulas integrating SJC, TJC, ESR or CRP and GH to measure 
overall disease activity (124).   
 
Van der Heijde et al, introduced disease activity score (DAS) in 1990 with a view to 
help physicians grade the level of disease activity and to assess treatment response. 
The original DAS is based on Ritchie articular index (RAI) and 44-swollen joint 
count and it employs a complex formula, using square root and logarithmic 
transformation of variables and different weights for each variable (141;142). This 
was later modified to include the reduced 28-joint count, DAS28, which shows 
similar validity and reliability compared to DAS and has been widely used 
(84;136;137). Both DAS and DAS28 have been modified in several ways to exclude 
the assessment of GH (DAS-3 and DAS28-3) and to include CRP instead of ESR 






Formulae to calculate DAS with 4 or 3 variables and with ESR or CRP 
 
DAS   = 0.54 x √(Ritchie) + 0.065 x SJC44 + 0.33 x lognat(ESR) 
   + 0.0072 x GH  
 
DAS-CRP   =  0.54 x √(Ritchie) + 0.065 x SJC44 + 0.17 x 
lognat(CRP+1) + 0.0072 x GH  + 0.45 
 
DAS-3   =  0.54 x √(Ritchie) + 0.065 x SJC44 + 0.33 x lognat(ESR) 
+ 0.224  
 
DAS-3 CRP  = 0.54 x √(Ritchie) + 0.065 x SJC44 + 0.17 x 
   lognat(CRP+1) + 0.65  
 
Formulae to calculate DAS28 with 4 or 3 variables and with ESR or CRP 
 
DAS28    =   0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.70 x  
lognat(ESR) + 0.014 x GH   
 
DAS28-CRP  =   0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.36 x 
lognat(CRP+1) + 0.014 x GH + 0.96 
 
DAS28 -3   =   [0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.70 x 
lognat(ESR)] x 1.08 + 0.16 
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DAS28 -3 CRP  =   [0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.36 x  
   lognat(CRP+1) x 1.10 + 1.15 
 
Because of the complexities of the above formulae, which require calculator or 
computer program, simpler joint indices, based on ACR and EULAR core sets, have 
been developed. The advantages of these relatively newer indices are that they 
employ a linear sum of variables, which are untransformed and unweighted and they 
include PGA and EGA as well. One of them is the simplified disease activity index 
(SDAI), which is based on SJC, TJC, PGA, EGA and CRP and it has been used in 
several studies as well as routine clinical practice (85).  
 
SDAI = SJC28 + TJC28 + PGA + EGA + CRP 
  
The SDAI has been later modified by omitting CRP to help physicians calculate 
disease activity and make treatment decisions at the time of clinical assessment itself 
without having to wait for CRP, termed clinical disease activity index (CDAI) (82).  
 
CDAI = SJC28 + TJC28 + PGA + EGA 
 
f) Criteria to assess disease activity including remission 
After the introduction of the composite disease activity indices, a number of criteria 
have been validated, based on DAS, DAS28, SDAI and CDAI, to assess different 
levels of disease activity including remission (79;81-83;85;143;144). EULAR has 
adapted disease activity criteria based on DAS and DAS28, which have been widely 
used in several studies (79;81-83;85;143;144).  
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 EULAR criteria based on DAS 
  DAS < 1.60   - remission 
  DAS ≥1.60 and ≤ 2.40 - low disease activity 
  DAS >2.40 and ≤ 3.70 - moderate disease activity 
  DAS> 3.70   - high disease activity 
 
EULAR criteria based on DAS 28  
 
 DAS 28 < 2.6   - remission 
  DAS 28 ≥ 2.6 and ≤ 3.2 - low disease activity 
  DAS 28 >3.2 and ≤ 5.1 - moderate disease activity 
 DAS 28 > 5.1 - high disease activity 
 
SDAI criteria for disease activity 
 SDAI ≤ 3.3 - remission 
 SDAI ≤ 11 - low disease activity 
 SDAI ≤ 26 - moderate disease activity 
 SDAI > 26 - high disease activity 
 
CDAI criteria for disease activity 
 CDAI ≤ 2.8 - remission 
 CDAI ≤ 10 - low disease activity 
 CDAI ≤ 22 - moderate disease activity 
 CDAI > 22 - high disease activity 
 
The United States (US) Food and Drug Administration (FDA) has also proposed 
remission criteria, which is based on ACR remission criteria, but also takes into 
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account structural damage on x-rays and treatment status at the time of assessment. 
According to this, 5 out of 6 ACR remission criteria have to be fulfilled plus 
radiographic arrest for ≥ 6 months with no drug therapy (144). 
 
g) Criteria to assess treatment response 
Several criteria have been developed over the years to assess treatment response in 
RA and they are mainly used in clinical trials to measure treatment effect. As these 
criteria express improvement relative to a baseline, they are less useful in clinical 
practice (124).  
 
In 1990, Paulus response criteria was developed, which required four out of six 
selected measures for improvement as follows: ≥ 20% improvement for morning 
stiffness, ESR, joint pain/tenderness score, joint swelling score, and two or more 
grades on a 5-grade scale for PGA and EGA (145). 
 
The ACR response criteria, based on ACR core set variables, was introduced later in 
1995 and it require 20% improvement (ACR20) in swollen and tender joint counts 
and three of the five remaining core set of variables such as joint pain, PGA, EGA, 
ESR or CRP and function (146). The ACR response criteria were expanded 
subsequently to include 50% improvement (ACR50) and 70% improvement (ACR70) 
in order to express significant improvement that are clinically meaningful. 
 
The ACR numeric percentage (ACR-N) response criteria were a modification of the 
original ACR response criteria (147). It gives a quantitative measurement by grading 
a 0% to 100% improvement according to the smallest relative improvement in the 
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following three measures: SJC, TJC and median of the five remaining core set 
variables such as joint pain, PGA, EGA, ESR or CRP and function. These criteria, 
using a continuous scale, did not seem to discriminate reliably between drug 
treatments and so not used (124). 
 
The US FDA response criteria include radiographic details and require patients to 
continue with drug therapy. According to this, patients are said to have major clinical 
response if they fulfil ACR70 response plus radiographic arrest for ≥ 6 months with 
continuing drug therapy. Complete clinical response is defined as, presence of 5 out 
of 6 ACR remission criteria plus radiographic arrest for ≥ 6 months with continuing 
drug therapy (144).  
 
The EULAR response criteria are based on DAS and DAS28 scores. It categorize 
treatment response into no response, moderate response and good response according 
to the level of improvement in the DAS or DAS28 scores after treatment compared to 
baseline (79;81). The ACR20, 50 and 70 response criteria and the EULAR response 
criteria have been the most commonly used in the clinical trials. The EULAR 
response criteria have also been used in clinical practice since the introduction of 
biological agents to make decisions on either continuing or withdrawing biologic 
therapy depending upon the treatment response in a specified period of time.  
 
1.4.2 Assessment of radiological progression 
Conventional radiography has been traditionally used to assess structural damage in 
RA. X-rays of hands and feet and/or large joints have been used to define radiological 
damage at a given time point as well as progression of structural damage over a 
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period of time. The advantage of radiographic assessment of disease progression over 
other methods is that the damage seen on x-rays is largely irreversible and it 
represents the cumulative measure of disease activity and destructive process over 
time. The other major advantage is that apart from providing permanent records, 
radiographs can also be randomized and blinded for clinical investigations of new 
therapeutic agents in clinical trials (87;148).  
 
It has been widely recognised that radiological damage on x-rays has to be quantified 
to define the disease status of the patient and more importantly to assess disease 
progression, treatment response and outcome (87;91;149). As there are no truly 
quantitative methods, semi-quantitative methods have been developed to translate the 
amount of structural damage on x-rays into a score value (149). There have been 
several studies and expert opinions including consensus statements about the scoring 
methodology, to answer some important questions such as, which abnormalities 
should be included, which joints should be scored, which views, which order the films 
should be read and which scoring system to use (150;151). 
 
a) Radiographic abnormalities to be included 
There are lot of abnormalities that can be seen on radiographs in patients with RA. 
These include soft tissue swelling, juxtaarticular and diffuse osteoporosis, erosions, 
subchondral cysts, joint space narrowing (JSN), subluxation and malalignment, and 
ankylosis. Erosions and, to a lesser extent, JSN are widely accepted to be included in 
the scoring methods as they give reliable and additive information on radiological 
progression (152-154). The relative weight given to erosion versus JSN varies 
between scoring methods and no consensus has yet been established (152). 
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Sometimes scoring these radiologic abnormalities can be made difficult by the 
presence of other features such as, severe subluxation or luxation and cyst formation.  
 
b) Joints to be included 
Although any synovial joints can be affected in RA, it is not feasible to include all 
joints in scoring radiological damage. Therefore, it was recognised that a 
representative group of joints should be selected to reflect changes in other joints. 
Hands (including wrists) and feet have been chosen to represent the overall 
radiological status of the disease as they are the most commonly involved joints in a 
majority of patients with RA. Also, erosions and JSN can be seen very early in the 
hands and feet especially the latter and it is easy to evaluate (87-91). It has been 
shown that radiographic damage on the hands and feet, correlate well with the large 
joints both at a specific time point for the extent of damage and over a period of time 
for progression (93-95).  
 
The joints that are usually evaluated in the scoring methods include PIP joints, MCP 
joints, IP joints of thumbs, wrist joint as a whole or as individual joints, MTP joints 
and IP joints of the 1
st
 toes (151). It has been shown that omitting joint areas that are 
technically difficult to read and not commonly affected from the assessment can still 
provide accurate information about the overall radiological abnormalities in patients 
with RA (154;155). Although RA is typically a symmetrical polyarthritis, radiological 
changes can appear asymmetrically and so both hands and feet should be included in 




c) Standard views of radiographs 
The technical quality of the radiographs is important for accurate assessment of 
structural damage, particularly in studies using radiographic outcome as a primary 
objective. Other factors such as, good positioning of the hands and feet and proper 
exposure of the film is also essential in obtaining accurate information.  
 
Posteroanterior (PA) view of the hands and feet x-rays is the most commonly used 
technique, although other views such as, Norgaard view (a 45
0
 supine view with 
straight finger) and Brewerton view (a tangential view with the MCP joints flexed at 
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0 
and with a 15
0
 volar beam) have been used without any significant advantage 
(156). Therefore, PA views are being widely used in the radiographic assessment of 
RA and exposure of the film is also vital in detecting subtle changes as tiny erosions 
may be missed on under or over-penetrated films. 
 
d) Scoring order of the films 
Serial x-rays of hands and feet help to monitor structural damage progression in RA 
and the films can be read in 3 different ways, 1. random order (single film at a time), 2. 
paired reading (films grouped together per patient and read without known sequence) 
and 3. chronological reading (serial x ray films read with known sequence) (151).  
 
There are advantages and disadvantages for all these methods. Reading films randomly 
can introduce measurement error, as the reader will not be able to correct for variation 
in positioning of hands and films or for the quality of the films (157). It has been shown 
that paired reading is more precise than reading films randomly in assessing 
radiological progression (152;158;159).   
 56 
The advantage of reading films in chronological order is its increased sensitivity to 
detect change compared to paired reading, although an overestimated progression of 
joint damage by the readers (expectation bias) can not be ruled out in reading films 
with known sequence. Also, with the paired or random reading, there is a possibility of 
introducing measurement error by limiting the information to the reader, that the signal 
is lost in the noise (signal-to-noise ratio). Reading films in chronological order also 
results in increased sensitivity of detecting radiological progression that is clinically 
meaningful (157;160;161).  
 
e) Scoring methods 
Several scoring methods have been developed and subsequently modified over the last 
few decades to quantify the radiographic damage in RA. Some of the very earlier 
scoring methods such as the Steinbrocker and the Kellgren methods assessed the worst 
affected joints and gave a global assessment with grading for the entire patient 
(162;163).  
 
The scoring methods that were developed subsequently have been designed to assess 
individual joints and some of them scored erosions and JSN together with one overall 
score (global method), whereas others scored erosions and JSN individually with a 
separate score for each that are added together at the end to give a overall score 
(composite method).  
 
In 1971, Sharp et al proposed a composite scoring method for the hands and wrists, 
which was later modified in 1985 and in these methods feet were not included. The 
modified Sharp method has been used in several studies and with this method the 
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erosion scores range from 0 to 170 and the JSN scores range from 0 to 144. Further 
modification of the Sharp method was proposed by Fries et al in 1986, which was more 
time consuming without any significant advantage and so not been used 
(98;152;154;164). 
 
Genant et al, developed a composite scoring method in 1983 to include hands and feet 
and this method requires a standard reference set of radiographs for comparison. This 
method was later modified by the same group and this method is still being used but 
less commonly (165-167).  
Kaye et al, combined the methods described by Sharp and Genant and introduced a new 
composite scoring method, which used the standard reference set of radiographs for 
comparison developed by Genant and included only hands and wrists (155;168). In this 
method, postoperative joint was taken into account and given a maximum score and 
joints that could not be evaluated were excluded from the total score. 
 
In 1989, van der Heijde modified the Sharp method, described in 1985, and in this 
method (Sharp-van der Heijde/SvdH), feet were included. The SvdH method scores 
erosions and joint space narrowing separately and is expressed as erosion score, joint 







Following joints are assessed in the SvdH method for erosions: 
a. 10 MCP joints 
b. 8 PIP joints 
c. 2 IP joints of the thumbs 
d. right and left 1st metacarpal bone 
e. right and left radius and ulnar bones 
f. right and left trapezium and trapezoid as one unit 
g. right and left navicular bones 
h. 10 MTP joints 
i. 2 IP joints of the big toes  
 
Erosions are scored 1 if they are discrete and 2 or 3 depending on the surface area of 
the joint involved. In the carpal bones it is sometimes very difficult to score erosions as 
the bone collapses completely and in this case the collapsed area is given a score 
according to the surface area involved and a complete collapse is scored as 5. 
In each hand including the wrists, 16 joint areas are scored for erosions and a 
maximum erosion score for each joint is 5, whereas, in the feet 6 joint areas are scored 
for erosions in each foot with a maximum erosion score of 10 for each joint area, to 
increase weight of the feet joints in the total erosion score. Therefore, erosion score 
ranges from 0 to 160 in the hands and 0 to 120 in the feet with a total erosion score 





Following joints are assessed in the SvdH method for joint space narrowing: 
a. 10 MCP joints 
b. 8 PIP joints 
c. right and left 3rd, 4th and 5th carpometacarpal joints 
d. right and left multangular-navicular joints 
e. right and left capitate-navicular-lunate joints 
f. right and left radio carpal joints 
g. 10 MTP joints 
h. 2 IP joints of the big toes 
 
Joint space narrowing is combined with score for (sub)luxation and is scored as: 
 0 = normal,   
 1 = focal or doubtful 
 2 = generalised but less than 50% of the original joint space,  
 3 = generalised and more than 50% of the original joint space or 
subluxation     
 4 = bony ankylosis or complete luxation   
JSN is assessed in 15 joint areas in each hand including the wrists and in the feet 6 joint 
areas in each foot are scored. Therefore, JSN score in the hands ranges from 0 to 120 
and in the feet it ranges from 0 to 48 with a total JSN score ranging between 0 and 168. 
Erosion score and JSN score are added together to give a total Sharp score, which 
ranges from 0 to 448 in the SvdH method. SvdH method has been used widely in 
several studies and is currently the most common method used in clinical trials.  
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In 1999, van der Heijde described simplified erosion, narrowing scoring method 
(SENS), which was essentially a simplification of the SvdH method (170). SENS 
assesses the same joints as the SvdH, but instead of grading, the number of joints with 
erosions and with JSN is simply summed in this method. In the erosion score, a joint is 
scored as 0 or 1 depending upon the absence or presence of erosions respectively and 
likewise, JSN score in each joint is scored as 0 or 1 depending upon the absence or 
presence of JSN. The score, both erosion and JSN, for each joint can therefore range 
from 0 to 2. Erosion is assessed in 32 joint areas in the hands and 12 in the feet, 
whereas JSN is evaluated in 30 joint areas in the hands and 12 in the feet. Therefore, 
erosion score ranges from 0 to 44 and JSN score ranges from 0 to 42 with a total score 
ranging from 0 to 86.  
 
Larsen developed a global scoring method in 1974, based on a set of standard 
radiographs. In this method, both hands and feet were included and erosions and joint 
space narrowing were scored together. The original Larsen method was modified 
several times in the following years both by Larsen and by other groups (171-176). The 
number of joint areas assessed and the grading of radiographic abnormalities vary 
between the original and modified methods and so the total score range was also 
different between them. Scoring details of Larsen method, that was used in this thesis is 












Following joints are assessed in this modified Larsen method: 
   
 Proximal interphalangeal(PIP) joints of  both hands   - 8
   
 Interphalangeal(IP) joints of both thumbs   - 2 
 Metacarpophalangeal (MCP) joints of both hands   - 10 
 Both wrists (score multiplied by 5)   - 2 




 toes on both sides - 8 
 Interphalangeal (IP) joint of big toes on both sides   - 2 
 
Grading of radiographic abnormalities in this modified Larsen method: 
 
 Grade 0: Normal finding  
Grade 1: Soft tissue swelling, juxta-articular osteoporosis, possibly with 
slight narrowing of the joint space 
 Grade 2: Early but definite abnormality consisting of bone erosion and  
   
  distinct narrowing of the joint space.  
  
 Grade 3: Medium destructive abnormality with marked narrowing of the 
   
  joint space 
 Grade 4: Severe destructive abnormality. Only minor parts of the  
articular surfaces remain  
 
 Grade 5: Mutilating lesions 
 
In this modified Larsen method, 20 joint areas in the hands and 10 joint areas in the 
feet are assessed with a maximum score of 5 for each joint area. The wrist is assessed 
as one unit and then multiplied by 5, which gives a maximum score of 25 for each 
wrist. Therefore, the total score in this method ranges from 0 to 200.  
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In 1998, Rau et al introduced a new scoring method, Ratingen score, which was 
derived from the Larsen score (177). There are also some unfamiliar scoring methods 
such as, the carpometacarpal ratio (C:MC), a quantitative measure of the wrist 
involvement, and  the short erosion scale (SES), which was a modification of the 
Larsen method (178;179).  
 
Although there are several scoring methods available to measure radiographic 
damage, Larsen and Sharp and their modifications, mainly SvdH, have been the most 
commonly used. Each of these scoring methods has their own advantages and 
disadvantages. The advantage of Larsen‟s score is that an experienced reader can 
perform it quickly whereas SvdH method is more time consuming (180). However, 
inclusion of soft tissue swelling in the Larsen‟s score may lead to a relatively high 
score at baseline, decreasing with response to treatment. This may reduce the total 
possible increased score due to progressive damage, contributing to low sensitivity to 
change (149). It has been shown that that SvdH method is better than others in 
relation to its sensitivity to detect a real change in x-ray progression over time 
(sensitivity to change) and in detecting changes that are clinically meaningful, termed 
minimal clinically important difference (MCID) i.e. smallest radiographic change that 
necessitates the physicians to alter their treatment (181-188).   
 
Regarding evaluation of the radiographic data, there have been recommendations 
from the expert committees and the Outcome Measures in Rheumatology Clinical 
Trials Conference (OMERACT) about the standards and minimum requirements for 
reporting the radiographic results in clinical trials, which are described below. 
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f) Number of observers 
It was recommended that in clinical trials a minimum of 2 observers should read the 
films and the average score of 2 observers should be used to express the analyses, to 
reduce measurement error, although it is expensive and time consuming. However, in 
epidemiologic studies and non-drug trials, one observer is acceptable provided 
intraobserver agreement is presented as a measure of the consistency of the results. 
Interobserver agreement of the single observer with another experienced reader or 
trainer should also be presented to ensure reliability of the results (189).  
 
g) Reliability 
The value of any scoring method depends on its reliability as shown by inter and 
intraobserver reproducibility and this is calculated using statistical tests. Pearson or 
Spearman correlation coefficients have been used for this but they are not the correct 
methods as they measure the strength of association and not of agreement. Intraclass 
correlation coefficient (ICC) and kappa statistics are the appropriate tests to measure 
inter and intraobserver agreement and a maximum score of 1.0 give perfect reliability 
(151;189).  
 
Bland and Altman proposed another method, where the difference of the observers‟ 
scores (y axis) is plotted against the mean of the observers‟ scores (x axis). This 
method gives a graphical illustration of measurement error over the total range of 
scores and it will reveal whether there is a systematic difference between the 2 
observers. The ideal situation would be for all points to be situated on or close to        
y = 0 (190;191). If only a single observer is used, readings from the same observer at 
different time points can be used for this method. 
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h) Sensitivity to change 
The ability of a scoring method to detect a real change in radiographic progression 
over time is called sensitivity to change. In assessing longitudinal radiographic 
progression in RA, it is important to use a scoring method with high sensitivity to 
change and so better discriminative power. Methods such as standardised response 
mean (SRM) and smallest detectable difference (SDD) or change (SDC) have been 
used to assess the sensitivity to change of a particular scoring method and also to 
compare the discriminative power of different scoring methods (150;185;189;192).  
 
SRM is calculated by dividing the mean of the difference between scores at two time 
points by the standard deviation (SD) of change score and a value above 0.80 is 
considered to have a high sensitivity to detect changes (150).  
SDD or SDC is the difference or change that is greater than the measurement error 
and this can be derived from the intraobserver reproducibility if one observer is used 
or from reproducibility of the average scores if 2 observers‟ average scores were used 
(185;192).  
 
SDD and SDC are calculated as follows: 
 SDD = ± 1.96 x SDdifference / √ k 
 SDC = ± 1.96 x SDdifference / (√ 2 x √ k) 
SDdifference  is the standard deviation of difference between two readings and k 
represents the number of readings or observers used for the actual analyses of a trial. 
 
SRM and SDD and its relation to MCID have been used to compare different scoring 
methods like Larsen‟s and SvdH (183;184;187). The scoring method that has got high 
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SRM value is considered to be more powerful in assessing sensitivity to change. The 
lower the SDD value the higher the sensitivity of a scoring method in detecting 
radiographic progression that are considered clinically important 
(161;183;184;187;193).   
 
i) Presentation of radiographic results 
Erosions and joint space narrowing provide independent information as they represent 
different aspects of the biologic process underlying the development of structural 
damage. Therefore, if possible, erosion and JSN score should be presented as 
secondary endpoints for composite scoring methods like Sharp and SvdH (189).  
 
The main purpose of scoring radiographic damage is to measure the change or 
progression between two study points and the results can be presented at group level 
as well as at individual level using appropriate statistical tools. 
 
At group level, a change in mean or median score has been used to assess radiological 
damage and treatment response in studies involving large number of patients (161). 
However, in patients with extreme stages of radiological damage, a change in mean 
score ± SD may not indicate the specific stages of radiographic progression as the 
data is probably skewed (161). Median score with interquartile range (IQR) may be 
more useful to report radiologic progression in patients with different levels of disease 
activity and radiological damage (161). Therefore, both mean ± SD and median value 
with IQR have to be used to present radiographic data at group level (189).  
 
 66 
At individual level, some studies have used arbitrary cut-off values (1-5 points/year) 
to measure the change or progression between two study points whereas others used 
the cut-off values based on SDD, which is a study or trial specific number (161;193). 
Although, SDD can be used to show progression above measurement error, there is a 
chance that patients with progression less than SDD may be missed. Therefore, 
percentage of patients with progression > 0.5 (for two readers) or > 0 (for single 
reader) should also be presented along with percentage of patients with progression > 
SDD (189). Also in early RA studies, it may be useful to know the number of patients 
with new erosions and the percentage of patients with a score of 0 at the study start 
and at the end (189).  
 
Radiographic progression can also be presented as increase in absolute number or 
increase in percentage. One of the problems with these scoring methods, particularly 
in patients with a lot of structural damage at the start, is the „ceiling effect‟ i.e. when a 
maximum joint score is reached in a joint, further joint damage can not be quantified 
(194). Scott and his colleagues proposed a method to reduce the ceiling effect, in 
which the progression is represented in relation to the radiographic score at the start 
and this is calculated as follows: absolute progression /(maximum score of the 
method-score at the start) x 100 % (195).   
 
As each scoring method has a different score range, absolute numbers or mean ± SD 
and median with IQR do not provide exact information, if the scoring methods have 
to be directly compared. It has been suggested, that in order to make a direct 
comparison between two different scoring methods, the scores from each method can 
be linearly transformed from their original scale to a scale of 0 to 100. For example, to 
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transform SvdH (range 0-448) and Larsen scores (range 0-200) from their original 
scale to a scale of 0 to 100, the SvdH scores have to be multiplied by 0.2232 and the 
Larsen scores have to be multiplied by 0.5 (185). Another method called percentage 
or mean percentage of the maximum possible score has also been proposed to make 
direct comparisons between scoring methods and is calculated as follows: increase in 
absolute score / maximum score of the method x 100 % (189). 
 
j) Radiographic remission 
The FDA has included radiographic status of the disease in their strict remission 
criteria and according to this 5 out of 6 ACR remission criteria have to be fulfilled 
plus radiographic arrest (Larsen or SvdH method) for ≥ 6 months with no drug 
therapy (144). Some studies have reported on radiographic remission using different 
criteria such as, no extension of existing erosions and no development of new erosions 
between two time points (119) or no increase in radiographic score (Larsen) by > 1 
point between the study points (196). 
 
k) Radiographic healing 
Interestingly, it has been reported that healing of radiographic damage or erosions can 
occur during sustained disease inactivity or remission in RA, as a result of treatment 
with DMARDS and/or biological agents (197). Radiographic healing has been 
described as a reparative process, which may be represented by various features, such 
as recortication, sclerosis, filling in, remodelling and restoration (197;198). Healing of 
erosions in patients with RA between two time points may result in decreased or 
negative radiographic scores at group or individual level. However, measurement 
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error should be considered and excluded before making a diagnosis of radiographic 
healing, particularly in clinical trials that investigate treatment effects (198). 
 
Finally, in studies involving large number of patients with long-term follow-up, 
missing data may be an unavoidable problem. Methods such as „last observation 
carried forward‟ (LOCF), mean substitution, and data imputation have been suggested 
to handle this but unfortunately no consensus has been reached to resolve this 
important issue (189).  
 
1.4.3 Assessment of function 
Functioning is an important aspect of overall health status and it strongly influences 
quality of life (QoL). Different types of instruments have been used over the years to 
evaluate health status and QoL. In general, they are classified as global measures (to 
measure overall QoL) and health related measures (health related QoL). The latter can 
be used either to compare different patient populations across different diseases 
(generic measures) or to evaluate problems associated with a particular disease 
(disease-specific measures) (124). The Medical Outcomes Study Short Form-36 (SF-
36) is the most commonly used generic measure, which assesses both physical and 
mental aspects of QoL (199).  
 
Functional assessment in patients with RA is a vital component in the evaluation of 
disease progression as it significantly correlates with disease activity, structural 
damage and long-term outcomes (12;56;57;107). Measures such as, Steinbrocker‟s 
functional grade (FG), patient self-reported questionnaires and quantitative objective 
instruments have traditionally been used to assess function.  
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In 1949, Steinbrocker et al introduced a grading method based on clinician‟s 
assessment of functional impairment according to a scale of I to IV, whereby FG III 
applies to patients mainly housebound and/or work disabled, and FG IV to mainly 
wheelchair or bed bound patients (163). This was later largely replaced by patient 
self-report questionnaires such as health assessment questionnaire (HAQ), which has 
been widely used in clinical trials and clinical practice to evaluate physical function. 
Steinbrocker‟s FG has been shown to correlate well with HAQ in relation to 
functional assessment in RA (8;200).   
 
The HAQ or HAQ-disability index (HAQ-DI) is a 20-question instrument, which 
assess the degree of difficulty a patient has in accomplishing his or her tasks in eight 
functional categories such as dressing, rising, eating, walking, hygiene, reaching, 
gripping and usual day to day activities. For each question there is a four-level 
difficulty scale ranging from 0 to 3. The final score is the mean of the highest scores 
across eight categories and it ranges from 0 to 3, with higher levels indicating more 
disability (201;202). The HAQ has been modified several times subsequently to 
simplify it and to make it user friendly and also to include other domains such as 
depression and anxiety (203-205).  
 
 
Previous studies have attempted to identify specific cut-off points for HAQ to define 
clinically meaningful response between two time points i.e. real improvement in HAQ 
that is noticeable by the patient after treatment, and in one study the cut-off point was 
found to be 0.25 (206;207). However, an improvement in HAQ depends upon the 
duration of disease as it assesses both reversible and irreversible components of 
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functional impairment. It has been shown that during the early stages of the disease (< 
5 years duration), the HAQ score is mainly influenced by joint pain and swelling due 
to inflammation, which can improve with treatment (reversible), whereas in the late 
stages, the HAQ scores strongly correlate with structural damage (irreversible) and so 
the reversibility of HAQ in patients with established RA may not be as significant as 
in early RA (208). 
 
The Arthritis Impact Measurement Scale (AIMS) is another form of patient self-
reported functional questionnaire, which include assessment of depression and anxiety 
(209). There are longer and shorter versions of the AIMS, which have been used to 
evaluate function in patients with arthritis including RA (124).  
 
Objective quantitative instruments have also been used to assess function and these 
include measures of grip strength and locomotion (210). Grip strength has been 
widely used to assess hand function and this is measured using a vigorimeter or a 
dynamometer, with readout indicating the pressure attained by squeezing a 
compressible rubber bulb (211). These instruments appear to be reliable and correlate 








1.5) Outcomes and prognostic factors 
The natural (treated) course of RA varies greatly. At one end of the spectrum patients 
have mild disease, which remains stable for many years, whereas at the other end 
patients have severe disease with rapid progression. A significant proportion of 
patients do not follow such a consistent or predictable course and their disease 
progression may fluctuate with relapsing and remitting pattern.  
 
Various factors have been shown to determine the disease onset, subsequent 
progression and outcomes in RA, but the results can be inconsistent and vary to a 
great extent among individual patients (153;213-219). Nonetheless, it is very 
important to learn the outcomes and prognostic factors in RA, both from the 
clinicians‟ and patients‟ perspective, as it not only helps in better understanding of the 
disease process but also in developing targeted management strategies to reduce the 
morbidity and mortality.      
 
1.5.1 Outcomes  
Outcomes in RA can either be due to the disease itself (disease specific) or due to the 
consequence of the disease (non-disease specific). Remission, radiographic damage 
and functional disability are examples for disease specific outcomes, whereas work 
disability, costs and mortality reflect non-disease specific outcomes. Other important 
disease specific outcomes include pain, global assessment of disease activity, joint 





1.5.2 Outcome measures 
Studies have been reporting outcomes in RA cohorts for several decades. However, it 
was widely recognised that standard and validated measures have to be developed to 
measure or quantify outcomes in RA clinical trials. Therefore, outcome measures 
have been developed by the international associations such as ACR, ILAR and 
OMERACT to be used in clinical trials involving RA patients (121;220;221). 
Outcome measures are used to analyse different types of the disease specific 
outcomes and they can be broadly classified as clinical, radiological and functional.  
 
a) Clinical 
Clinical outcome measures include VAS for pain, DAS or DAS28 for joint tenderness 
(TJC) and joint swelling (SJC) and acute phase reactants (APRs) (121;124;220;221). 
ACR 20, 50 and 70 and EULAR response criteria are used to assess disease activity 
and treatment response using the standard clinical variables and APRs and so they 
have been widely used to measure clinical outcomes in RA studies (79;146).  
 
b) Radiological 
Structural damage seen on x-rays such as, erosions, JSN and deformities are 
considered as valuable radiographic outcomes in RA (87). The various scoring 
methods described in a previous section have been used as radiological outcome 
measures in most of the clinical trials, particularly in studies that analyse treatment 






Patient self report questionnaires have been the most commonly used tool to measure 
functional disability in RA, which sometimes include details on the use of aids and 
other appliances (124). Although several such questionnaires have been developed 
and modified over the years, HAQ is the most commonly used functional outcome 
measure in RA clinical trials as well as in routine clinical practice (124). Other 
measures that have been used to assess functional disability include Steinbrocker‟s 
FG I-IV and grip strength (12;124).     
 
1.5.3 Prognostic factors 
Prediction of disease progression and outcome in RA is crucial for optimal clinical 
management. Reliable prognostic factors would allow aggressive therapy to be 
targeted to patients at high risk early. However, the predictive value of many of the 
baseline variables can be inconsistent, particularly at the individual level.  
Observational studies and clinical trials have both reported on the power of various 
predictive factors for severity of RA, but the results have not been consistent because 
of differences in patient demographics, study design, methodology, treatment and 
choice of outcome measures.   
 
Wolfe and Hawley analysed predictive factors for remission (ARA criteria) in a 
cohort of established RA and they have reported that female sex, disease onset before 
age 60 and early development of erosions were associated with decreased proportion 
of remission (116). Eberhardt and Fex have reported that the presence of rheumatoid 
factor (seropositivity) and presence of shared epitope were associated with reduced 
frequency of remission in their prospective study of early RA patients (118).  
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Several other studies have also analysed the predictive factors for remission and in 
general factors such as gender, age at disease onset, disease duration, TJC, RAI, SJC, 
DAS, morning stiffness, ESR, CRP, rheumatoid factor (RF), HAQ, baseline 
radiographic damage and type of treatment have all been shown to have some 
prognostic value, although the results have been inconsistent (223). Some of these 
factors are consistently reported for their prognostic value and they include female 
sex, RF, level of baseline disease activity and radiographic damage.   
 
Prognosis for radiographic progression can only be studied reliably in a prospective 
study of early RA patients with regular clinical assessments and standardized 
laboratory and radiological measures at baseline and then at regular intervals.  
Combe et al, studied the prognostic factors for radiographic damage and radiological 
progression in a prospective cohort of early RA patients who were followed up for 3 
years (224). In this study, baseline variables such as RF positivity, HLA-DRB1, pain 
score and total Sharp score were predictive of radiologic damage at 3 years, whereas 
ESR, RF positivity, HLA-DRB1 and erosion score were predictive of radiographic 
progression.  
 
Few other studies, which used radiographic damage as their primary outcome 
measure, have reported on various factors that are associated with worse radiological 
outcome and they include long disease duration, RF positivity, high ESR or CRP, and 
higher Sharp scores at baseline (225-229). Dixey et al studied radiographic 
progression over 3 years in a large sample of early RA patients from their Early 
Rheumatoid Arthritis Study (ERAS) (68). In their study baseline variables such as RF, 
shared epitope and rheumatoid nodules showed predictive value for development of 
 75 
erosions at 3 years. They have also reported that certain variables at 1year follow-up 
had more powerful predictive value for radiographic damage (Larsen score), 
including RF positivity, high ESR, low haemoglobin (Hb) and high erosion score. 
Based on these studies, positive RF and high radiographic damage at baseline appear 
to be consistently associated with worst radiological outcome (68;224;226;228-230).  
 
It is generally agreed that active disease and progressive structural damage are 
associated with functional disability and so it is logical to assume that bad prognostic 
factors for disease activity and radiological damage can be related to functional 
disability as well. There is only limited information on prediction of functional 
disability from prospective RA studies, which used functional outcome as the primary 
outcome measure. Some of the baseline variables have been shown to be associated 
with worse functional outcome and they include female sex, older age at disease onset 
and worse HAQ score (>1.0) (12). Other factors such as, poor grip strength, RF 
positivity and development of erosions within the first 2 years of disease presentation 
have also shown to be associated with poor functional outcome (8). 
 
1.6) Clinical versus radiological disease activity 
In RA, clinical and radiological disease activities are two important aspects of disease 
evolution, which affects subsequent disease progression and outcome.  
 
1.6.1 Relationship between clinical and radiological disease activity 
Local inflammation of the affected joints, manifesting as joint pain and swelling, 
generally represents the clinical disease activity in RA and is measured by various 
joint indices and acute phase reactants (APRs) (124). Persistent inflammation in the 
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affected joints leads to structural damage visualised as erosions, JSN and deformity 
on plain radiographs (161).  
 
There is a close link between clinical and radiological disease activity in RA. How 
strong is this correlation when other factors are taken into account, for example 
disease heterogeneity and treatment effect? (107;231). Previous studies have shown 
that joint damage occurs early in the course of RA and about 60 to 70 % of early RA 
patients in these studies developed erosions within the first year or two of disease 
onset (87;90). As the disease progresses, most of the patients (> 90%) develop erosive 
disease and the disease duration has been shown to have a significant correlation with 
structural damage, assessed by Sharp or Larsen scores (90;107).  
 
Several clinical trials, using various treatment strategies, have demonstrated that more 
the improvement in disease activity less is the joint damage (232-241). Also, time-
integrated measures of disease activity such as, area under the curve (AUC) for DAS 
and ESR or CRP have been shown to correlate with radiological progression and 
treatments that control these measures more effectively lead to significant reduction in 
radiographic progression (138-140;242-244).  
 
Welsing et al, however, argued that time-averaged estimates for disease activity do 
not reflect individual variability within patients (245). This group studied the 
longitudinal relationship between disease activity and radiological progression in two 
different early RA cohorts with a maximum follow-up of 9 years, by using a special 
regression technique called generalized estimating equations (GEE). They found that 
radiological progression was not linear in individual patients and fluctuations in 
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clinical disease activity (mean interval DAS and SD of the mean interval DAS) were 
directly related to changes in radiographic progression. Other studies have also 
showed similar results that radiographic progression may be highly variable at 
individual level, particularly in early RA, although it is approximately linear at group 
level (90;100).  
 
The type of treatment may also have an influence on the link between clinical and 
radiological disease progression. In the COBRA trial, which studied the effect of 
DMARD combination therapy against monotherapy in patients with active RA, 
radiological progression was significantly reduced even in patients who did not 
respond clinically (ACR response criteria) to the combination therapy (246). 
However, it has been suggested that this paradox may be due to misinterpretation of 
the data as further detailed analyses of this cohort showed that time-integrated DAS 
was lower in the combination therapy group, even in non-responders, compared to 
monotherapy and this was not shown by the ACR response criteria as it was a 
measure of change only (245).  
 
Other clinical trials have also shown that the radiographic progression may be reduced 
even in patients with no significant clinical improvement to anti-TNF therapy (247). It 
was suggested that it might be due to the inhibitory effect of anti-TNF on osteoclast 
induced bone resorption, independent of clinical disease activity, mediated via 





1.6.2 Radiological progression despite clinical disease inactivity 
There is robust evidence that RA patients with active disease develop progressive 
structural damage compared to patients with low disease activity or remission 
(232;236;238;239). However, it has been shown that significant radiographic 
progression can occur even in patients with clinically inactive disease or remission 
(196;224;243;249-257). Several possible mechanisms or hypotheses have been 
suggested to explain this disconnect between clinical and radiological disease activity 
in patients with clinical remission and they are as follows:  
 
1. Pathogenesis of joint inflammation and destruction may differ from each other 
in RA 
Previous studies have shown that joint counts and acute phase reactants, reflecting 
synovial inflammation, continued to improve whilst radiological damage progressed 
(251;255;258). To explain this, it was suggested that the mechanisms, which are 
responsible for articular cartilage damage and synovial inflammation, may differ from 
each other (254). This hypothesis was supported by a study, which showed that 
synovial macrophages, but not lymphocytes, correlate with radiological progression, 
whereas both lymphocytic and non-lymphocytic populations correlate with measures 
of clinical disease activity (254;255).  
 
It has been suggested that synovial macrophages and other non-lymphocytic 
populations such as fibroblasts along with various cytokines may lead to progressive 
radiological damage despite little evidence of synovial inflammation and this may not 
respond to treatment with conventional DMARDs. On the other hand, clinical and 
laboratory manifestations of synovial inflammation may reflect both lymphocytic and 
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non-lymphocytic populations in the synovium, which may respond to conventional 
therapy (254). This is supported by subsequent findings that biological therapies, 
targeting synovial macrophages and various proinflammatory cytokies as well as 
lymphocytic populations, have been shown to achieve better clinical response with 
retardation of radiographic progression compared to DMARDs (233;259-263). 
 
2. Residual tender or swollen joint counts despite fulfilling DAS or DAS 28 
remission criteria because of the weighting in the formulas 
Assessment of disease activity using DAS involves comprehensive assessment of 
joints, which include 68 TJC and 44 SJC. On the other hand, using DAS28, disease 
activity (TJC and SJC) is assessed in 28 joints only omitting ankles and feet. 
Therefore, there is a possibility that patients classified as being in DAS28 remission 
may still have active inflammation in the ankles or feet (264-266).  
 
Landewe et al compared DAS remission with DAS28 remission  in patients with early 
RA who participated in the COBRA trial (266) . They have found that in patients who 
were in remission according to either DAS or DAS28, but not both, the discordance 
between those remission criteria was mainly (96%) due to patients fulfilling DAS28 
remission but not DAS remission criteria. In this study, patients fulfilling DAS28 
remission, but not DAS remission, had residual disease activity as indicated by high 
TJC and SJC (266). This was also supported by findings from other groups, who 
showed that DAS28 remission is less stringent, allowing for higher joint counts, 




3. Time lag between clinical disease activity and structural damage 
Cumulative clinical disease activity could have been higher in the period prior to the 
point when DAS and structural damage on plain radiography are compared. 
Matsuda et al studied the correlation between swollen joints, acute phase reactants, 
Larsen scores and number of erosive joints in early RA patients at 6 and 12 months 
(268). They have reported that there was certainly a time lag between active synovitis 
and the appearance of new joint erosions in their cohort. Aletaha et al recently studied 
a subgroup of early RA patients from the PREMIER study, who were in clinical 
remission (SDAI ≤ 3.3) at 2 years. This study showed that radiographic progression 
during clinical remission was actually related to level of disease activity preceding the 
period of radiographic assessment (269).  
 
4. Lack of sensitivity of conventional radiography in detecting erosions 
Conventional radiography is less sensitive than MRI and US in analysing 
radiographic progression as there may be a significant time-lag between the 
appearance of an erosion on MRI and the subsequent change on plain radiographs 
(101-104). Studies that used these advanced imaging techniques have shown that 
synovitis can be detected on US and MRI in apparently „normal looking joints‟ (sub-
clinical synovitis) or in patients who were classified in remission (270-272). 
 
5. Scoring methodology (Scoring methods and the sequence of reading x-rays)  
Although several scoring methods are available to measure structural damage, SvdH 
method has been shown to be better than others in relation to its sensitivity to change, 
smallest detectable difference and minimal clinically important difference 
(181;182;184). Therefore, SvdH scoring method may have a better discriminative 
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power in assessing longitudinal radiographic progression, particularly in patients with 
remission or low disease activity.                                                                                                                
 
Paired reading of the x-ray films is more precise in assessing radiological progression 
than reading films in random order as the later method can introduce measurement 
error (152;157-159). However, chronological scoring of x-rays may be better than 
random or paired reading in assessing longitudinal radiographic progression. This is 
because chronological order is more sensitive in detecting radiographic progression 
above measurement error and in identifying clinically relevant changes, although 
expectation bias can occur with this method (157;160;161). 
 
6. Treatment effects 
Remission in RA can either be due to the natural course of disease („spontaneous 
remission‟) or following therapy („drug induced remission‟). In observational studies 
difficulties with analysis of drug effects arise due to several factors including the large 
variations in drugs actually used and their timing, drug terminations due to adverse 
events or drug interactions, co morbidity and drug compliance. For various reasons a 
patient may temporarily cease important disease modifying therapy.  
 
Some patients stop taking DMARDs once remission is achieved either on their own 
accord or according to their doctors‟ advice. This may have an influence on 
radiographic progression. Ten Wolde et al studied the effect of stopping DMARDs in 
RA patients who had stable disease and had been on treatment for at least 2 years 
(273). In this study, patients who fulfilled ACR remission criteria were randomised 
either to receive placebo or to continue with their DMARDs and were followed up for 
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52 weeks. Disease flares were more common in the placebo group compared to the 
DMARD group and the disease control was not adequate even after re-institution of 
DMARDs in the former group (273;274). Radiographic outcome was not analysed in 
this study, nonetheless, it is logical to expect relatively more radiographic progression 
in the placebo group who experienced increased disease flares.                                                         
 
Some DMARDs may be less effective and may take more time in reducing the 
structural damage even after a good clinical response.  In the COBRA trial, 
Sulphasalazine as a monotherapy has been shown to be less effective in reducing 
radiological progression compared to aggressive combination therapy (SZP + MTX + 
Prednisolone). It was also demonstrated in this study that combined therapy 
immediately suppressed damage progression, whereas SZP did so less effectively and 
with a lag of 6 to 12 months (232). In the FIN-RACo study, long-term use of 
combination therapy (SZP + MTX + hydroxychloroquine + prednisolone) was 
compared with monotherapy (SZP or MTX or azathioprine ± prednisolone) in 
reducing joint damage in patients with early RA (252). In this study, more patients 
achieved remission in the combination group compared to monotherapy at 2 years but 
the difference was not sustained at 5 years. However, the radiographic progression 
(Larsen scores) was still significantly less in the combination therapy group at 5 years. 
   
7. Progression of radiographic damage can be mediated by mechanisms other 
than clinical disease activity 
Radiographic progression may occur independently of joint inflammation. In a study 
by Molenaar et al, increased urinary levels of bone turnover biomarkers such as 
pyridinoline, desoxypyridinoline, N-terminal telopeptide (NTX), and C-terminal 
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telopeptide (CTX) were found in RA patients with clinically inactive disease (258). It 
has also been demonstrated that urinary CTX-2 levels correlate with radiographic 
progression, independent of joint inflammation and disease duration, in patients in 
remission (275). These biomarkers of collagen breakdown and bone turnover have 
been shown to predict the effect of DMARDs on radiographic progression, 
independent of changes in clinical disease activity (276-278).  
 
Therefore, progression of structural damage can occur despite clinical remission or 
disease inactivity in RA. The link between clinical disease progression and 
radiological damage can be variable and unpredictable, particularly in early RA and it 














1.7) Rationale for this thesis  
 
This section will first report on previous similar studies to this thesis and discuss some 
unanswered questions and unresolved issues and in the following section the main 
aims & objectives of this thesis will be discussed.   
A detailed list of critical appraisal of the relevant studies is included in the appendices 
section. 
 
Table 1.2 shows a brief summary of the main early RA studies reporting on frequency 
of clinical remission using validated criteria.  
RA studies that used biological agents to achieve remission are not summarised here 















Table 1.2 Previous early RA studies on remission  
Study & Year Type of study Disease 
duration at 
study entry 










Prevoo et al, 
1996 (279) 








criteria (4 out of 5) 
20%  SJC 
Mottonen et al, 
1996 (238) 
Longitudinal  < 2 years 142  6 years ACR criteria 32% N/A 
Eberhardt et al, 
1998 (118) 
Observational < 2 years 183 5 years 1. Modified ARA 
criteria (4 out of 5) 

















entered into a 
prospective 
study 
N/A 135 15 years ARA criteria 24% N/A 









therapy and 98 
received 
monotherapy) 
2 years Modified ACR 
criteria (5 out of 5 
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< 2 years 732 5 years ARA criteria 13% Male sex, 
baseline 
HAQ < 1.0 






< 1 year 231 3 years ARA criteria (4 
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ESR and fatigue) 













< 1 year 90 2 years DAS < 1.6 36% Male sex, 
low DAS 
and HAQ at 
baseline 
Visser et al, 
2002 (282) 
Observational < 2 years 156 2 years Natural remission 
(no arthritis and no 
DMARDS or 
steroids in the last 
3 months) 
10% N/A 
Lindqvist et al, 
2002 (11) 





Gossec et al, 
2004 (223) 
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negative RF  
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Study & Year Type of study Disease 
duration at 
study entry 
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As shown in table 1.2, several RA studies have already reported on frequency and 
prognostic factors for remission. However, there is still lack of information on long-
term radiological and functional outcome in early RA patients in sustained clinical 
remission (period remission) rather than remission at one time point (point remission).  
 
Moreover, the inter-relationship between clinical, radiological and functional disease 
progression in early RA patients in sustained remission, treated with conventional 
DMARDs, has not been studied in long-term observational studies.  
 
Previous studies that have reported on radiological progression despite clinical 
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Table 1.3 shows that few studies have already reported radiographic progression in 
spite of clinical improvement or disease inactivity in RA. Nonetheless, prognostic 
factors for radiographic progression despite persistent clinical remission in early RA 
have not been reported before.  
Also, long-term outcomes in a subset of early RA patients who show relentless 
structural damage progression irrespective of their clinical disease activity have not 
been studied so far. 
 
Furthermore, influence of scoring methodology in measuring longitudinal 
radiographic progression in early RA patients, treated with traditional DMARDs, has 
not been analysed in detail previously.  
Analysis of different x-ray scoring methods and reading sequence of films in this 
thesis may help to determine if there is any significant difference between these 
methods in relation to their sensitivity to change and discriminative power in 
detecting clinically meaningful radiographic progression in early RA and to evaluate 
their role as an important outcome measure. 
  
The Early Rheumatoid Arthritis Study (ERAS) is a multicenter, inception cohort of 
early RA, which has recruited more than 1400 patients since 1986 with a maximum 
follow-up of 20 years. Standard clinical and functional assessments were recorded at 
baseline and then at regular intervals and serial x-rays of hands and feet were 
available for a majority of patients. This cohort is ideal to study the nature of disease 




1.8) Aims and Objectives of this thesis 
 
The main aim of this thesis is to examine the relationship between clinical and 
radiological disease activity in the ERAS cohort over 5 years from disease 
presentation, particularly in patients with clinically inactive disease, and to analyse 
their long-term outcomes with a view to answer some unresolved questions such as, 
  
1. What proportion of early RA patients continue to develop radiological damage 
despite being in clinical remission and what are their long-term outcomes? 
2. At what stage of the disease (early vs. late) does the coupling between clinical and 
radiological progression of the disease become unlinked? 
3. What is the influence of scoring methodology (Larsen vs. SvdH vs. SENS and 
random vs. chronological order) in studying the correlation between clinical disease 
activity and radiological progression in early RA 
4. Can RA patients, who continue to develop x-ray damage despite clinical remission, 
be predicted early on using baseline disease variables?  
 
In addition, this thesis will help to compare and to determine if there is any difference 
in radiological progression among patients with active or inactive disease based on 
clinical measures. Analysing disease progression and radiological damage in this 
inception cohort, with relevance to various disease related variables might help to 
identify prognostic factors that are associated with poor outcomes.  
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 Primary objectives: 
 
 i.    To study frequency of point and sustained remission based on DAS (DAS 
remission), in the ERAS cohort and to analyse prognostic factors for 
sustained DAS remission 
 ii. To study longitudinal radiographic progression in early RA, particularly 
during clinical disease inactivity 
iii. To evaluate the influence of scoring methodology in measuring radiographic 
progression in RA 
- Larsen vs. SvdH vs. SENS 
- random vs. chronological order 
iv. To analyse prognostic factors for progressive structural damage on x-rays 
despite DAS remission 
v. To study clinical, radiological and functional progression over 5 years in 

















































2: PATIENTS, MATERIALS AND METHODS 
 
2.1 Early Rheumatoid Arthritis Study (ERAS) 
2.1.1 Background 
The Early Rheumatoid Arthritis Study (ERAS) is a multicenter, inception cohort of 
early RA, which was formed in 1986 as collaboration between nine rheumatologists, 
who were working in different regions of England. The primary aim of the ERAS was 
to recruit and to follow-up at least 1000 early RA patients receiving conventional 
therapies including traditional DMARDs, in ordinary clinical settings for a minimum 
of 10 years. Ethical approval for the ERAS was obtained from the West Hertfordshire 
ethics committee.  
The main purpose of this observational study was to evaluate long-term outcomes, 
and to develop prognostic factors for clinical, radiological and functional outcomes. 
This study covers quite different regions of England, including rural, urban and inner 
city communities, and so it has been possible to investigate differences in 
socioeconomic effects and resource use on the outcome of RA. 
 
2.1.2 Patient recruitment 
All consecutive patients with RA of less than 2 years duration, who were seen in the 
rheumatology outpatient clinics in any of those participating centres, were recruited 
into the ERAS between 1988 and 1998.  
Inclusion criteria: Patients fulfilling the 1987 revised ARA criteria for RA with 
disease duration of less than 2 years and no prior DMARDs at the time of study entry 
were included in this study. Patients who were thought to have RA by their treating 
physicians but only had 2 or 3 features instead of ≥ 4 out of 7 ARA classification 
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criteria for RA, were also included in this study and followed up to see if they fulfil 
the ARA criteria subsequently.  
Exclusion criteria: Patients, whose initial diagnosis was RA, but later developed 
connective tissue diseases such as lupus or seronegative spondyloarthropathies were 
excluded from the study.  
Recruitment stopped at 1500 in 1999 and a large proportion of patients have 
completed their 5 and 10 year follow-ups. 
 
2.1.3 Data collection and storage 
Each centre has recorded clinical, laboratory and functional features of all the ERAS 
patients at baseline, 3, 6 and 12 months in the first year and then once yearly. X-rays 
of hands and feet were done at baseline and then at 1, 2, 3, 5, 7 and 10 years and were 
digitized onto CD-ROM. X-rays of cervical spine were also done at regular intervals. 
Standard forms have been used across all the ERAS centres for data collection and 
entry both at the first visit and at follow-up visits and they are included in the 
appendices. 
The recorded details of all the study patients were stored in a database, which was 
regularly checked and managed by the ERAS co-ordinator. One of the participating 
centres (St Albans) has co-ordinated the study, where all the data collation, entry and 
preliminary analyses were performed.  
 
a) Clinical 
Trained metrologists, under the supervision of rheumatologists, have recorded the 
standard clinical assessments for each patient at the study entry and then at regular 
intervals. These assessments are in accordance with the core data set recommended by 
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the national and international associations for rheumatology and they included, onset 
and pattern of joint symptoms, body mass index (BMI), duration of morning stiffness, 
pain score (VAS), tender and swollen joint counts, Ritchie articular index (RAI), 
ARA criteria, grip strength, extra-articular manifestations and co-morbid conditions. 
Clinical disease activity including remission in the ERAS cohort was assessed using 
DAS, and is calculated as follows (141;142):  
 
DAS = 0.54 x √(Ritchie) + 0.065 x SJC44 + 0.33 x lognat(ESR) + 0.224  
 
In the study population, EULAR criteria were used to categorize patients into 
different clinical subgroups, based on their DAS scores (81): 
 
Table 2.1 Clinical disease activity based on EULAR criteria 
Disease activity score (DAS) values Disease activity 
DAS < 1.60 Remission 
DAS ≥1.60 and ≤ 2.40 Low or mild disease activity 
DAS >2.40 and ≤ 3.70 Moderate disease activity 




Each patient had standard blood tests done at baseline and then at regular intervals 
and the results were entered into the ERAS database. These tests included, FBC, ESR, 
IgM rheumatoid factor (RF) and anti nuclear antibody (ANA). Stored blood samples 
were used to extract DNA. HLA-DRβ1 type was assigned using sequence 
 98 
oligonucleotide typing and number of copies of the RA related shared epitope was 
determined, in collaboration with the Arthritis research campaign epidemiology 
research unit (ARC ERU) at Manchester.  
 
c) Radiological 
 i) Scoring methodology for ERAS 
X-rays of hands and feet from baseline up to a maximum of 10 year follow-ups for all 
the ERAS patients were scored, using Larsen‟s method in random order, by an 
experienced rheumatologist, Dr Csilla Solymossy (CS), who was unaware of the 
patients‟ clinical details including treatment (68;290) . Larsen scoring method that 
was used in the ERAS patients has already been described in the previous chapter 
(172). Intra-observer variability for observer CS was checked regularly using 
intraclass correlation coefficient (ICC) and the values were > 0 .85 (68;290).  
X-rays of cervical spine were done in flexion and extension views and the treating 
clinicians according to the degree of damage and deformity graded the changes seen 
on x-rays.  
 
 ii) Scoring methodology and training for this thesis 
For the purpose of this thesis, apart from the Larsen scoring method, SvdH and SENS 
methods were also used to score hands and feet x-rays of certain clinical subgroups of 
ERAS patients and these methods have already been described in detail in chapter 1 
(169;170). Observer KJ (myself), have used Larsen, SvdH and SENS methods to score 
hands and feet x-rays of selected groups of ERAS patients from baseline up to a 
maximum follow-up of 5 years in chronological order. Observer KJ was blinded to 
patients‟ clinical information including treatment details and previous x-ray scores, by 
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masking patients‟ details and by giving different ids to x-rays by the ERAS 
coordinator. Once the films were all scored, x-ray scores from each scoring method 
were entered into the ERAS database and the clinical and radiographic data were all 
merged together by the ERAS coordinator for further analyses. Radiographic data 
collection, entry and storage have all been regularly checked and validated by the 
ERAS coordinator and research students from the University of Hertfordshire (UH).   
 
Observer KJ had received adequate training and supervision by experienced readers in 
the relevant scoring methods, before start reading the x-ray films for this project. 
First, observer KJ learnt the Larsen scoring method by attending hands-on training 
sessions with Dr CS, who scored hands and feet x-rays of all ERAS patients using the 
Larsen method. After this, observer KJ scored a random sample of hands and feet x-
rays from the ERAS cohort twice with an interval of 4 weeks between the two reading 
sessions in order to check inter and intra observer variability, after being blinded to 
patient‟s clinical details and previous Larsen scores. Inter and intra observer 
variability was calculated using ICC and they were 0.96 and 0.95 respectively. 
 
Observer KJ had then learnt the SvdH and SENS scoring methods by attending a 
training workshop at the Maastricht University hospital, Maastricht, Netherlands 
organized by Dr Desiree van der Heijde, who introduced the SvdH and SENS 
methods after some modification of Sharp‟s original scoring technique. Dr Annelies 
Boonen (AB), a very experienced reader in Dr van der Heijde‟s unit, has conducted 
this session and this provided hands-on experience for observer KJ with the trainer 
and with other trainees. Observer KJ‟s scoring technique and accuracy was supervised 
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by the trainer and was given some practical tips and positive feedback at the end of 
the session.  
 
Few weeks after this training session, observer KJ was asked to score 20 sets of hands 
and feet x-rays (SvdH method) from Maastricht rheumatology unit‟s research 
database twice with an interval of 4 to 6 weeks between the two scoring sessions in 
order to check the inter and intra observer variability. Inter and intra observer 
variability for SvdH method was calculated using ICC and are as follows: erosion 
0.88 (inter) 0.95 (intra); narrowing 0.88 (inter) 0.97 (intra) and total score 0.81(inter) 
0.97 (intra). After these scoring sessions, observer KJ has attended a further session 
with the trainer, Dr AB, to go through some of the x-rays and to clarify some minor 
discrepancies in the SvdH scores between the two readers.  
 
d) Functional 
Functional ability of the ERAS patients was assessed at the time of study entry and 
then at regular intervals using Steinbrocker‟s FG and HAQ, as described in the 
previous chapter. Using Steinbrocker‟s FG, functional ability was graded from I to 
IV: Grade I = ability to perform normal activity; Grade II = moderate restriction of 
normal activities; Grade III = marked restriction of day to day activities; Grade IV = 
incapacitated, bed-ridden or confined to a wheelchair.  
 
Modified HAQ was used in the ERAS to assess patients‟ functional capacity in 8 
different physical domains with scores ranging between 0 and 3, as described earlier. 
Grip strength was assessed using standard handgrip measure with scores ranging 
between 20 and 300, the higher scores indicating better grips. 
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e) Other outcomes 
Outcome measures other than clinical, radiological and functional assessments were 
also recorded at baseline, 3 and 5 years. This included job status, social service 
benefits and allowances, use of standard aids and appliances such as splints, walking 
aids and major adaptations (wheel chair, stair lifts, hoists). All types of orthopaedic 
surgeries were also recorded and for study analysis they were grouped as minor 
(nodule removal, arthroscopy), intermediate (synovectomy, tendon repair, excision 
arthroplasty, arthrodesis) and major (joint replacements, cervical spine fusion). Other 
details including joint range of movement, accommodation, social class, education, 
co-morbid conditions and in-patient episodes were also included in the ERAS 
outcome assessment forms.  
 
2.1.4 Treatment profile 
All centres followed the framework of the published UK guidelines for management 
of RA, which include the provision of therapy services, appropriate orthopaedic 
interventions, and sequential use of DMARDs together with symptom relieving 
measures, with judicious use of steroids when required. DMARD combination 
therapy was used in severe and non-responsive RA and biological agents were not 
used. The DMARDs used were chosen according to the physician‟s preference, 
although dosage schedules employing graduated regimens were previously agreed 
according to standard practice for each drug.  
 
Reasons for discontinuation of DMARDs were based on clinical judgements and 
coded according to loss or lack of effect, to adverse events, both reasons, remission, 
or miscellaneous (e.g. pregnancy).  
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2.1.5 Statistics 
Statistical Package for Social Sciences (SPSS) was used to analyse the ERAS 
database. A number of collaborations including the Clinical Operational Research 
Unit (CORU) at University College London, ERU at the School of Hygiene, London, 
Health Research Development and Support Unit (HRDSU) at the University of 
Hertfordshire (UH), ScHARR, Sheffield, and Department of Mathematics, Keele 
University, Keele, Staffordshire have provided statistical support for the ERAS 
projects.  
 
For this thesis, statistical support was mainly provided by the HRDSU, UH and Keele 
University, Keele. Dr Annelies Boonen (AB) from the University Hospital, 
Maastricht, Netherlands has kindly provided the necessary advice and appropriate 
guidance on specific statistical tools to be used for the radiological data analyses and 
reporting for this project. 
 
Summary statistics have been used to analyse the study data and to report results. 
Continuous variables were expressed as mean with standard deviation (SD) or median 
with interquartile ranges (IQR) and categorical variables were shown as counts with 
percentages.   
Chi square (
 χ2) for categorical variables and Mann Whitney U (MWU) or Kruskal-
Wallis H (KWH) for non-parametric and ANOVA for parametric data were used to 
compare the study groups. Wilcoxon signed rank test or paired samples t-test were 
used to assess the significance of difference in outcomes between different time points 
within the individual study groups. Pearson or Spearman correlation tests have been 
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used to assess the strength of association between clinical or laboratory measures and 
x-ray scores in the study groups.    
 
Radiographic progression at group level was analysed using summary statistics and 
absolute scores, whereas at individual level smallest detectable difference (SDD) was 
used to detect significant x-ray progression i.e. progression above measurement error 
(185).  
Reliability analysis for inter and intra observer agreement for different x-ray scoring 
methods was performed using intraclass correlation coefficients (ICC) and Bland and 
Altman scatter plot graphs. Intraclass correlations, termed intra-cluster correlations 
for readings and inter-cluster correlations for readers, were estimated using one-way 
random effects ANOVA. 
 
Univariate analysis using odds ratios (OR) with 95% confidence interval (CI) and 
multiple logistic regression, using stepwise procedure were used to examine 
prognostic factors for radiological progression. Variables used for the multivariate 
model were chosen from the univariate analysis and a p-value of ≤ 0.05 (two sided) 

































3. REMISSION IN EARLY RHEUMATOID ARTHRITIS 
 
3.1 Background 
Patients with active rheumatoid arthritis (RA) usually progress to develop more 
radiological damage and poor outcomes compared to inactive disease or remission 
(7;8;106). Therefore, the ultimate goal of treatment in RA is to achieve remission as 
early as possible (291). Maintaining disease inactivity after remission induction is also 
important to have a favourable influence on subsequent disease progression and long-
term outcomes. 
 
Remission either occurs spontaneously or can be achieved by using specific anti-
rheumatic drugs such as disease modifying anti rheumatic drugs (DMARD), steroids 
and/or biological agents. Some RA patients can maintain remission even after 
stopping the treatment and remission can be described as spontaneous, drug induced 
or DMARD/biologics-free, based on current or previous treatment (233).   
 
In RA studies, ARA and EULAR criteria have been widely used to assess clinical 
disease activity including remission (79;118). The EULAR criteria is based on DAS 
or DAS28, which is calculated using swollen joint count (SJC), tender joint count 
(TJC) or Ritchie articular index (RAI), erythrocyte sedimentation rate (ESR) and 
patients global health (GH) (79;84;142). Previous RA studies have reported frequency 
of remission varying between 7 and 65 % depending upon the patient demographics, 
study design and type of remission criteria used (292). Studies that have examined 
duration of remission and prognostic factors have also shown inconsistent results 
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[270,273,274,276] and there is only limited information on the effect of sustained 
clinical remission on long-term outcomes in early RA. 
 
3.2 Objectives 
1. To study frequency of point and sustained remission based on DAS 
(DAS remission), at years 3, 4 and 5 from disease presentation in the 
ERAS cohort  
2. To study prognostic factors for: 
i.  Sustained DAS remission  
ii.  Sustained DMARD-free remission 
3. To assess outcomes in patients in sustained DAS remission 
 
 
3.3 Patients and Methods 
Patients 
For the purpose of this analysis, a total of 704 patients from the ERAS who had 







follow-up visits were selected. Patients who did not complete 5 year follow-up were 
excluded from the analysis (n=304, reasons as follows: attends other hospital (n=7, 2 
%); moved  (n=25, 8 %); unable to attend (n=3, 1 %); declined (n=18, 6 %); patient 
reported remission (n=9, 3 %); deceased (n=195, 64 %); discharged (n=1); not known 
(n=20, 7 %); not traced (n=26, 9 %). A separate analysis of these patients with less 
than 5 yr follow-ups has shown similar disease characteristics except that mean age of 
disease onset (60 vs. 54, p <0.001) and baseline disease activity was slightly higher 
(DAS 4.5 vs. 4.2, p <0.01) in this group.   
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Study assessments 
Patients were assessed at 0, 3 and 6 months in the first year and then annually. 
Standard clinical measurements were recorded at baseline and then annually as 
described in the previous chapter. X-rays of hands and feet were performed at 0, 1, 2, 
3 and 5 years and the films were scored using Larsen‟s method in random order by an 
independent observer (CS), unaware of the clinical details. Disease outcomes were 
recorded at 3 and 5 years using standard forms. 
 
Definition of DAS remission 
DAS remission was defined as DAS < 1.6, either at one time point (point remission) 
or at consecutive time points (sustained remission). For this study, sustained DAS 
remission was defined as DAS < 1.6 at years 3, 4 and 5 from disease presentation. 
 
Definition of sustained DMARD-free remission 
1) No current use of DMARD or steroids 2) No swollen joints and 3) Confirmation of 
DMARD-free remission by the patient‟s rheumatologist. Patients had to fulfil all three 
criteria and absence of swollen joints had to have been observed by a rheumatologist 
for at least one year after discontinuation of DMARD-therapy to ensure sustained 
remission.  
 
Predictive factors for DAS remission 
Predictive factors for DAS remission at year 3 (point remission) and at years 3, 4 and 
5 (sustained remission) were analysed in patients who have had DAS recorded at all 
the above study points (n=704).  
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Predictive factors for sustained DMARD-free remission were also analysed in the 
ERAS patients who had at least two consecutive annual clinical assessments at some 
point during their follow up (n=895). This particular analysis was done as part of a 
collaboration with another similar cohort, which used this definition of remission as 
the optimal target in the management of RA. The ERAS cohort was used to validate 
the findings in the Early Arthritis Cohort (EAC) from Leiden, The Netherlands. 




Study cohort was treated with standard DMARDs as described earlier, either as 
sequential monotherapy or combination therapy and/or steroids. None of the patients 
received biological agents as the study period was in the pre-biologic era.   
 
Statistical analysis 
Summary statistics have been used to demonstrate the differences in clinical and 
laboratory features with disease outcomes. Continuous variables were expressed as 
either mean ± standard deviation (SD) or median with interquartile ranges (IQR) and 
categorical variables were shown as counts with percentages. Chi square
 
 (
 χ2) for 
categorical variables and Mann Whitney U (MWU) for continuous data were used to 
compare the study groups. Wilcoxon signed rank test was used to test the difference 
in outcomes between 3 and 5 years within the remission and non-remission groups.  
 
Univariate analysis using odds ratios (OR) with 95 % confidence intervals (CI) was 
used to assess predictive value of baseline variables for DAS clinical remission and 
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multivariate analysis was performed using the stepwise procedure. For continuous 
variables, median values were used as cut off points to dichotomise them into 
categorical variables except Larsen scores, where 75
th
 percentile was used because of 
a large number of patients with non-erosive disease at baseline. Baseline variables 
with significant ORs in the univariate analysis were entered in the multivariate model 
and a p-value of ≤ 0.05 (two sided) was considered statistically significant.  
 
Predictive factors for sustained DMARD-free remission were analysed in conjunction 
with the Departments of Rheumatology and Medical Statistics, Leiden University 
Medical Centre, Leiden, The Netherlands. To take into account the difference in 
follow-up times among patients, analyses were performed by Cox regression analysis, 
after verification that the proportional hazards assumption was satisfied. In the Cox 
regression model the dependent variable is the “time-to-event”, which consisted of the 
time to remission for the remission patients, and the time to last follow-up (with a 
maximum of 10 years) for the non-remission patients.  
 
In order to investigate the predictive ability of baseline characteristics in univariate 
analysis, each variable was included as a covariate in a separate non-conditional 
analysis. The results of the univariate analyses were subjected to correction for 
multiple testing by the Holm method.  Subsequently, multivariate Cox regression 
analysis was performed to identify significant independent predictors for achieving 
remission. As possible explanatory variables, all baseline variables with a p-value 
below 0.10 in univariate analysis were included in the model. A two-step modelling 
approach was performed, which in the first step identified independent predictive 
variables by a backward step selection procedure that removed variables with a         
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p-value greater than 0.10. To verify that the identified predictive variables were 
indeed independent predictors for the entire cohort, they were then entered as 

























Baseline demographics of the study cohort (n=704) are shown in table 3.1, which is 
very much representative of early RA.        
Table 3.1 Baseline disease characteristics   






Non-remission   
(n=626) 
p-value 
Women 66% (462) 45% (35) 68% (427) < 0.001 
Age of disease onset 
(years) 
54 (± 13.7) 53 (±14.7) 54 (±13.6) 0.77 
Duration of symptoms 
(months) 
8.5 (± 6.3) 7 (±5.8) 8.7 (±6.4) 0.16 
RF positive 66 % (461) 59% (46) 66% (415) 0.20 
Shared epitope  57% (402) 54% (42) 57% (360) 0.63 
Erosions 26% (182) 23% (18) 27% (164) 0.58 
RAI 13.1 (± 11) 7.5 (±6.7) 13.8 (±11.2) 0.98 
SJC 16.9 (± 13.3) 12 (±11.1) 17.5 (±13.5) < 0.001 
ESR 42.5 (± 28.5) 37.5 (±24.9) 43.2 (±29) 0.25 
DAS 4.2 (± 1.6) 3.4 (±1.3) 4.3 (±1.6) 0.31 
HAQ 1.0 (± 0.717) 0.8 (±0.7) 1.1 (±0.7) < 0.001 
Larsen [Median (IQR)] 0 (0-4) 0 (0-3) 0 (0-4)     - 
DMARD use at 1yr   76% (537) 65% (51) 78% (486) 0.005 
 
Values are expressed as mean (± SD) unless otherwise indicated 
  % (count) 
  
Persistent  remission (DAS < 1.6) at 3, 4 and 5 yr follow-ups 
 
RF = Rheumatoid factor 
RAI = Ritchie articular index, SJC = Swollen joint count 
ESR = Erythrocyte sedimentation rate, DAS = Disease activity score 
HAQ = Health assessment questionnaire 





DMARDs either as mono or combination therapy were used in 76% of patients at year 
1 (mono=60%, combi=16%) and the respective figures at 3 and 5 years were 83 % 
(mono=51%, combi=32%) and 85% (mono=46%, combi=39%).  Mean DMARD use 
at 1 year 0.96 (range 0-5), at 3 years 1.25 (range 0-6) and at 5 years 1.52 (range 0-6). 
Median time to the start of first DMARD after study entry was 2 months (1-5.5). 
Sulphasalazine (SSZ) was the most commonly used first line DMARD (80%) 
followed by intramuscular (i.m) gold injection (7%) and D-penicillamine (6%). 
Methotrexate (MTX) was the most commonly used second line DMARD (51%) 
followed by gold injection (18%). Oral steroids were used in 15% of patients by 5 
years and most of them (81%) have had ≤ 7.5 mg/day of prednisolone.  
 
DAS remission 
179 patients (25%) achieved DAS remission at 3 years and the corresponding figures 
at 4 and 5 years were 183 (26%) and 158 (22%) respectively. Amongst patients in 
remission at year3, disease inactivity persisted for 12 months in 63% and for 24 
months in 44%. Frequency of sustained DAS remission was 11% (n=78) at all three 
study points (year3, 4 and 5) and 13% (n=95) at time points 3 and 5 years only (17 pts 
had a disease flare at year4 but were in remission at yr3 and 5). DMARDs were used 
in 70% of patients who were in sustained DAS remission at year5 (mono=60%; 
combi=10%). 
 
The study cohort (n=704) was divided into two subgroups, to analyse outcomes and 
prognostic factors in relation to clinical disease activity. Patients with a DAS of < 1.6 
at all three study points (yr 3, 4 and 5) were grouped as remission (n=78) and the rest 
as non-remission (n=626).  
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Use of DMARDs in the remission group was 65% (mono=63%, combi=2%) at yr1 
and 70% (mono=60%, combi=10%) at both 3 and 5 year visits. DMARDs either as 
mono or combination therapy were used more frequently in the non-remission group 
compared to remission group at all time points (yr1 = 78% vs 65%, p=.006; yr3 = 
85% vs 70%, p=.002; yr5 = 87% vs 70%, p=.000). Mean DMARD use in remission 
group was 0.83 (range 0-3) at the end of 3 and 5 years and in the non-remission group 
it was 1.3 (range 0-6) at yr3 and 1.6 (range 0-6) at yr5.  
 
In both groups, sulphasalazine (SSZ) was the most common first line DMARD 
followed by i.m gold and D-penicillamine. SSZ+MTX were the most frequently used 
combination therapy in the non-remission group and no combination therapy was 
used in the persistent remission group. Median time to the start of first DMARD from 
disease onset was 3 months (1-7) in the remission group and 2 months (1-5) in the 
non-remission group. Although more patients were treated with oral steroids in the 
non-remission group (16% vs. 9%, p=0.5), the difference was not statistically 
significant.  
 
Predictive factors for DAS remission 
Predictive value of baseline variables for point remission (year3) and sustained 







Table 3.2 Predictive factors for DAS remission on univariate analysis 
Baseline variable Remission at 
year 3 
 
OR (95% CI)  
Sustained 
remission at 
year 3, 4 and 5  
OR (95% CI) 
Men  2.0 (1.4-2.8) 2.6 (1.6-4.2) 
Duration of symptoms < 6 months at study 
entry 
1.6 (1.1-2.2) 1.6 (1.0-2.7) 
 
Social class I, II 2.2 (1.5-3.4)  2.4 (1.4-4.1) 
Rheumatoid factor (RF) negative 1.0 (0.7-1.5) 1.4 (0.9-2.2) 
Shared epitope (SE) negative 1.1 (0.7-1.7) 1.2 (0.7-2.1) 
American College of Rheumatology (ACR) 
diagnostic criteria < 4 
1.6 (1.1-2.3) 1.8 (1.1-2.9) 
No erosions 1.1 (0.7-1.6) 1.2 (0.7-2.1) 
Pain score < 45 (Visual analogue scale) 1.4 (1.0-1.9) 2.1 (1.3-3.6) 
Early morning stiffness (EMS) < 1 hour 1.7 (1.2-2.4) 1.6 (1.0-2.6) 
Grip strength >140 (range 0-300) 1.8 (1.3-2.6) 1.6 (1.0-2.7) 
Ritchie articular index (RAI) < 10 2.1 (1.5-3.0) 3.0 (1.7-5.0) 
Swollen joint count (SJC) < 13 1.6 (1.1-2.3) 1.9 (1.1-3.0) 
Erythrocyte sedimentation rate (ESR) < 37 1.0 (0.7-1.4) 1.1 (0.7-1.8) 
Disease activity score (DAS) < 4.1 2.2 (1.5-3.1) 2.7 (1.6-4.6) 
Health assessment questionnaire (HAQ <1.0) 1.7 (1.2-2.5) 2.1 (1.3-3.6) 
Larsen score < 4 1.2 (0.8-1.9) 1.6 (0.8-3.0) 
 
 
Table 3.3 Predictive factors for sustained DAS remission on multivariate analysis 
Baseline variable 
 
OR 95% CI  p-value  
Men 2.6 1.5 – 4.5 < 0.001 
Symptom duration < 6 months 3.2 1.0 – 9.8 0.046 
Ritchie articular index (RAI) < 5 3.7 1.3 – 10.9 0.016 
 
OR = Odds ratio, CI = confidence interval 
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On univariate analysis, male sex, higher social class (I&II), RAI <10, DAS < 4.1 and 
HAQ < 1.0 at baseline have shown better predictive value for remission, whereas, 
ESR, RF, shared epitope, and Larsen score did not show any prognostic value in this 
study cohort. Although there was a significant difference in DMARD use between 
remission and non-remission groups, early use of DMARDs i.e. within 1 year of 
disease presentation did not show any predictive value for remission in this study. 
 
Using multiple logistic regression, male sex, shorter duration of symptoms and lower 




Predictive factors for sustained DMARD-free remission 
Predictive abilities of baseline disease variables for sustained DMARD-free remission 











Table 3.4 Predictive factors for sustained DMARD-free remission on univariate 
analysis (Cox regression method)  
Baseline variable Hazard 
Ratio # 
95% CI p-value 
    
Age of onset 1.00 0.98-1.01 0.58 
    
Gender  0.78 0.50-1.22 0.28 
    
Duration of symptoms at 
presentation 
0.96 0.92-1.00 0.038 
    
Smoking, n (%) 0.54 0.29-1.02 0.059 
    
Family history of RA  0.87 0.53-1.44 0.59 
    
Body mass index (BMI)     
mean (SD) 
0.98 0.93-1.04 0.54 
    
Acute onset of symptoms  1.71 1.10-2.67 0.017 
    
Symmetrical onset 1.18 0.67-2.07 0.56 
    
Rheumatoid factor (RF) 0.31 0.20-0.50 <0.001 
    
Shared epitope  0.47 0.28-0.78 0.003 
    
Ritchie articualr index (RAI) 0.91 0.88-0.95 <0.001 
    
Swollen joint count (SJC) 0.97 0.95-0.99 0.005 
    
Erythrocyte sedimentation rate 
(ESR) 
0.99 0.99-1.0 0.21 
    
Disease activity score (DAS) 0.65  0.55-0.76 <0.001 
    
Health assessment questionnaire 
(HAQ) 
0.51 0.36-0.71 <0.001 
    
Larsen score 0.94 0.88-1.00 0.050 
 
# Hazard ratio is the effect measure generated by Cox regression analysis and it can 
be interpreted similar to an odds ratio i.e. higher hazard ratio signifies a higher chance 
of remission. 
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Table 3.5 Predictive factors for sustained DMARD-free remission on 
multivariate analysis (Cox regression) 
 
Baseline variable Hazard 
Ratio 
95% CI p-value 
    
Duration of symptoms at 
presentation 
0.94 0.89-0.99 0.029 
    
Acute onset of symptoms 2.03 1.15-3.59 0.015 
    
Rheumatoid factor (RF)  0.28 0.16-0.49 <0.001 
    
Shared epitope 0.44 0.26-0.73 0.002 
    
Ritchie articular index (RAI) 0.92 0.88-0.97 0.001 
    
Health assessment 
questionnaire (HAQ) 













As shown in the above tables, baseline variables such as nature of disease onset, 
duration of symptoms, RF, shared epitope, clinical disease activity, HAQ and x-ray 
scores (Larsen) showed prognostic value for sustained DMARD-free remission. 
 
 
Disease progression and outcomes at 5 yrs 
Radiological and functional disease progression during the study period and outcomes 
at 3 and 5 years were analysed in the DAS remission and non-remission groups and 





































In Fig 3.1, Larsen scores are shown as median values (horizontal line) within quartile 
ranges (boxes) for remission and non-remission groups between 1 and 5 years (yr).  























In fig 3.2, Health assessment questionnaire (HAQ) scores are shown as median values 
(horizontal line) within quartile ranges (boxes) for remission and non-remission 
groups between 1 and 5 years.  
Whiskers (vertical lines) extend to values within 1.5 box lengths 
 
Outliers are shown as circles and clinical details of these patients were identified from 
the database. Three of the outliers had relevant co-morbidities that may explain HAQ 
scores higher than expected for inactive RA: Patient1 with a HAQ of 3 at yr2 and 2.25 
at yr3, 4 and 5 had myelopathy secondary to degenerative cervical spine disease, 
Patient2 with a HAQ of 0.88, 1.50 and 0.63 at yr3, 4 and 5 had polymyalgia 
rheumatica, and Patient3 with a HAQ of 1.13, 1.50 and 1.25 at yr3, 4 and 5 had 
osteoarthritis of knees. 
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Table 3.6 Outcomes at 3 and 5 years in the DAS remission and non-remission 
groups at same time points 
 









































Job status    
Continue to work 
Stopped working 
     Due to RA 
     Unrelated to RA 
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Total number of patients with erosive disease increased between 3 and 5 years in both 
groups. However, radiographic progression at group level was worse in the non-
remission group (p<0.001), and only mild & not statistically significant in the 
remission group (p=0.08).  
 
Mean HAQ score in the remission group decreased from 0.17 to 0.13 (-0.04, 
p<0.001), whereas in the non-remission group, it increased from 0.92 to 1.1 (+0.18, 
p<0.001) during the study period. More patients in the non-remission group had 
advanced from Steinbrocker‟s FG I & II (favourable) to FG III & IV (worse) between 
3 and 5 years (+6%, p<0.001), whereas in the remission group there was no change. 
The total number of patients receiving disability allowances increased significantly in 
the former group (+8%, p<0.001 vs. +3%, p=0.10).  
 
Although more patients stopped working between 3 and 5 year follow-ups in both 
groups, RA was the most frequent cause of work disability in the non-remission 
group, but not in the remission group. The number of patients who required major 
adaptations at home such as stair lifts and hoists and the rate of major orthopaedic 
surgeries such as joint replacements was significantly greater between 3 and 5 years 
in the non-remission group (+6%; p<0.001 and +4%; p<0.001 respectively). More 
patients in the non-remission group died after 5 years of disease presentation 
compared to remission group but the difference was not statistically significant (23% 






Frequency of sustained DAS remission at 3, 4 and 5 years follow-up in this study was 
11% and much lower than the remission rate at individual time points (year3-25%; 
year4-26%; year5-22%). Remission occurred slightly less frequently in 9.4% of 
ERAS patients using the different criteria of sustained DMARD-free remission. The 
baseline variables age, acute onset of symptoms, absence of RF and SE showed 
predictive value for DMARD-free remission but not for remission based on DAS. 
Male sex showed strong independent predictive value for DAS remission but not for 
sustained DMARD-free remission. Duration of symptoms, RAI and HAQ at disease 
presentation all showed prognostic value for subsequent remission irrespective of the 
remission criteria used.  
 
Comparisons with other studies are complicated by the different remission criteria 
used (ARA, DAS, DAS 28, clinical, sustained, DMARD-free). Most other studies 
have also shown that sustained disease inactivity in RA is less frequent than remission 
at a single time point, but reports on prognostic markers and their relative predictive 
value vary considerably (116;118;223;238;253;279). This latter point may be due, at 
least partially, to the many and different definitions of clinical remission. 
 
The modified ARA criteria were reported in a previous ERAS report in 732 patients. 
The remission rate at 5 year was 13%, which is less than reported in this thesis using 
DAS (22%), but prognostic markers were similar, male sex and baseline HAQ of < 1 
were predictive of remission (12). Wolfe et al reported ARA remission rates of 18% 
and median remission duration of 12 months in a large prospective cohort of 458 RA 
patients with mean disease duration of 7.7 years. They reported male sex, disease 
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onset > 60 yrs and absence of erosions at baseline as predictive factors for subsequent 
remission (116).  
In a prospective study of 142 early RA patients (< 2 yrs) with a mean follow-up of 6.2 
years, Mottonen et al reported ARA remission in 20%, 27% and 32% at year 1 , 2 and 
last visit, but only 19% were in remission both at year2 and at the last visit (238). 
These higher remission rates may be partly due to the more intensive treatment 
strategies employed in this study. These results are consistent with the findings 
reported in this thesis that remission at individual time points was greater than 
sustained remission rates. 
 
Eberhardt et al prospectively studied disease course for 5 years in 183 early RA 
patients and in this study 37 patients (20%) achieved modified ARA remission. Mean 
duration of remission was 20.5 (range 6-48) months and the presence of RF and SE 
reduced the chances of remission in their cohort (118). It is interesting that in this 
thesis, although RF and SE showed independent predictive value for sustained 
DMARD-free remission, they were not of any prognostic significance for sustained 
DAS remission. This again confirms previous findings that other than disease 
characteristics and treatment effect, remission criteria may also influence the 
prognostic value of standard disease variables in RA.  
 
In a study by Molenaar et al, 187 patients with established RA who were in modified 
ARA remission were followed-up for 2 years. At the study start, only 59% and 81% 
of the patients fulfilled preliminary ARA and DAS remission criteria respectively and 
only 57% fulfilled both sets of criteria. At the end of 2 years, modified ARA 
remission persisted in 52% of patients and DAS remission persisted in 42% (243).  
 125 
Two large prospective early RA studies analysed influence of sex on disease course 
including remission, based on DAS28, over 2 and 5 years (283;285). Similar to this 
thesis, those studies also showed that the frequency and duration of remission was 
higher in men and in the later study, male sex, short disease duration, RF negativity, 
low DAS28 and HAQ at baseline were predictive of remission (285) 
 
In a French multi-centre, prospective study of early RA patients (n=191) with a mean 
disease duration of 3.3 months, frequency of DAS remission at year3, year5 and at 
both study points were 25%, 20% and 16% respectively. 80% of patients in remission 
at 3 years were also in remission at 5 years. In that study, baseline DAS, RAI and 
Sharp score showed independent predictive value for both point and sustained DAS 
remission (223), similar to this thesis findings.   
 
Several studies have compared different remission criteria. Prevoo et al studied the 
relationship of ARA remission criteria with DAS in their observational study of early 
RA (< 1 yr) and found that 37% fulfilled modified ARA remission criteria at least 
once and 21% on two consecutive visits. DAS of < 1.6 correlated with ARA criteria 
for remission in their study and SJC was the most influential factor in deciding 
remission (279).  
Makinen et al compared 3 sets of remission criteria in an inception cohort of early RA 
over 5 years. Frequency of clinical remission was 39%, 37% and 21% at 2 years, 5 
years and at both 2 and 5 years respectively. Among patients in clinical remission at 2 
years, remission persisted in less than 50% of patients at 5 years. 17% had modified 
ACR remission and 55% had radiographic remission (no new erosions or worsening 
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of erosions) at 5 years (119). These findings confirm that frequency of remission may 
vary depending upon the type of remission criteria.  
 
A comparative analysis of DMARD-free remission in ERAS patients with a similar 
inception cohort (EAC) in the Netherlands showed different remission rates but 
similar, but not identical predictive markers. In the EAC (study patients=454), 
frequency of DMARD-free remission was 15% compared to 9.4% in the ERAS (study 
patients=895), partially explained by the study design of EAC, which was likely to 
recruit milder RA. Baseline variables such as symptom duration, RF, shared epitope 
(SE) and radiographic damage showed predictive value for subsequent remission in 
both cohorts. Other features such as onset of symptoms, RAI and HAQ in the ERAS, 
but not in the EAC showed independent predictive value for DMARD-free remission. 
CRP and anti-CCP antibodies showed prognostic value for remission in the EAC, but 
these variables were not collected in the ERAS patients (293). Few studies have 
validated a set of prognostic markers generated in one cohort in a similar but 
independent cohort in this way. For uncommon outcomes and therefore small 
numbers like remission, this is a powerful tool, and sound evidence for reliability.  
 
A French cohort reported radiographic and functional progression during the period of 
sustained DAS remission (288). Although 5 out of 30 patients (16.7%) showed 
clinically meaningful x-ray progression, no significant radiographic damage 
progression was noted at group level during sustained DAS remission, consistent with 
findings from this thesis. There was a significant functional progression (HAQ) 
between the remission and non-remission groups at 3 and 5 years but no difference 
between 3 and 5 years in the French study.  
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However in this thesis, there was a significant difference between the study points 
within the DAS remission and non-remission groups in relation to radiological and 
functional progression, with the former group showing significantly less progression.  
Moreover, patients in sustained DAS remission had fewer requirements for supportive 
aids & major appliances and orthopaedic surgeries compared to non-remission group.  
Although, there were fewer deaths in patients in sustained DAS remission (15% vs 
23%), the difference was not statistically significant.   
 
The strengths of this study are large numbers of early RA patients with a long 
duration of follow-up. Details of work disability, orthopaedic surgery and mortality in 
relation to sustained remission in early RA, treated with traditional DMARDs, have 
not been reported in any of the previous observational studies. It is encouraging to see 
in this study of pre-biologic era that patients in sustained DAS remission maintained 
or improved their functional ability with fewer requirements for orthopaedic 
surgeries.    
 
Limitations of this study include possible patient selection effects. Observational 
studies involving only patients attending secondary care may not include patients who 
go into remission early and do not attend hospital (left censoring). In contrast, patients 
who died or became too unwell to continue to attend could not be included in analysis 
(right censoring). Secondly, DAS was recorded only annually and there is a 
possibility of disease exacerbations in between. However, patients were assessed 
clinically every 3 to 6 months as part of normal practice and no change in therapy was 
noted to suggest any flare-ups. 
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In conclusion, frequency of sustained remission can be much lower than point 
remission. Frequency of remission and prognostic value of baseline disease variables 
may vary depending upon the remission criteria used. In this early RA cohort, male 
sex, short duration of symptoms and low RAI at baseline showed significant 
predictive value for sustained DAS remission. Persistent clinical disease inactivity in 
the study cohort has had a positive impact on radiographic, functional and surgical 
outcomes. Therefore, remission induction and maintenance should both be considered 
as equally important and as ideal therapeutic targets to achieve better long-term 












































Disease progression in RA is usually assessed by standard clinical, laboratory and 
radiological measures. X-rays of hands and feet at regular intervals help to assess 
radiographic disease progression in RA. A number of scoring methods have been 
developed to quantify radiographic damage and the most commonly used methods are 
Larsen‟s and Sharp‟s and their modifications (150).  
 
The advantage of radiographic assessment using validated scoring systems is that the 
structural damage seen on x-rays is largely irreversible and it represents the 
cumulative measure of disease activity and disability (161). Also, quantification of x-
ray damage is an important outcome measure in RA, as it strongly correlates with key 
outcomes such as, function, work disability, surgery and use of health resources 
(7;231).  
 
Structural damage in RA is progressive and some prospective studies have shown that 
by 3 years from disease onset, 60-80% of patients developed joint erosions 
(68;88;92).  The relationship of x-ray damage with time is uncertain and different 
models of x-ray progression including flat, linear, square-root, first-order kinetics and 
sigmoid types, have been proposed, as described in chapter1 (90;100).    
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The relationship between clinical disease activity and radiographic damage can be 
inconsistent and unpredictable, particularly in early stages. It has been shown that the 
link between structural damage and disability is weak early in the disease course (< 5 
years duration), but is stronger late in the disease (107). This is because that in 
patients with early RA, persisting joint inflammation rather than structural damage 
accounts for functional disability or high HAQ scores (55;107).  
 
Nonetheless, there is only limited information from early RA observational studies on 
longitudinal radiographic progression and its relationship to clinical and functional 
measures in patients treated with traditional disease modifying anti-rheumatic drugs 
(DMARDs). Therefore, this study aimed to analyse the above in the ERAS cohort. 
 
4.2 Objectives 
1. To study the nature of radiological progression over 5 years in the ERAS 
cohort 
2. To analyse the correlation between radiographic progression and other 
standard measures of disease activity in early RA 
 
4.3 Patients and Methods 
Patients 
Only those ERAS patients who completed at least 5year follow-up and had serial x-
rays of hands and feet were included for this analysis (n=712).  172 (14%) patients 




9%), declined follow-up mainly for social and work related reasons
 
(19, 11%), 
patient reported remission (6, 4%) and lost to follow-up (71, 41%). A separate 
analysis of these excluded patients showed that baseline disease characteristics were 
similar to the study cohort except that mean age of disease onset and baseline disease 
activity were slightly higher in this group, as described in the previous reports (12).  
Study assessments 
Details on standard clinical, laboratory and functional assessments in the ERAS 
cohort have already been described in detail in the previous chapters.  
Radiographs of the hands and feet were performed at baseline, 1, 2, 3, and 5yrs and 
were digitized onto CD-ROM. The films were scored randomly using Larsen‟s 
method by a trained independent observer who was unaware of the clinical details 
including treatment. Intra-observer reliability was checked using ICC as described 
before (68;290).   
Treatment 
The study cohort was treated with standard DMARD therapy, either as sequential 
monotherapy or as combination therapy, as described in the earlier chapters and 
steroids were used in a small proportion of patients.                            
Statistics 
Statistical help for this research project was obtained from the Department of 
Mathematics, Keele University, Keele. Results are presented as summary statistics, 
which include median and inter quartile ranges, means with standard error & 
deviations, & 95% confidence intervals, where appropriate. The rates over all one 
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year periods were compared using the paired sample t-tests, with Bonferroni 
correction for multiple testing.  Pearson correlation was used to study the relationship 
of continuous variables. Independent groups were compared using independent 




















Table 4.1 Baseline disease characteristics of the study cohort  
Baseline variable Study cohort 
(n=712) 
Women  65% (462) 
Age of disease onset in years 53 (± 13.4) 
Duration of symptoms in months [Median (IQR)] 6 (4-11) 
Rheumatoid factor (RF) positive 62 % (442) 
Shared epitope (SE)  66% (405) 
Erosions 23% (163) 
Ritchie articular index (RAI) 12.4 (± 10.7) 
Swollen joint count (SJC) 17.2 (± 13.2) 
Erythrocyte sedimentation rate (ESR) 40.6 (± 28.6) 
Disease activity score (DAS) 4.1 (± 1.6) 
Health assessment questionnaire (HAQ) 1.0 (± 0.75) 
Larsen score        Mean (± SD) 
                            Median (IQR) 
3 (± 7.6) 
0 (0-3) 
Disease modifying anti-rheumatic drug (DMARD) 
use at 1yr   
72% (514) 
 
Values are expressed as mean (± SD) unless otherwise indicated  






Baseline demographics of this subgroup are similar to rest of the ERAS cohort and are 
typical of early RA patients. DMARDs were used in 72% (n=514, monotherapy 58%; 
combination therapy 14%) of patients at year1 and the respective figures at year3 and 
year5 follow-up were 81% (mono 51%; combi 30%) and 83% (mono 43%; combi 
40%). Median (IQR) time to start of first DMARD was 2 (0-4) months and  
sulphasalazine (SSZ) was the most frequently used first line DMARD followed by 
methotrexate (MTX). Steroids were used in 15% percentage of patients both at year3 
and 5 and majority of patients were treated with a prednisolone dose of  ≤ 7.5 mg/day.  
 
Radiographic progression   
At baseline, 248 (35%) had radiological evidence of joint damage, and by 5yrs this 
had risen to 519 (73%). Radiographic progression over 5 years is reported as mean or 
median change in Larsen score over time and is as follows: 
 
Table 4.2 Larsen score progression from year 1 to 5 
Larsen score Baseline Yr1 Yr2 Yr3 Yr5  
Mean (SD) 3.0 (7.6) 5.2 (10.1) 7.5 (12.1) 12.2 (16.2) 15 (19.7) 






Figure 4.1 Larsen score progression from 1 to 5 years    
  
Error Bars show  95.0% Cl of Mean
Dot/Lines show  Means





































Figure 4.1 shows that the rate of change in mean Larsen scores over the first 5yr of 
RA was approximately constant except for an accelerated phase between years 2 and 
3. Further analysis showed that the steeper (accelerated) curve seen in Larsen scores 
between years 2 and 3 was significantly different from years 0&1, 1&2, and 3&5 
(interpolation over 2yrs since x-rays were not performed at 4yrs).     
 
To assess whether the increased rate of change in the mean Larsen scores between 
year 2 and 3 apparent from the graph was significant, the change in Larsen score was 
calculated for each period (taking the mean yearly increase between the study points).  
The slope between years two and three was then tested against the other three slopes 
















Table 4.3 Radiographic progression between year 2 and 3 in comparison to other 












95% Confidence Interval 
















3.27317 9.43719 .35367 2.57880 3.96754 9.255 711 .000 
 
 
*slp23 – slp01 = difference in x-ray (Larsen score) progression between year2 to year3 and 
baseline to year1  
**slp23 – slp12 = difference in x-ray (Larsen score) progression between year2 to year3 and 
year1 to year2 
***slp23 – slp35 = difference in x-ray (Larsen score) progression between year2 to year3 and 









After multiplying each p-value by 3 ( Bonferroni correction for multiple testing ), it is 
obvious that the increase in Larsen score between year 2 and 3 is significantly greater 
that that between the other time points (P <0.01). 
 
 
Possible explanations for the accelerated x-ray progression between year 2 and 3 
 
1. Worsening disease activity at this time or possibly earlier (i.e. 1-2yrs from  
baseline) to allow for any effect of inflammatory activity to be reflected on x-
ray progression  
 
2. DMARD effects. Loss of or resistance to DMARD therapy, or temporary 
cessation due to drug toxicities, or inadequate dosage 
 
3. Disease heterogeneity: a radiological subtype of RA with a rapid progressive 
phase early in RA, not related to clinical disease or treatment 
 
4. X-ray scoring methodology – Random scoring of x-ray films, using Larsen 
method, could have contributed to the variation in x-ray progression.    
 
 
1. Is accelerated radiographic damage related to preceding disease activity? 
In contrast to x-ray progression, clinical and laboratory measures such as ESR, DAS 
& HAQ improved from baseline, stabilised, and then gradually deteriorated around 4-
5yrs as shown below.  
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Figure 4.2 Progression of erythrocyte sedimentation rate (ESR) over 5 years 
Error Bars show  95.0% Cl of Mean
Dot/Lines show  Means






















Figure 4.3 Progression of disease activity score (DAS) over 5 years 
 
Error Bars  show 95.0% Cl of  Mean
Dot/Lines show Means






















Figure 4.4 Progression of health assessment questionnaire (HAQ) over 5 years 
 
Error Bars show  95.0% Cl of Mean
Dot/Lines show  Means
































The above figures do not support an immediate time related effect of disease activity 
measures on the accelerated phase of radiological progression.  
In addition, associations between Larsen scores and HAQ, joint score, ESR, DAS at 
the same time points (0 to 5yrs) were very modest. Correlation between Larsen scores 









































Table 4.4 Correlation between Larsen score and other disease measures at 






 Other disease measures at baseline  





.070 .119 .044 .083 






at Year 1 
 Other disease measures at Year 1  





.177 .179 .023 .078 






at Year 2 
 Other disease measures at Year 2  





.198 .209 .156 .180 






at Year 3 
 Other disease measures at Year 3  





.195 .192 .105 .125 






at Year 5 
 Other disease measures at Year 5 





.200 .179 .121 .158 
p-value .000 .000 .002 .000 
  
HAQ = Health assessment questionnaire 
ESR = Erythrocyte sedimentation rate 




Pearson correlation coefficients never reached 0.3 (range 0.02 to 0.21). Changes in 
standard clinical measures do not appear to explain the accelerated phase in x-ray 
progression shown in Fig 4.1 
Having examined the association between Larsen score & disease activity measures 
at individual time points & found none, the possibility that the steeper Larsen scores 
between years 2 and 3 could be related to cumulative disease activity measures was 
then explored.  
Area under the curve (AUC) was calculated for DAS, HAQ, ESR & joint score 
between years 0-2. The correlations between these summary measures and the slope 
of the 2-3 year Larsen score were calculated, with only those of HAQ and ESR being 
statistically significant with coefficients of 0.13 and 0.16 respectively.  These appear 
to be too small to be clinically relevant and achieve statistical significance due to the 
large sample size.   
To investigate the possibility that the increased slope could be due to a delayed effect, 
mean DAS in years 0-1 and years 1-2 were calculated and correlated with the 2-3 
year slope for Larsen score.  This was only statistically significant for the 1-2 year 
correlation, but at 0.11 was not large enough to be of interest.  This analysis supports 
the conclusion drawn from the above graphs that the accelerated radiological 







2. Could the accelerated x-ray progression be due to treatment effect? 
Another possible explanation for the accelerated phase between 2 and 3 year could be 
suboptimal DMARD therapy leading to inadequate disease control. The time from 
onset of symptoms to presentation and from presentation to the initiation of the first 










































Figure 4.5 shows mean and 95% CI for Larsen scores over 5yrs in the 4 different drug 
groups 
 
Legend for Figure 4.5 
 
NSAIDS = patients treated with NSAIDs alone 
DMARDS ×1 = patients treated with one DMARD only 
DMARDS × 2 = patients who have had 2 DMARDs 









Error Bars  show 95.0% Cl of Mean
Dot/Lines  show Means



























































The rate and magnitude of x-ray progression was greater the more DMARDs were 
used, including the accelerated phase. The difference in the five-year Larsen scores 
when analysed between the drug groups was significant (ANOVA F=31.25 p <0.001).  
Similarly, the rate of x-ray progression as measured by calculating the slope of the 
regression line through the 0-5 year x-ray scores was also significantly different 





















Figure 4.6 Larsen score at year 3 (lar3) in 4 different treatment groups at 3 year 
follow-up (Drugs 3yrs) 
 
 
Legend for Figure 4.6 
NSAIDs = Patients treated with NSAIDs alone   
DMARD x 1 = Patients treated with one DMARD only  
DMARD x 2 = Patients who have had 2 DMARDS  
DMARD x 3 = Patients who have had 3 DMARDS  
 
Larsen scores are shown as median values (thick horizontal line) within quartile 
ranges (boxes) for each of 4 treatment groups by 3yrs. Whiskers (vertical lines) 
extend to values within 1.5 box lengths 
O indicates outliers (between 1.5 and 3 IQRs from top of box)  
* indicates extreme values (more than 3 IQRs from top of box) 
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Since clinicians base their decisions on the use of, and changes in, drug therapies 
mainly on disease activity measures, these were also compared to DMARD use. 
Similar to x-ray scores & drug therapy shown in above Figures 4.5 & 4.6, disease 
activity scores were worse the greater the number of DMARDs used. There was a 
significant difference in mean DAS over years 0-3 across the drug groups (F=3.82; 
p<0.05). Similar significant differences across the drug groups were seen for HAQ, 
ESR and joint scores.  
These findings imply that drug therapies were escalated in line with the severity of 
disease and were also related to radiological progression. The main exception to this 
was those patients who had marked x-ray changes by 3years, shown as Larsen scores 
greater than 75
th
 percentiles in Figure 4.6, but who had been treated with either none 
(n=25) or only one DMARD (n=86). This raises the question whether these patients 
were being under treated, and whether delayed therapy was responsible for the 
accelerated radiological progression. 
 
As previously shown in Fig 4.1 to 4.4, correlations between disease activity over 3yr 
and Larsen scores were low and this was consistent within each of the four drug 
therapy groups. Of the 25 patients with high Larsen scores not on DMARDs, 19 had 
low disease activity. 6 had DAS scores in the higher ranges (mean >3.0), and did not 
receive DMARDs because of either co morbidity (n=4), preference for steroid use (1) 
or patient choice (1). Of the 86 patients with marked x-ray progression treated with 1 
DMARD only over 3yrs (6 also on steroids), 40 had low DAS. The remaining 46 had 
DAS in higher ranges and 20 reported major problems with DMARD therapy: 6 had 
marked adverse events and 14 had problems with co morbidity.  
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These findings suggest that in terms of x-ray damage these patients were not treated 
optimally, but probably were treated appropriately based on clinical measures, 
individual patient responses and treatment practices of the 1980/90s era. The 
important finding was the small subgroup of 59 patients (19+40) in whom the marked 
x-ray progression was out of proportion to low disease activity. The details of the 
other patients who received more than 1 DMARD were reviewed for interrupted drug 
therapies and whether drug toxicity, poor compliance or co-morbidity were major 
factors. This was not the case as most drug terminations were due to lack or loss of 
effect.   
 
 
3. Disease heterogeneity as a possible reason for accelerated x-ray damage  
Rates of x-ray progression were compared to baseline features, including age of 














Table 4.5 Baseline features compared to Larsen scores at baseline and 5yrs 
            
 
            Larsen scores 
           __________________________________________________________ 
                                          Baseline     5yrs 
                                        _____________ _______________ 
                                         Mean     SD    Mean    SD 
           __________________________________________________________ 
           Total           712    100%   3.0     7.60   15.0    19.66 
 
            Gender 
           Men             250     35%   3.0     6.16   14.1    17.78 
           Women           462     65%   3.1     8.29   15.5    20.61 
 
            Age onset 
           <45             184     26%   1.9     4.93   15.7     8.05 
           45-60           295     41%   2.8     8.95   14.7    19.04 
           >60             233     33%   4.2     8.57   14.8    18.55 
 
            *RA symptoms  
           0-3             162     23%   2.3     4.13   13.5    17.13 
           4-6             197     28%   2.3     4.93   14.5    19.05 
           7-12            227     32%   2.7     6.26   14.2    19.01 
           13-24           126     18%   5.6    13.77   19.2    23.86 
 
            #Rheumatoid Factor 
           Neg             187     26%   2.0     4.01    9.3    14.01 
           -/+              82     12%   2.9     5.97   11.5    16.22 
            +              184     26%   2.9     5.64   17.6    21.14 
            ++             258     36%   3.9    10.61   18.4    21.91 
 
           __________________________________________________________            
  
 
* Rheumatoid arthritis (RA) symptom duration in months at the time of study entry  
# Rheumatoid factor test results at baseline 
 Neg = negative 
 -/+ = borderline positive 
 + = positive 







There was no significant difference in the mean 2-3 years slope between males and 
females (independent samples t-test) and no significant correlation of the mean 2-3 
year slope with age of onset or duration of RA symptoms to study entry. There were 
significant differences (ANOVA F=3.18; p<0.05) in the means of the 2-3 year slope 
in none, one or two copies of the DRB1 HLA shared epitope, although the difference 
in the means was fairly small at 3.41 (SD 7.1), 5.04 (8.1) and 5.51 (9.1) respectively. 
The higher the RF titre, the greater the rate of progression between 2 and 3year 
(ANOVA F=4.9; p<0.05). 
 
4. Could the  difference in x-ray progression be due to the scoring methodology? 
In order to determine whether Larsen‟s scoring method itself favoured different rates 
of progression according to site, rates of progression within each of the different 
domains of the Larsen score were analysed. Separate scores for metatarsal, metacarpal 
and proximal inter phalangeal and wrist joints all exhibited similar accelerated phases 
between 2-3yrs, most noticeable in the wrist.  
Possible influence of scoring methodology i.e. x-rays scoring method and scoring 
sequence of films, on longitudinal radiographic progression is discussed in detail in 




In this inception cohort of early RA, 248 patients (35%) already had radiological 
evidence of joint damage at baseline and this was 519 (73%) by 5 years.  The increase 
in radiographic damage, as measured by Larsen scores over the first 5yrs of disease, 
was constant except between years 2 and 3 without any clear explanation for this 
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accelerated phase. Correlations between radiographic damage and measures of 
disease activity and function at the same time points were weak. An important finding 
was a small subgroup of patients with marked x-ray progression, which was out of 
proportion to disease activity. 
  
The progression of joint damage with time in this cohort compares broadly with other 
published reports (7;69;88;90;92). Some of these studies have shown that 
radiographic damage is most rapid within the first 2yrs of disease (88;90;92). Could 
the accelerated phase of radiological progression in the ERAS cohort represent the 
slow/fast pattern as described previously? (90;100).  
 
The accelerated phase could reflect a delay between inflammatory activity early on 
before x-ray changes become apparent by years 2-3. A time lag between high disease 
activity and structural damage has been reported (268), but does not explain fully the 
accelerated phase at 2-3yrs.  Certainly, when compared to MRI and ultrasound, 
analysis of radiographs is relatively insensitive as there is a significant time-lag 
between the appearance of an erosion on MRI to subsequent change on plain film 
(101;102).  There are few studies of repeated MR scans in early RA, but one report 
on wrist changes showed that only one in four MRI erosions progressed to x-ray 
erosions over one year, possibly owing to healing, observer error or technical 
limitations of radiography at the wrist (103).  
 
Could this phenomenon therefore be a methodological problem where Larsen scoring 
of radiographs does not adequately demonstrate structural joint damage in years 1 & 
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2?  Larsen‟s method was used to score x-rays in the ERAS patients from the start of 
the study in 1988. However, since then SvdH method has been shown to be better 
than Larsen‟s in relation to its sensitivity to change and in detecting minimal 
clinically important difference (181;182). For greater objectivity, radiographic 
scoring of films was performed randomly in the ERAS. However, chronological 
scoring seems to be better than random reading in detecting radiological progression 
above measurement error (157). This is going to be discussed in detail in the next 
chapter.   
 
Variation in disease activity has been reported to affect radiological outcomes (245). 
This study results show that measures of disease activity and function (HAQ), and 
structural joint damage, as measured by Larsen, correlate weakly in early RA at the 
same time points.  The main reasons for this are firstly, local swelling and 
inflammation of joints rather than deformity are the main causes of disability in early 
disease and often in the presence of normal x-rays (55).   
Secondly, in contrast to x-ray scores, clinical scores were reversible and varied 
considerably with time in individuals particularly in early disease. Most clinical 
measures including HAQ characteristically improved from disease-onset, stabilised 
before a gradual deterioration with time, in contrast to radiographic scores, which 
increased progressively from onset.  This finding is entirely consistent with previous 
reports (7;12).  Later in disease, the correlation between structural damage and 
disability becomes stronger as joint deformity becomes more prominent and other 
factors such as reduced range of movement of small & large joints also contribute to 
overall disability (12;172;231).  
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Furthermore, HAQ at disease-onset is a poor predictor of radiographic outcome in the 
medium term (3 & 5 years) (55;68) but correlation is strengthened if HAQ at 1 year 
from onset is adopted as a predictor (68). Structural damage in early RA may be a 
surrogate marker for disability later in disease.  
 
An important finding was that marked radiological deterioration was out of 
proportion to disease activity in a small but important group of patients. Many of 
these patients‟ disease activity measures were low with appropriate treatment, yet x-
ray progression was marked. One explanation is possible difference in the 
pathogenesis between synovitis and erosions (254). Another could be the delay in 
detecting erosions with conventional radiography compared to US and MRI (102), 
especially early in RA when disease activity may be high.   
 
Might this accelerated phase be related in some way to drug therapy? This thesis has 
investigated the relationship between disease activity, DMARD therapy and 
radiographic change, and the possible effects of delay to or under use of DMARDs 
and time lost from drug withdrawal due to toxicity or co morbidity. The majority 
(80%) of ERAS patients were prescribed sulphasalazine (SSZ) as their first DMARD, 
with methotrexate (MTX) the most frequently used second drug (38%). This was 
common practice in the UK in the 1980/90s (12). Lack of efficacy was the 
commonest reason for discontinuation and only 10% due to toxicity.  
 
As with other DMARDs, the benefit of SSZ often wears off after an initial favourable 
response, a pharmacological characteristic termed „drug resistance‟.  It is possible 
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therefore, that accelerated joint damage in years 2-3 is a consequence of the 
resistance to SSZ developing in year 2 or before.  This concept is potentially 
important as it would indicate that timing of any change in drug therapy for RA may 
be critical in preventing subsequent joint damage. There were not enough patients in 
this study whose first drug was MTX to compare with SSZ.   
 
The strength of this study lies in the large number of patients studied and low drop 
out rates. A weakness, typical of longitudinal studies, is that measurements of clinical 
activity and x-rays are only performed yearly and do not coincide with initiation or 
changes in therapy. Possible sources of bias in this study are left or right censoring as 
described in the previous chapter and treatment effects.   
 
In summary, this study of early RA patients showed that radiographic progression 
was accelerated between year 2 and 3 and correlations with clinical, functional and 
laboratory measures at the same time points were only modest. A small, but 
significant proportion of patients developed marked x-ray damage in spite of low 
clinical disease activity. Although ultra sound & MRI are more sensitive to change, 
they are still not widely available in standard clinical settings. Only by performing 
yearly x-rays in early RA can clinicians identify the small subgroup of patients with 
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5. INFLUENCE OF SCORING METHODOLOGY ON 




Quantification of radiographic damage in rheumatoid arthritis (RA) is important to 
determine disease progression, treatment response and outcomes. Although several 
scoring methods are available, Larsen, Sharp and their modifications e.g. SvdH and 
SENS have been widely used for this purpose (150).  
 
The ability of a scoring method to detect a real change in radiographic progression 
over time is called sensitivity to change. In assessing longitudinal radiographic 
progression in RA, it is important to use a scoring method with high sensitivity to 
change and so better discriminative power. Methods such as smallest detectable 
difference (SDD) or change (SDC) have been used to assess the sensitivity to change 
of a particular scoring method (185;192).  
 
However, each of these methods has a different score range and so it would be 
difficult to directly compare the results in RA studies using absolute numbers and 
mean or median values alone.  SDD and its relation to minimal clinically important 
difference (MCID) have been used to compare different scoring methods (181). The 
lower the SDD value the higher the sensitivity of a scoring method in detecting 
radiographic progression that are considered clinically important.  
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SvdH method has shown to be superior to others in relation to its sensitivity to change 
and discriminative power in detecting MCID (182). Other methods such as linear 
transformation of scores from their original scale to a scale of 0 to 100 and percentage 
or mean percentage of the maximum possible score have also been suggested to make 
direct comparisons between scoring methods (185;189). 
 
Serial x-rays of hands and feet can be read in random (single film at a time), paired 
(films read without known sequence) and chronological order (serial films read with 
known sequence) (160). Although each of this scoring sequence has its own 
advantages and disadvantages, chronological reading of x-ray films has shown to 
have increased sensitivity to change in detecting radiographic progression over time 
(157).  
 
As described in the previous chapter, radiographic progression in the ERAS cohort 
was accelerated between 2 and 3 years from disease presentation without any 
correlation to other disease specific measures. Therefore, this thesis wanted to explore 
whether the scoring methodology i.e. scoring method and reading order of the films, 
has had any influence on the nature of radiographic progression in the ERAS cohort.  
 
This study also wanted to compare Larsen, SvdH and SENS methods in a subgroup of 
the ERAS patients to see if there was any significant difference between them in 






1. To compare random and chronological scoring of x-rays using Larsen method 
in a subset of early RA patients from the ERAS cohort.  
2. To analyse radiographic progression using Larsen, SvdH and SENS scoring 




5.3 Patients and Methods 
The analysis was carried out in three steps in three different subgroups of the ERAS 
patients as follows: 1. Random versus Chronological order of x-ray scoring using 
Larsen method (n=62); 2. Larsen versus SvdH (n=38); and 3. Larsen versus SvdH 
versus SENS methods (n=278) 
 
Patients 
The study sample for each of these analyses was randomly selected from the ERAS 
cohort, as long as patients had completed 5 year follow-up and had serial x-rays of 
hands and feet available from baseline up to 5 years.   
 
Radiographic assessment 
X-rays of hands and feet of the study population were done at baseline, 1, 2, 3 and 5 
years as described in the previous chapters. All serial x-rays of the ERAS patients 
were digitized onto CD-ROM and scored by an independent observer (CS), using 
Larsen method in random order.  
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For this study, observer KJ has scored serial x-rays of a selected group of patients 
using Larsen method in chronological order. Observer KJ has also used SVDH and 
SENS methods to analyse radiographic progression in a subgroup of patients and 
compared it with Larsen scores from the ERAS database. As described earlier, 
observer KJ had received adequate hands-on training and supervision from 
experienced readers in all three scoring methods before scoring the x-rays for the 
study patients and was unaware of the clinical details including treatment and 
previous Larsen scores from observer CS, whilst reading x-rays. 
 
After scoring all the study films using different methods or reading order, the x-ray 
scores were then entered on to the ERAS database by the ERAS coordinator. The x-
ray data were then merged together with other clinical details for further analysis. 
 
Comparison of scoring methods 
Direct comparisons between the scoring methods were made using summary 
statistics. Other methods such as SDD and mean percentage of maximum possible 
score (mean % MPS) have also been used to analyse and report radiographic data, 
based on different scoring methods.   
 
Statistical analysis 
Statistical help for this project was obtained from Maastricht University Hospital, 
Maastricht, Netherlands. Summary statistics using mean (SD) and median (IQR) 
values were used to compare the x-ray data at group level, whereas SDD was used to 
compare radiographic data at individual level in the study population and was 
calculated as follows: 
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SDD = ± 1.96 x SDdifference / √ k 
 
SDdifference  is the standard deviation of difference between two readings and k 
represents the number of readings or observers used for the actual analyses of a trial. 
 
For this study, SDD for Larsen and SvdH methods were 4 and 5 respectively. 
Reliability of scoring techniques was tested by inter and intra observer variability 
using intraclass correlation coefficients (ICC) and Bland Altman scatter plot graphs. 
 
5.4 Results 
Reliability test results 
Intraclass correlation coefficient (ICC) values* 
 
Larsen method (Global score) 
   Inter observer reliability = 0.96 
   Intra observer reliability = 0.95 
SvdH method: Erosion score  
  Inter observer reliability = 0.88 
   Intra observer reliability = 0.95 
SvdH method: Narrowing score 
  Inter observer reliability = 0.88 
   Intra observer reliability = 0.97 
SvdH method: Total score 
  Inter observer reliability = 0.81 
   Intra observer reliability = 0.97 
 
* Maximum score for ICC is 1, indicating perfect reliability and higher the ICC 




Bland and Altman graphs  
 








































SvdH score – Intra observer reliability 
 






Figure 5.4 Narrowing score 
 
 165 




In figures 5.1 to 5.5, difference of the observers‟ scores (y axis) is plotted against the 
mean of the observers‟ scores (x axis). This is to reveal whether there is a systematic 
difference between either two observers (inter) or two readings from the same 
observer (intra). The ideal situation would be for all points to be situated on or close 
to y = 0. These figures show that the scatter plots are close to reference line y = 0, 









Analysis 1: Random versus chronological scoring of x-rays using Larsen method 
 
Baseline disease characteristics of the study group are shown in the table below, 
which are similar to the rest of the ERAS cohort. 
 
 
Table 5.1 Baseline disease characteristics (n=62) 
Women 43 (69%) 
Age of disease onset (years) 52.7 (13) 
Duration of symptoms (months) 8.7 (6) 
Rheumatoid factor (RF) positive 45 (73%) 
Erosions 25 (40%) 
Erythrocyte sedimentation rate (ESR) 46.7 (32.8) 
Disease activity score (DAS) 3.8  1.5) 
Health assessment questionnaire (HAQ) 1.0 (0.7) 
Disease modifying anti-rheumatic drugs 



















Baseline Year 1 Year 2 Year 3 Year 5 
Random  Mean (SD) 4.0 (7.6) 12.5 (12.1) 18.9 (15.5) 33.5 (12.0) 38.1(17.6) 
Median 
(IQR) 
0.5 (0-4) 10 (2-17) 18 (5-30) 31 (23-40) 38 (28-48) 
Chronological  Mean (SD) 3.7 (6.0) 8.8 (8.8) 13.4 (12.4) 18.8 (14.1) 27.8 (17.3) 
Median 
(IQR) 





























SE = Standard error, TSX = Larsen score  
FUPXR = Follow-up years 
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SE = Standard error, TS = Larsen score 
FUPXR = Follow-up years 
 






























Radiographic progression using Larsen score in random order by observer CS and in 
chronological order by observer KJ are shown in table 5.2 and figures 5.6, 5.7 and 
5.8. As shown in the above figures, chronological reading of x-rays did not show 




Analysis 2: Radiographic progression using Larsen and Sharp-van der Heijde 
(SvdH) methods 
Baseline demographics of this subgroup was also similar to the rest of the ERAS 
cohort and is shown in the table below 
 
Table 5.3 Baseline disease characteristics (n=38) 
Women 26 (68%) 
Age of disease onset (years) 54.2 (12.8) 
Duration of symptoms (months) 9.1 (6.3) 
Rheumatoid factor (RF) positive 27 (71%) 
Erythrocyte sedimentation rate (ESR) 45.8 (35.2) 
Disease activity score (DAS) 3.6 (1.4) 
Health assessment questionnaire (HAQ) 1.0 (0.7) 
Disease modifying anti-rheumatic drugs 
(DMARDs) at year 1 
                  
26 (68%) 
 








Table 5.4 X-ray progression based on Larsen and SvdH methods  
 
 












































































































Radiographic progression, based on Larsen method (chronological reading) 
 


























Radiographic progression based on SvdH method (chronological reading) at 0, 1, 
2, 3 and 5 year follow-ups (FUP) 
 















































































































Radiographic progression between 1 and 5 years from disease presentation is shown 
in table 5.4 as well as in figures 5.9 to 5.12. Both Larsen and SvdH scoring methods 
showed fairly constant yearly rate of radiographic progression, based on 
chronological reading, over 5 years in this cohort. 
 
Radiographic progression, based on Larsen and SvdH methods was analysed at 
individual level using SDD, which was 4 for Larsen and 5 for SvdH in this study. This 
means that patients with a change in Larsen score of > 4 between baseline and year5 
were described as having significant x-ray progression i.e. progression above 
measurement error, whereas in the SvdH method, significant x-ray progression was 
defined as an increase in total score of > 5 between the study points.  
According to Larsen method, 35 out of 38 patients (92%) showed significant x-ray 
progression and the corresponding figure for SvdH was 37 (97%). 3 out of 37 patients 
(8%), who showed clinically relevant radiological progression on SvdH method failed 












Analysis 3: Radiographic progression using Larsen, Sharp-van der Heijde 
(SvdH) and Simplified Erosion Narrowing Score (SENS) methods 
Table 5.5 Baseline disease characteristics (n=278) 
Women 178 (64%) 
Age of disease onset (years) 52.7 (13.9) 
Duration of symptoms (months) 8.0 (5.9) 
Rheumatoid factor (RF) positive 164 (59%) 
Erythrocyte sedimentation rate (ESR) 37.9 (26.5) 
Disease activity score (DAS) 3.9 (1.5) 
Health assessment questionnaire (HAQ) 1.0 (0.7) 
Disease modifying anti-rheumatic drugs (DMARDs) at 
year1  
191 (69%)                                                  
 









Mean ( SD) 
Median (IQR) 
% of  MPS 
Year1 
Mean ( SD) 
Median (IQR) 
% of  MPS 
Year2 
Mean ( SD) 
Median (IQR) 
% of  MPS 
Year3 
Mean ( SD) 
Median (IQR) 
% of  MPS 
Year5 
Mean (2 SD) 
Median (IQR) 














































































































The above tables and figures show that radiographic progression at group level was 
essentially linear between baseline and 5 years using SvdH and SENS (chronological 
scoring) methods. However, using Larsen‟s method and random scoring, x-ray 
progression was not uniformly linear but exhibited an accelerated phase between 
year2 and year3. This latter finding was expected and described in the previous 
chapter, but in a larger number of patients in the ERAS cohort. This could be related 
to the scoring methodology, as this phase of accelerated progression between year 2 
and 3 was not seen with SvdH method nor with chronological reading of x-rays in a 
subgroup of patients using the same Larsen method.  
 
According to Larsen method, 21% of patients (n=59) had erosions at baseline, which 
progressed to 65% (n=182) at the end of 5 years. However, using SvdH and SENS 
methods, the frequency of erosive disease was slightly higher both at baseline (32%; 
n=85 out of 263) and at 5 years (71%; n=191 out of 270).  
 
5.5 Discussion 
This study has shown that radiological progression at group level was constant and 
linear from baseline up to 5 years, despite using three different scoring methods, as 
long as the x-ray films were read in chronological order. Nonetheless, a subgroup 
analysis showed that x-ray progression between year 2 and 3, based on random and 
chronological reading was different even though the same Larsen scoring method was 
used. This could either be due to difference in scoring order of the films or due to 
variability in scoring techniques by observers CS and KJ. 
  
 181 
It has been suggested that reading films randomly can introduce measurement error, as 
the reader will not be able to correct for variation in positioning of hands and films or 
for the quality of the films (160). Also, with the random reading, there is a possibility 
of introducing measurement error by limiting the information to the reader, that the 
signal is lost in the noise (signal-to-noise ratio). On the other hand, chronological 
reading has increased sensitivity and more discriminative power in detecting x-ray 
progression that is clinically meaningful, although an overestimated progression of 
joint damage by the readers (expectation bias) can‟t be ruled out (157).  
 
Observer KJ was trained in the Larsen method by observer CS and inter observer 
reliability between CS and KJ using ICC was very close to 1 (0.96), indicating good 
reliability between the readers. However, it has been shown that in patients with high 
disease activity and/or with higher radiographic damage, inter observer agreement can 
be unreliable (149). Therefore, it is difficult to say that the difference in x-ray 
progression between random and chronological reading in this study is entirely due to 
scoring order of the films.   
 
Larsen, SvdH and SENS are the most commonly used scoring methods and they all 
have their own strengths and limitations. The advantage of Larsen score is that an 
experienced reader can perform it quickly, whereas SvdH method is more time 
consuming (180). However, inclusion of soft tissue swelling in the Larsen‟s score may 
lead to a relatively high score at baseline, decreasing with response to treatment. This 
may reduce the total possible increased score due to progressive damage, contributing 
to low sensitivity to change (149).  
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On the other hand, SENS method, a simplified version of SvdH, is a quick and reliable 
technique, which can be practised in the day-to-day clinical setting as well.  Previous 
studies have compared Larsen, SvdH and SENS scoring methods in RA patients with 
conflicting results. In general, SvdH method seems to be superior to others in relation 
to its sensitivity to change and discriminative power in detecting x-ray progression that 
is considered clinically meaningful by clinicians (181;182).  
 
In this study, x-ray progression at group level was essentially linear during the study 
period using three different scoring methods, but there were differences with Larsen 
between year2 and 3. Furthermore, at individual level, SvdH and SENS methods 
showed that more patients had erosive disease at baseline (32% vs 21%) and at 5 years 
(71% vs 65%) compared to Larsen method. This may be due to the difference between 
individual scoring methods or due to measurement error between the readers. Usually 
inconsistency between readers and scoring methods is greater in late disease than early 
RA, because of the difficulty in scoring advanced changes (149). Adequate training in a 
particular scoring method is very important for the readers as the quality and 
consistency of the observers are considered to be more important than the actual 
method used on analysing radiographic progression (149).  
 
Also, the validation of a scoring method relies on the reproducibility in terms of inter 
and intra observer reliability, which was very good in this study with ICC values closer 
to 1. However, wide range of x-ray scores can influence the ICC results with extreme 
values having the greatest effect. In contrast, Bland and Altman‟s scatter plot graph is 
not affected by values at extreme range and in this study it showed good inter and intra 
observer reliability. Therefore, difference in scoring methodology rather than 
 183 
measurement error is the more likely explanation for the observed variation in x-ray 
progression in this study cohort. 
 
As far as is known, these three scoring methods have not been analysed together in 
relation to their sensitivity to detect significant x-ray progression over 5 years in early 
RA patients, treated in routine outpatient clinics. Also, the influence of scoring order of 
the films on measuring structural damage progression in early RA has not been 
reported before.  
 
This study, however, has some limitations. One of them is that different subgroup 
analyses were performed with relatively less number of patients and so the results may 
lack statistical power. Also, direct comparisons between different scoring order of the 
films or various scoring methods can be complex and difficult, particularly if different 
observers were involved.  
 
In conclusion, progression of structural damage on x-rays appeared to be similar in 
this study cohort, although different scoring methods were used. However, the type of 
radiographic progression based on random and chronological reading of x-rays was 
different, despite using the same scoring method. SvdH and SENS methods revealed 
higher frequency of erosive disease compared to Larsen method. SvdH method in 
chronological order showed better discriminative power in detecting significant x-ray 
progression in this study. Therefore, apart from disease characteristics and treatment 
effect, scoring methodology may also have an influence on radiographic progression 
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6. PROGRESSION OF X-RAY DAMAGE DESPITE REMISSION 
IN EARLY RHEUMATOID ARTHRITIS 
 
6.1 Background 
The ultimate goal of treatment in rheumatoid arthritis (RA) is remission as early as 
possible to avoid structural damage and to improve outcomes (74). Several studies 
have shown that structural damage on x-rays does not progress significantly in 
patients with clinically inactive disease compared to active disease (7;80;239). 
However, it has also been demonstrated that radiographic damage in RA can progress 
despite clinical remission and various reasons have been suggested to explain this 
dissociation, including difference in pathogenesis between joint inflammation and 
destruction (243;254;288).  
 
There is only limited information from previous early RA studies on longitudinal x-
ray progression during persistent clinical remission. A majority of the clinical studies 
or drug intervention trials usually report x-ray progression using mean or median 
radiographic scores from validated scoring systems. However, this type of traditional 
analysis would not reveal the true nature of structural damage progression on x-rays at 
individual level, particularly in patients with low or inactive disease.  
 
Methods such as smallest detectable difference (SDD) or change (SDC) have been 
suggested as reliable measures in clinical trials, to detect clinically meaningful 
radiographic progression at individual level, i.e. progression above measurement error 
(185;192). However, only very few prospective studies have analysed x-ray 
progression in RA using SDD or SDC during clinical remission and these studies 
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have shown that significant radiographic progression including new erosions could 
occur despite clinically inactive disease (243;288). Also, as described in chapter 4, 
previous analysis of x-ray progression in the ERAS cohort showed that a small 
proportion of patients had significant structural damage progression in spite of low 
clinical disease activity.   
 
This study therefore aimed to analyse radiographic progression in detail in early RA 
patients, who were in sustained remission based on DAS (sustained DAS remission).  
Prognostic factors for radiological progression despite sustained DAS remission and 






1.  To study radiological disease progression over 3 years, at group as well as 
at individual level, in early RA patients during sustained DAS remission 
2.  To analyse baseline predictive factors for radiographic progression despite 
sustained DAS remission in early RA 
3.  To assess if there is any difference in outcomes between patients in DAS 






6.3 Patients and Methods  
 
Patients 
For the purpose of this study, only those ERAS patients who have had their DAS 
recorded at 1, 2 and 3 year follow-ups were included (n=1003). A separate analysis of 
patients who could not complete at least 3 year follow-ups due to various reasons 
(moved  (n=11, 8 %); unable to attend (n=2, 1 %); declined (n=3, 2 %); patient 
reported remission (n=3, 2 %); deceased (n=116, 79 %); discharged (n=1); not known 
(n=4, 3 %); not traced (n=6, 4 %) were excluded from this study. A separate analysis 
of these patients (n=146) showed that mean age of disease onset (62 vs. 54, p<0.001) 
and disease activity score (DAS) were slightly higher (4.5 vs. 4.2, p <0.05) in this 
group at baseline.  
 
Study assessments 
Patients were assessed at 0, 3, 6 and 12 months and then annually. Standard clinical 
assessments including blood tests were recorded at each study visit as described 
earlier. X-rays of hands and feet were performed at baseline and then yearly during 
the study period. The films were scored using Larsen method (total score 0 – 200) in 
random order by an independent observer and the intra-observer variability was 
checked using intraclass correlation coefficient (> 0.85) as described in the previous 
chapters.  
Outcome measures including HAQ, Steinbrocker‟s functional grade (FG I-IV), work 
disability and surgery were recorded at the 3
rd





Remission in the study cohort was assessed using the original 3-variable DAS, based 
on EULAR criteria, as described in chapter 3. Sustained DAS remission in this study 






 year follow-ups. 
 
Radiographic progression 
Progression of structural damage on hands and feet x-rays of the study cohort was 
assessed in detail, both at group and at individual level. Radiographic progression at 
group level was assessed and reported using mean and median Larsen scores, whereas 
at individual level, clinically meaningful x-ray progression or progression above 
measurement error was calculated using SDD, as described in the earlier chapters.  
SDD for this study was calculated by scoring twice a random sample of 20 pairs of 
hands and feet radiographs, representative of the study population and it was ≥ 4.  
Also, frequency of erosive disease or new erosions in patients in sustained clinical 
remission was analysed.  
 
Prognostic factors and outcomes 
Prognostic value of baseline variables to predict progressive x-ray damage in patients 
in persistent DAS remission was studied. Various outcomes at 3 years were analysed 
in patients in sustained DAS remission to see if there was any difference in outcomes 







The study cohort was treated with standard DMARDS as described previously using 
sequential monotherapy or combination therapy and/or steroids. None of the patients 
received biological agents as the study was in the pre-biologic era.   
 
Statistical analysis 
Summary statistics have been used to characterise the data. Continuous variables were 
expressed as either mean ± standard deviation (SD) or median with interquartile 
ranges (IQR) and categorical variables were shown as counts with percentages. Chi 
square (χ2) for categorical and Mann Whitney U for continuous variables were used to 
compare the study groups. Wilcoxon signed rank test was used to test the difference 
in disease outcome between the study points within individual groups. Spearman‟s 
correlation coefficient was used to assess the strength of association between various 
clinical indices and x-ray scores at different study points.  
 
Univariate analysis using odds ratios (OR) and multiple logistic regression, using the 
stepwise procedure were performed to study predictive factors for radiological 
progression. Variables used for the multivariate model were chosen from the 










Table 6.1 Baseline demographics of the study cohort 
Baseline variable Whole study 
cohort (n=1003) 
Persistent 
remission at yr 




Women 65% (655) 53% (48) 67% (607) < 0.01 
Age of disease onset 
(years) 
54 (± 14.2) 53 (± 15.3) 54 (± 14.1) 0.36 
Duration of symptoms 
(months) 
8.2 ( ±  6) 7.2 (± 5.7) 8.3 (± 6) < 0.05 
RF positive 63 % (633) 62% (56) 64% (577) 0.81 
Shared epitope  55% (550) 48% (43) 55% (507) 0.69 
Erosions (Larsen 
score ≥ 2) 
26% (259) 24% (22) 26% (237) 0.80 
RAI 13.2 (± 11.2) 7.2 (± 7.2) 13.8 (± 11.4) < 0.01 
SJC 17.1 (± 13.1) 12.7 (± 11.5) 17.6 (± 13.2) < 0.01 
ESR 42.2 (±  28.9) 39.5 (± 28.1) 42.5 (±  29) 0.34 
DAS 4.2 (± 1.6) 3.4 (± 1.4) 4.3 (± 1.6) < 0.01 
HAQ 1.1 (± 0.7) 0.8 (± 0.7) 1.1 (± 0.7) < 0.01 
Larsen  
    Mean (± SD) 
    Median (IQR) 
 
4.3 (± 10) 
0 (0-4) 
 
2.8 (± 6.7) 
0 (0-2.5) 
 




DMARD use at 1year 
 




Values are expressed as mean (± SD) unless otherwise indicated  
 % (count) 
 
RF = Rheumatoid factor, RAI = Ritchie articular index 
SJC = Swollen joint count, ESR = Erythrocyte sedimentation rate 
DAS = Disease activity score, HAQ = Health assessment questionnaire 
DMARD = Disease modifying anti-rheumatic drug 
 
Baseline disease characteristics of whole of the study population as well as the 
individual study groups are shown in table 6.1 
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DAS remission 
90 out of 1003 patients (9%) were found to be in sustained DAS remission at 1, 2 and 
3 years although more patients achieved remission at individual time points (yr 1 = 
21%; yr 2 = 25%; yr 3 = 23%). Out of 209 patients who were in remission at yr 1, 
63% (n=132) remained in remission at year 2 and 43% (n=90) remained in remission 
at both yr 2 and 3.  
DMARD use in the remission group was 70% (mono=66%, combi=4%) at yr1 and 
72% (mono=68%, combi=4%) at year 3. DMARDs, either as mono or combination 
therapy were used more frequently in the non-remission group and the difference was 
significant at year 3 (83% vs 72%; p < 0.001). In both groups, median time to the start 
of first DMARD was 2 months and SSZ was the most commonly used DMARD 
followed by MTX.  Mean DMARD use in remission group was 0.77 (range 0-2) at the 
end of 3 years and in the non-remission group it was 1.3 (range 0-6). Although more 
patients received oral steroids in the non-remission group (16% vs. 9%), the 













Figure 6.1 Radiological progression (Larsen) in relation to cumulative clinical 
disease activity 
 


























Legend for figure 6.1 
LAR0 = Larsen score at baseline 
LAR1 = Larsen score at year 1 
LAR2 = Larsen score at year 2 
LAR3 = Larsen score at year 3 
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Figure 6.1 shows that structural damage on hands and feet x-rays has progressed in 
both groups during the study period but it was relatively less in patients with 
persistent DAS remission. In the remission group, median Larsen score progressed 
from 0 to 2 (mean 2.8 → 6.6; p <0.001) between baseline and yr 3, whereas in the  
non-remission group, it increased from 0 to 10 (mean 4.5 →16.5; p <0.001). 
 
Radiographic progression was also analysed at individual level in patients who had 
serial x-rays throughout the study period [remission = 78 (87%); non- remission= 719 
(79%)]. 17 out of 78 patients (22%) in the remission group showed radiographic 
progression above SDD (≥ 4) i.e. an increase in Larsen score of ≥ 4 during the study 
period, and the corresponding figure in the non-remission group was 363 (50%).  
Amongst patients showing significant x-ray progression, a majority of them did so 
between yr 2 and 3 (82% and 64% in the remission and non-remission groups 
respectively). Although only 17 out of 78 patients (22%) showed Larsen score 
progression of ≥ 4 (above SDD) during the study period, 19 patients (24%) actually 
developed new erosions during this time, (2 pts at yr 2, 16 pts at yr 3 and one patient 
at both time points) and 5 (26%) of them were DMARD naïve.  
 
Radiographic progression despite DAS remission 
Patients in DAS remission who had serial x-rays (n=78) throughout the study period 
were divided into two subgroups, based on SDD, for further analysis:  
Group1 = DAS remission without significant x-ray progression (n=61)  




Table 6.2 Baseline disease characteristics in Group1 (DAS remission without 
significant x-ray progression and Group2 (DAS remission with significant x-ray 
progression) 
 
Baseline variable Group1 (n=61) Group2 (n=17) p-value 
 
Women 64% (39) 24% (4) < 0.01 
 
Age of disease onset (years) 52.4 (± 15.3) 51.9 (± 14.1) 0.87 
Duration of symptoms 
(months) 
6.6 (± 5.1) 8.1 (± 6.2) 0.43 
RF positive 61% (37) 59% (10) 0.89 
Erosions 18% (11) 47% (8) < 0.05 
ESR 37.3 (± 23.9) 46.8 (± 36) 0.53 
DAS 3.4 (± 1.5) 3.4 (± 1.2) 0.78 
HAQ 0.90 (± 0.75) 0.88 (± 0.78) 0.97 
Larsen [Median (IQR)] 0 (0-1.75) 3 (0-15)    - 
 
Values are expressed as mean (± SD) unless otherwise indicated  
 % (count) 
 
RF = Rheumatoid factor 
ESR = Erythrocyte sedimentation rate 
DAS = Disease activity score 








Baseline disease characteristics of patients in persistent remission with or without x-
ray progression are shown in the above table. There were fewer women and more 
patients with erosive disease at baseline in Group2 who went onto have x-ray 
progression despite clinical remission. 
 
There was no significant difference in the DMARD use between Groups 1 and 2 at 
yr1 (67% vs 71%; p=0.95), and by 3 years 71% of patients were on DMARDs in both 
groups. SSZ was the most frequently used first line DMARD in both groups and there 
was no significant difference in the time to initiate first DMARD between the two 

















Fig 6.2 Scatter plots showing change in Larsen scores from yr1 (lar1) to yr3 




X-axis = Larsen score at year 1 
Y-axis = Larsen score at year 3 
Reference line indicates smallest detectable difference (SDD) for this study 
 
Circles on or above the reference line are patients who had increase in their Larsen 
score of ≥ 4 (significant x-ray progression) between year 1 and 3 (n=17), whereas 
circles below the reference line indicate patients with a change in Larsen score of < 4 
(non- significant x-ray progression) during the study period (n=61). 
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Predictive factors for x-ray progression despite DAS remission  
 




            Univariate                     Multivariate  
OR 95% CI OR  95% CI p-value 
Men 5.7 1.6 – 19.8 5.3 1.4 - 20 < 0.05 
Erosive disease 4.0 1.2 – 12.8 1.5 0.3 – 9.1 0.67 
Larsen score  5.0 1.5 – 15.9 3.3 0.6 - 20 0.18 
Age of onset 0.7 0.2 – 2.3    
Duration of symptoms 1.3 0.4 – 4.0    
RF  0.9 0.3 – 2.7    
Shared epitope  0.7 0.1 – 2.5    
ESR 1.0 0.3 – 2.9    
DAS 1.9 0.2 – 17.0    
HAQ 1.1 0.3 – 3.5    
DMARD by 1 year 1.0 0.3 – 3.5    
 
OR = Odds ratio, CI = Confidence interval 
 
RF = Rheumatoid factor 
ESR = Erythrocyte sedimentation rate 
DAS = Disease activity score 
HAQ = Health assessment questionnaire 





Men, erosive disease and Larsen score at baseline showed prognostic value for 
subsequent x-ray progression in this study. However, only male sex showed 
independent predictive value for radiographic progression despite sustained DAS 
remission and other variables including age of onset, duration of symptoms, RF and 
























Table 6.4 Outcomes at 3 years in Groups 1 & 2 in relation to x-ray progression  
Disease 
groups 
Erosions Larsen score 
Median (IQR) 
HAQ 
Mean ( SD) 

























































* p-value based on chi-square (categorical variables) and Mann Whitney tests (HAQ) 
 
DAS = Disease activity score 
HAQ = Health assessment questionnaire 







Figure 6.3 Functional (Health assessment questionnaire/HAQ) progression in 


































Legend for figure 6.3 
HAQ 0yr = HAQ score at baseline 
HAQ 1yr = HAQ score at year 1 
HAQ 2yr = HAQ score at year 2 








In Group1 (DAS remission without significant x-ray progression), 41% had erosive 
disease at 3 years and median Larsen score increased from 0 to 1 (mean 1.2 → 2.6; 
p<0.005) during the study period. However, in Group2 (DAS remission with 
significant x-ray progression), 76% had erosive disease at 3 years and median Larsen 
score progressed from 4 to 16.5 (mean: 5.9 → 21.5; p<0.005) between the study 
points.  
Further attempts to explore the correlation between Larsen scores and various clinical 
and laboratory disease indices in Group 2 did not explain the dissociation between 
clinical and x-ray progression in this group. 
 
HAQ score was not significantly different between Groups 1 and 2 at yr-3 (0.16 vs 
0.04; p=0.44) and both groups were very similar in their functional ability. Also, there 
was no significant difference in other outcomes such as extra-articular disease, work 
disability and orthopaedic surgery between the two sub-groups, although there was a 
marked difference in radiographic progression. 
 
6.5 Discussion 
The results of this study are consistent with previous reports that sustained remission 
is less frequent than remission at individual study points and structural damage can 
progress despite clinically inactive disease (243;254).  Although several studies have 
looked at the frequency of remission in early RA, there is only limited information 
from prospective studies about longitudinal radiographic progression during sustained 
remission. The results so far have been conflicting, as some studies have shown 
reduced radiographic progression in patients with clinically inactive disease (80;239), 
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whereas in other studies significant x-ray damage progression was noted despite  
remission (243;288).  
In a study by Molenaar et al, 187 RA patients (median disease duration 7 years) who 
were in modified ARA remission for at least 6 months were followed-up for 2 years 
(243). Remission persisted in 52% of patients at 2 years and clinically relevant 
radiographic progression despite remission (above SDD) was noted in 7%. DAS area 
under the curve (AUC) was a stronger predictor of radiographic progression than was 
the absence of persistent remission and 15% of patients developed new erosions 
despite disease inactivity. 
 
In a French, multi-centre, prospective study of early RA patients (n=191), frequency 
of DAS remission at year3, year5 and at both study points were 25%, 20% and 16% 
respectively (223;288). Radiological damage progression at group level was not 
significant during sustained remission. However at individual level, 5 out of 30 
patients (16.7%) showed x-ray progression above SDD and 20% developed new 
erosions.  
 
In the ERAS cohort, 22% showed significant x-ray progression despite DAS 
remission (above SDD) and 24% developed new erosions. Male sex and baseline x-
ray damage showed predictive value for subsequent radiographic progression despite 
DAS remission. In this cohort, Larsen method was used to assess x-ray progression as 
opposed to above two studies, which used SvdH method.  Furthermore, x-rays were 
scored in random order in the ERAS cohort, as was in the study by Molenaar et al, 
whereas in the French study the films were scored in chronological order. As 
described in the previous chapter, apart from disease characteristics, scoring 
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methodology in these studies could have influenced the different results observed in 
these cohorts. Nonetheless, all these studies including the ERAS have shown that the 
total number of patients who had developed new erosions during the study was 
actually higher than those reported to show significant radiographic progression 
(above SDD). Therefore, although SDD can be used to show x-ray progression above 
measurement error, there is a chance that patients below the SDD cutoff may still 
have clinically significant progressive disease.   
 
There may be other explanations for progressive x-ray damage despite remission, and 
these include: 1) residual tender or swollen joint counts despite fulfilling DAS or 
DAS 28 remission criteria because of the weighting in the formulas (264-266); 2) lag 
time between clinical disease activity and the appearance of erosions on x-rays 
(268;269); 3) presence of sub-clinical synovitis in apparently normal looking joints, 
shown up only on US or MRI (270). 
 
Brown et al studied radiological progression in RA patients in clinical remission using 
x-rays, US and MRI. At 12 months, a majority of patients in clinical remission 
showed evidence of inflammation on US and MRI (289).  Radiographic progression 
in this cohort was analysed using SDC and 16% of patients with asymptomatic joints 
(no pain, swelling or tenderness) showed significant x-ray progression and the 
respective figures in the ACR and DAS 28 remission groups were 11% and 12%. 
Baseline predictors for subsequent x-ray progression in this study were positive power 
Doppler (PD) signal (OR 12.2) and synovial hypertrophy (OR 2.3) on US and 
presence of synovitis (OR 2.9) on MRI.  
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Other possible reason for radiographic progression despite inactive disease could be 
treatment effect, as discussed in chapter 4. Only 72% of the study patients in clinical 
remission were on DMARDs by 3 years and out of them 4% received combination 
therapy. Also, SSZ was the most common DMARD in this study and it has been 
shown that SSZ as monotherapy may be less effective in reducing joint damage (232). 
None of the study patients received biological agents and it has been shown that these 
novel agents could reduce radiographic progression independent of clinical 
improvement (247). It may be due to the inhibitory effect of anti-TNF on osteoclast 
induced bone resorption, independent of clinical disease activity, mediated via 
specific molecules such as receptor activator of nuclear factor kappa β ligand 
(RANKL) and osteoprotegerin (248).  
 
The advantage of this study is that it was observational and patients were managed in 
a „real life setting‟ with traditional DMARDs. Also, it is the first to report on baseline 
disease variables, particularly male sex, as predictors of progressive structural damage 
despite DAS remission in early RA.  
One of the study limitations, as described earlier, is that the assessments were made 
annually and so possibility of disease exacerbations in between the study assessments. 
Nonetheless, patients were reviewed in the clinic every 3 to 6 months and there was 
no evidence of disease flares that required treatment change.  
    
In conclusion, this study showed that significant x-ray damage could still occur during 
sustained DAS remission. Gender and radiographic status of the disease at baseline 
may have a prognostic value in determining subsequent radiographic progression in 
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patients in sustained DAS remission. Patients in persistent DAS remission had better 
outcomes despite differences in radiographic progression.  
X-rays of hands and feet at regular intervals in early RA may prove to be crucial in 
monitoring disease progression, even in patients with clinically inactive disease. This 
in turn might influence the treatment decisions and may have an impact on long-term 
outcomes. Further long-term randomised studies may be of more prognostic value in 














































The natural course of rheumatoid arthritis (RA) can be variable and unpredictable in 
many patients.  Although the most common disease course is chronic and progressive, 
it can vary or fluctuate depending upon the patients‟ or disease characteristics and 
treatment effect (5;6). The level of clinical disease activity at a given time point or 
over a period of time can be graded as remission, low, moderate and high using the 
disease activity scores (DAS & DAS28), based on EULAR criteria (79;84)  
 
Active RA is usually associated with progressive x-ray damage, which is monitored 
by x-rays of hands and feet at regular intervals. Structural damage seen on x-rays is 
quantified by various scoring methods and they are considered as vital outcome 
measures in most of the RA clinical trials (87;149;222). Although several scoring 
methods have been developed over the years, Larsen, Sharp and their modifications 
e.g. Sharp-van der Heijde method (SvdH) are the most commonly used (181-184;186-
188). 
 
Patients with active disease often develop progressive decline in their functional 
ability and this is usually assessed by patient self-reported health assessment 
questionnaires (HAQ) (124). Other measures that have been used to assess functional 
disability include Steinbrocker‟s functional grade (FG I-IV) and grip strength 
(12;124).     
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Outcomes in RA can either be due to the disease itself (disease specific) or due to the 
consequence of the disease (non-disease specific). Remission, radiographic damage, 
functional disability and orthopaedic surgeries are examples for disease specific 
outcomes, whereas work disability, costs and mortality reflect non-disease specific 
outcomes. There is an overwhelming evidence to suggest that high disease activity and 
radiological damage is associated with poor outcomes including deformity, disability, 
high socioeconomic and other health care costs (12;114;115).  
 
Several studies have already reported on disease progression and outcomes in RA. 
However, there is only limited information on the inter-relationship between clinical, 
functional and radiological disease progression over the first 5 years in early RA 
patients, treated with traditional disease modifying anti rheumatic drugs (DMARDs). 
Also, as far as is known, long-term outcomes in early RA patients who have persistent 
low disease or remission for as long as 5 years in the pre-biologic era has not been 
reported before. 
 
Therefore, this study aimed to analyse the clinical and radiological disease 
progression (Larsen score) over 5 years in this early RA cohort and to examine the 
link between disease activity and radiological damage. This study also aimed to 
analyse long-term outcomes, both disease and non-disease specific, in the ERAS 
cohort in relation to cumulative clinical disease activity.   
 
Furthermore, as part of this study, a subgroup analysis of radiological progression in 
patients in sustained DAS remission from year1 to year5, using SvdH method in 
chronological order, was also carried out. This is because of the earlier findings 
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described in chapter 6. It showed that around one fifth of ERAS patients in sustained 
DAS remission from year1 to year3 developed significant x-ray progression, using 
Larsen method in random order, with no worsening of 3-year functional outcomes. 
However, previous studies have shown that both Larsen method and random reading 
of x-rays may not be as sensitive as SvdH and chronological scoring, to detect 
clinically meaningful radiographic progression i.e. progression above measurement 
error (157;160;161;181-184;186-188). Therefore, it was the intention of this thesis to 
analyse longitudinal x-ray progression, using SvdH method in chronological order, in 
a subgroup of ERAS patients who were in sustained DAS remission for as long as 5 





 1. To study clinical, functional and radiological disease progression over 5  
   years in the ERAS cohort  
 2. To evaluate long-term outcomes in relation to cumulative disease activity 
3. To analyse radiographic progression, using SvdH method in chronological 
order, in a subgroup of patients who were in persistent DAS remission from 







7.3 Patients and Methods 
Patients 
For the purpose of this study, only those ERAS patients who have completed at least 5 
year follow-up and have had their annual DAS recorded between baseline and year5 
were selected (n=653). A total of 304 patients failed to complete 5 year follow- up 
due to various reasons as follows: attends another hospital (n=7; 2%), moved (n=25; 
8%), unable to attend (n=3; 1%), declined (n=18; 6%), patient reported remission 
(n=9; 3%), deceased (n=195; 64%), discharged (n=1), not known (n=20; 7%) and not 
traced (n=26%; 9%).  
A separate analysis of this patients who were excluded from the study showed that 
baseline disease characteristics were similar to the study cohort except that mean age 
of disease onset (60 vs 54; p <0.001) and clinical disease activity (DAS 4.5 vs 4.2; p 
<0.05) were slightly higher at study entry in this group.   
 
Clinical assessment 
Details of patient recruitment and study assessments for the ERAS have already been 
described in detail in the previous chapters. Standard assessments including age of 
onset, disease duration, ACR diagnostic criteria, swollen joint count (SJC), Ritchie 
articular index (RAI), erythrocyte sedimentation rate (ESR), IgM RF, HLA-DRß 
shared epitope (SE) status and extra-articular disease were recorded at baseline and 
then at regular intervals.  
 
Clinical disease activity in the study cohort was assessed using the original 3-variable 
as described earlier (141) and disease activity was graded as remission, low, moderate 
or high, based on DAS, using the EULAR response criteria (79) 
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.   DAS < 1.60   - remission 
  DAS ≥1.60 and ≤ 2.40 - low disease activity 
  DAS >2.40 and ≤ 3.70 - moderate disease activity 
  DAS> 3.70   - high disease activity 
 
For the purpose of this analysis, study patients were grouped as persistent low disease, 











 year follow-ups. Patients who had DAS ≤ 2.40 at all the 
study points were classified as persistent low disease and patients with DAS of > 2.40 
through out the study period were grouped as persistent moderate or high disease and 
the remaining patients with variable DAS were named as fluctuating disease group.  
 
A further subgroup analysis of patients in the persistent low disease group, who had 
DAS < 1.6 at all the study points (persistent DAS remission), was also carried out to 
explore radiographic progression using SvdH method and prognostic factors. 
 
Radiographic assessment 
 X-rays of hands and feet were done at baseline and then at 1, 2, 3 and 5 years. Details 
of storage of films on CD-ROM and scoring of x-rays using Larsen method (total 
score 0 – 200) in random order by an independent observer (CS) have already been 
described.  
X-ray scoring methodology for the subgroup analysis 
As a subgroup analysis, observer KJ has scored radiographic progression in patients 
in persistent DAS remission, using Sharp van der Heijde (SvdH) method in 
chronological order. This is because previous analyses in this thesis showed that 
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SvdH method in chronological order is more sensitivity in detecting radiographic 
progression at individual level. The films were retrieved by the ERAS coordinator 
from the original database and observer KJ was unaware of the clinical details 
including treatment and Larsen scores by observer CS, whilst reading the x-rays. 
Serial x-rays of ERAS patients with different levels of disease activity were also 
randomly selected and mixed together with x-rays of persistent remission subgroup to 
avoid expectation bias for the reader and to make the analysis valid.   
 
Functional assessment 
Functional ability of the ERAS patients was assessed at the time of study entry and 
then at regular intervals using Steinbrocker‟s functional grade and HAQ as described 
in the earlier chapters. 
 
Other outcome assessments 
Outcome measures other than clinical, radiological and functional assessments were 
also recorded at baseline, 3 and 5 years. This included job status, allowances, use of 
standard aids and appliances such as splints, walking aids and major adaptations 
(wheel chair, stair lifts, hoists). All types of orthopaedic surgeries were also recorded 
and other details including co-morbidities and mortality were also recorded.  
 
Treatment 
The study cohort‟s treatment profile was similar to the rest of the ERAS cohort. 
Patients were treated with standard DMARD therapy either as sequential monotherpy 
or as step-up combination therapy depending upon the disease severity and 
physician‟s choice. Steroids were used in a small proportion of patients. 
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Statistical analysis 
Summary statistics have been used to demonstrate the differences in clinical and 
laboratory features with disease outcomes. Continuous variables were expressed as 
either mean with standard deviation (SD) or median with interquartile ranges (IQR) 
and categorical variables were shown as counts with percentages.  Chi square (
 χ2) for 
categorical variables and Mann Whitney U (MWU) or Kruskal-Wallis H (KWH) for 
non-parametric and ANOVA for parametric data were used to compare the study 
groups.    
 
Radiographic progression at group level was analysed using summary statistics and 
absolute scores, whereas at individual level smallest detectable difference (SDD) was 
used to detect significant x-ray progression i.e. progression above measurement error 
(185). SDD for SvdH method in this study was calculated as described in the previous 
chapters and the values are as follows: SDD for erosion = 3; narrowing = 4; and total 
score = 5. 
 
Univariate analysis using odds ratios (OR) and multiple logistic regression, using 
stepwise procedure were performed to study prognostic factors for radiological 
progression. Variables used for the multivariate model were chosen from the 








Baseline disease characteristics of the whole study cohort as well as the individual 
study groups are shown below. 
 




(n = 653) 
Low disease 
(n = 101) 
Mod/High 
disease 
(n = 222) 
Fluctuating 
disease 
(n = 330)  
Women * 428 (65%) 52 (52%) 170 (77%) 206 (62%) 
Age of onset 
(years) 
54 ( 13.7) 54 ( 14.2) 57 ( 13.2) 52 ( 13.6) 
Disease duration  
(months) # 
7 (4-12) 5 (3-8) 7 (4-12) 7 (4-12) 
RF positive * 425 (65%) 61 (61%) 138 (62%) 226 (69%) 
SE positive* 372 (71%) 51 (67%) 137 (72%) 184 (71%) 
Erosions * 173 (27%) 25 (25%) 66 (30%) 82 (25%) 
DAS 4.2 ( 1.6) 3.4 ( 1.4) 4.9 ( 1.6) 3.9 ( 1.4) 
HAQ 1.0 ( 0.7) 0.8 ( 0.7) 1.3 ( 0.7) 0.9 ( 0.7) 
Larsen # 0 (0-4) 0 (0-2) 0.5 (0-5) 0 (0-4) 
DMARDs by 1 
year * 
492 (75%) 69 (68%) 181 (82%) 242 (73%) 
Extra-articular 
disease* 
116 (18%) 17 (17%) 46 (21%) 53 (16%) 
 
Values are expressed as mean (± SD) unless otherwise indicated 
*Count (%), # Median (IQR) 
 
RF = Rheumatoid factor, SE = Shared epitope,                                                                      
DAS = Disease activity score, HAQ = Health assessment questionnaire                      
DMARDs = Disease modifying anti-rheumatic drugs 
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Table 7.1 shows that patients who went on to have persistently low disease had less  
disease activity (DAS) and low disability score (HAQ) at baseline with better 




DMARDs were used less frequently in patients low disease (Group1) compared to 
patients with moderate/high disease (Group2) or fluctuating disease (Group3) at all 
time points.  DMARD use at year 3 was: Group1 = 71% (monotherapy 60%; 
combination therapy 11%), Group2 = 92% (mono 42%; combi 50%), Group3 = 82% 
(56%; combi 26%); p <0.001 and at year 5: Group1 = 72% (mono 58%; combi 14%), 
Group2 = 93% (mono 28%; combi 65%), Group3 = 85% (mono 45%; combi 40%); p 
<0.001. Steroids were used in 11%, 19% and 14% of patients in Groups1, 2 and 3 
respectively at 5 years (p =0.10). 
 
Sulphasalazine (SSZ) was the most frequently used first line DMARD in all three 
groups (Gr1 = 82%, Gr2 = 80%, Gr3 = 80%; p =0.90) and methotrexate (MTX) was 
the most common second line DMARD (Gr1 = 59%, Gr2 = 52%, Gr3 = 50%; p 








Clinical disease progression 
Cumulative clinical disease activity during the study period is shown below. 
Table 7.2 Clinical disease progression based on DAS 
 
Disease activity 

























































X-ray progression between baseline and year 5 is shown in table 7.3 and fig 7.1 
 
Table 7.3 Radiographic progression in relation to clinical disease activity 
 
Disease activity 




























   3 (0-7) 
Mod/High (Gr2) 






































































Legend for figure 7.1 
LAR0 = Larsen score at baseline 
LAR1 = Larsen score at year 1 
LAR2 = Larsen score at year 2 
LAR3 = Larsen score at year 3 






It is clear from the above tables and graphs that patients with persistently high or 
fluctuating disease activity showed increased x-ray damage progression, compared to 






Table 7.4 Functional (HAQ) progression in relation to clinical disease activity 
 
Disease activity 























































Figure 7.2 Health assessment questionnaire (HAQ) progression between baseline 

































Legend for figure 7.2 
HAQ 0yr = HAQ score at baseline 
HAQ 1yr = HAQ score at year 1 
HAQ 2yr = HAQ score at year 2 
HAQ 3yr = HAQ score at year 3 
HAQ 4yr = HAQ score at year 4 






The above table and figure show that baseline HAQ scores were relatively lower in 
patients with persistently low disease, which then subsequently improved over the 
next 5 years. In patients with fluctuating disease, mean HAQ score has improved from 
baseline to year1, then stabilised until year2 after which, it showed gradual, but 
continued deterioration over the next 3 years. Patients in the active disease group had 
higher HAQ scores at the study start with little improvement over the next year and 





















Long-term outcomes were assessed at the end of 5 years in the study groups in 
relation to their preceding cumulative clinical disease activity.  







(Larsen > 10) 
Functional 
disability        
(FG III & IV)  
















































FG = Functional grade, HAQ = Health assessment questionnaire 
 





































































The above tables show that patients with persistent low disease had better outcomes at 






1. Radiographic progression, using SvdH method in chronological order, in 
patients in persistent DAS remission from year 1 to year 5 
2. Prognostic factors and outcomes in relation to radiological progression in 
patients in persistent DAS remission 
 
A total of 37 patients from Group1 (persistent low disease), who had DAS < 1.6 at all 
the study points i.e. year1, 2, 3, 4 and 5 (persistent DAS remission) were analysed 
separately to study radiographic progression, prognostic factors and outcomes.  
This subgroup analysis, to some extent, was similar to the methodology described 
previously in chapter 6. However in chapter 6, Larsen method in random order was 
used to study radiographic progression during sustained remission and the study 
duration was for 3 years. In this subgroup analysis though, SvdH method in 
chronological order was used to assess x-ray progression during sustained remission 
and the study period was extended up to 5 years.   
 
Radiographic progression 
Structural damage progression on x-rays from year1 to year 5 in patients in persistent 
DAS remission was measured using SvdH method in chronological order. X-ray 
progression was analysed both in terms of absolute scores and clinically meaningful 
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change, using smallest detectable difference (SDD = 5). 19 patients did not have 
erosions at year1and 13 of them remained non-erosive at 5 years.  
Although, 28 out of 35 patients (80%; 2 missing) showed an increase in total SvdH 
score of ≥ 1 between the study start and end points, only 15 of them (43%) showed 
clinically meaningful x-ray progression i.e. increase in SvdH score of > 5 (SDD) 
between the study points. In those 15 patients with significant x-ray progression, only 




In order to analyse outcomes and prognostic factors, the patients (n=35) were further 
subdivided into two groups, based on radiographic progression using SDD, Group1: 
DAS remission without significant x-ray progression (n=20) and Group 2: DAS 













Baseline disease characteristics of this subgroup of patients are as shown below. 
 
Table 7.7 Baseline demographics 
 
 




DAS remission with     
significant x-ray 
progression           
(n=15) 
p-value 
Women 14 (70%) 5 (33%) < 0.05 





6 (4-10.75) 6 (3-7) 0.38 
RF positive 9 (45%) 12 (80%) <0.05 
SE positive 9 (64%) 9 (75%) 0.68 
Erosions 4 (20%) 4 (27%) 0.70 
ESR* 39 (24) 47 (22) 0.41 
DAS* 3.3 (1.3) 4.2 (1.3) 0.07 





1.5 (0-5.5) 6 (0.5-10.5) 0.08 
 
 
 Values are expressed as count with percentages unless specified otherwise   




RF = Rheumatoid factor, SE = Shared epitope 
ESR = Erythrocyte sedimentation rate 
DAS = Disease activity score 
HAQ = Health assessment questionnaire 
SvdH = Sharp-van der Heijde score 
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Both groups were similar except that in patients with DAS remission but x-ray 
progression, there were more men with higher age of disease onset and more RF 
positivity at baseline.  
 
There was no significant difference in DMARD use between the two groups, both at 
study start and at the end (both at year1 & year5 = 55% vs 87%, p =0.06) as was the 


















Prognostic factors for radiographic progression despite DAS remission: 
Predictive value of baseline variables for subsequent x-ray progression in patients in 
persistent DAS remission was tested using univariate and multivariate analyses. 
 
 
Table 7.8 Univariate analysis 
Baseline variable Odds ratio (OR) 95% CI 
Men 4.7  1.1 - 19.6 
Rheumatoid factor (RF)  4.9 1.0 - 22.8 
Shared epitope (SE)  1.7 0.3 – 9.1 
Erosive disease 1.5 0.3 – 7.0 
Sharp-van der Heijde (SvdH) score > 5 4.8  1.1 – 21.7 
 
 
Male sex, RF and SvdH score at baseline showed significant predictive value for 
radiographic progression despite persistent DAS remission on univariate analysis. 
However, none of the baseline variables showed any prognostic value on multivariate 









Long-term outcomes at 5 years in patients in persistent DAS remission in relation to 
their x-ray progression were analysed. There was no significant difference in 
functional disability between the two groups at 5 years (mean HAQ 0.0 vs 0.1; p 
=0.69), but more patients stopped working by 5years in the DAS remission with x-ray 
progression group (20% vs 5%; p <0.05). Use of allowances was not significantly 
different between the two groups (n = 0 vs 2; p =0.22) and none of the patients in 




This study results confirm previous findings that clinical disease activity is directly 
related to subsequent radiographic progression and long-term outcomes (55;57;69). It 
also showed that sustained disease inactivity is more important than intermittent 
remission or low disease state at individual time points as the former group achieved 
better outcomes.  
 
Patients with persistent disease activity were treated with DMARDs more frequently 
than patients with low or inactive disease and this was an expected finding as 
clinicians usually make their treatment decisions depending upon the disease severity. 
Nonetheless, there was no significant difference in the choice of first line DMARD 
(SSZ) or the time to initiate first DMARD (median 2 months) in either of these 
groups. Therefore in general, this study cohort was treated with standard DMARD 
regime that was widely prevalent during that period of pre-biologic era in the UK i.e. 
between 1988 and 1998 (12). 
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Although several studies have reported on disease progression and outcomes in RA, 
there is only limited information on early RA patients who had persistent low disease 
and treated with traditional DMARDs in a „real-life setting‟ like ERAS. Patients with 
fluctuating disease activity showed significant x-ray damage progression and poor 
outcomes compared to persistent low disease, emphasizing the benefits of sustained 
disease control.  
 
Previous studies have shown that time-integrated measures of disease activity such as, 
area under the curve (AUC) for DAS and acute phase reactants correlate with 
radiological progression and treatments that control these measures lead to significant 
reduction in radiographic progression (138-140;242-244). Others, however, argued 
that time-averaged estimates for disease activity do not reflect individual variability 
within patients.  
Welsing et al, studied the longitudinal relationship between disease activity and 
radiologic progression in two different early RA cohorts with a maximum follow-up 
of 9 years, by using a special regression technique called generalized estimating 
equations (GEE). They found that radiologic progression was not linear in individual 
patients and fluctuations in clinical disease activity (mean interval DAS and SD of the 
mean interval DAS) were directly related to changes in radiographic progression 
(245). Few other studies also confirmed that radiographic progression may be highly 
variable at individual level, particularly in early RA, although it is approximately 
linear at group level (90;100).  
 
Functional disability can be labile in early RA with individual variation between 
patients, but it generally increases with disease duration at a fairly constant rate 
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(6;107). Patients in this study, who had fluctuating or persistent clinical disease 
activity showed continued worsening of the HAQ scores with progressive functional 
disability, particularly between year2 and year5.   
 
Functional status of an individual is an important determinant of his or her 
employment and it is a good predictor of future work disability (56;57;109). 
Functional impairment due to active RA is associated with increased rates of work 
disability and has shown to be important predictor of employment outcome (56).  
This study results show that persistent or fluctuating disease activity is associated with 
worse outcomes including increased work disability, higher frequency of extra-
articular disease, more requirements for orthopaedic surgery and excess mortality 
compared to patients with sustained low or inactive disease throughout the study 
period.  
It is reassuring to see that better outcomes can be achieved even in routine outpatient 
clinics with less aggressive use of DMARDs, as long as the disease is persistently low 
or inactive for a prolonged period. Several clinical trials, using various treatment 
strategies including biological agents, have demonstrated that more the improvement 
in disease activity less the joint damage and better the outcomes (233;234;236-241).  
Therefore, the ultimate goal of treatment in RA should be to control the inflammation 
as much as possible and to avoid structural damage in order to improve functional as 
well as socioeconomic outcomes.  
 
Subgroup analyses in this study showed that nearly half of patients (43%) in persistent 
DAS remission developed significant x-ray progression (above SDD), based on SvdH 
method.  However, clinically meaningful x-ray progression in patients in sustained 
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DAS remission appeared to be mainly due to JSN rather than new erosions in this 
study.  
 
Other studies have also reported on significant x-ray progression despite clinical 
remission (243;288;289). However, no studies have looked at sustained remission in 
early RA for as long as 5 years and analysed prognostic value of baseline clinical 
variables for subsequent x-ray damage like this thesis. It is interesting to see that a 
previous analysis of sustained DAS remission between year1 and year3, as part of this 
thesis, also showed that male sex and baseline radiographic scores were predictive of 
x-ray progression.  
 
None of the study patients with persistent low disease or remission received 
aggressive combination therapy or biological agents. This may partly explain the 
radiographic progression unrelated to clinical disease activity in this group, as 
previous studies using biological agents have shown that structural damage on x-rays 
could halt or improve even without significant clinical improvement, due to their 
novel mechanisms of action (247;248). 
 
Functional ability of patients in persistent DAS remission with or without x-ray 
progression appeared to be good in this study cohort. Frequency of work disability 
was slightly more in patients in DAS remission with x-ray progression compared to 
those without x-ray progression, but the patient numbers were too small (3 vs 1) to 
derive any meaningful conclusion. Otherwise there was no difference in any other 
outcomes. However, long-term follow-up with large number of patients may be 
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required to analyse functional outcomes as the correlation between x-ray damage and 
HAQ is stronger late in the disease i.e. > 5 years after disease onset (107).  
 
As far as is known, this thesis is the first to report on baseline disease variables, 
particularly male sex, as predictors of progressive structural damage despite DAS 
remission in early RA. However, a possible limiting factor is the low statistical power 
of the study as there were only few numbers of patients in each subgroup, limiting 
robust statistical analysis and so the results need to be validated in large cohorts. 
 
In conclusion, this study confirms that persistent low disease state is associated with 
reduced radiographic progression. Furthermore, patients with sustained clinical 
disease inactivity achieved better functional, surgical and other long-term outcomes, 
compared to patients with fluctuating or relapsing-remitting disease activity.  
Male sex, RF and x-ray scores at baseline may have predictive value on subsequent x-
ray progression in patients in persistent DAS remission. Sustained DAS remission in 
the study cohort had led to better functional outcomes at 5 years, although some of 

































8. GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
Early diagnosis is crucial in the management of RA, a prerequisite for timely 
intervention with targeted treatment strategies in order to achieve better outcomes.  
The concept of a „window of opportunity‟ has promoted the development of early 
arthritis clinics to initiate appropriate management early in the disease.  
 
Disease progression and outcomes in RA can be assessed in different ways and the 
important aspects from patients and physicians‟ perspective are clinical, radiological 
and functional. Various standard measures have been introduced over the years to 
assess disease activity in RA and they have been widely used in clinical trials as well 
as in outpatient clinics. Over the last few decades, several clinical studies have been 
designed to examine the natural course of early RA, using validated measures, outside 
clinical trial settings. These longitudinal observational studies of inception cohorts 
provide valuable information on the natural (treated) history of early RA, outcomes 
and prognostic factors. The rationale for inception cohort studies with long-term 
follow-up in RA is that they reflect „true-to-life‟ patient management in ordinary 
clinical settings, and if well designed, they can provide vital information on clinical 
effectiveness of RA management and often complement the results of randomised 
controlled trials (RCTs) (294).  
 
The Early Rheumatoid Arthritis Study (ERAS) is an observational cohort of early RA 
and more than 1000 patients have now completed 5-year follow-ups. The ERAS 
inception cohort provides an ideal opportunity to study the natural disease 
progression, outcomes and prognostic factors in early RA. A number of reports have 
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already been published by the ERAS group on various outcomes and prognostic 
factors including radiographic damage, functional disability, orthopaedic surgery and 
mortality (9;12;68;99;295;296).  
 
This thesis aimed to study both disease activity and radiological disease progression 
over 5 years in the ERAS cohort, and to examine the relationship between the two. 
There is only limited information on sustained remission in early RA, how this affects 
outcome, and prognostic factors for this.  
 
Several drug trials using intensive treatment regime involving aggressive combination 
therapy with or without steroids and biological agents have shown higher frequency 
of remission ranging between 30 and 65%. However, observational cohorts, where 
conventional DMARDS have been used according to their physicians‟ choice in a 
routine clinical setting, have reported lower rates of remission varying between 7 and 
30% depending upon the disease characteristics, remission criteria and treatment used 
(292).  
 
In a study by Wolfe et al, 458 patients with at least 3 consecutive clinic visits were 
analysed to study remission using ARA criteria (116). A majority of the study patients 
had established disease (median disease duration > 7 years) and only 27% had disease 
duration of <1 years at study entry. 18% of the patients achieved ARA remission and 
only 15% of these remissions lasted for more than 24 months. Median duration of 
remission was 10 months. In another observational study of 227 early RA patients 
(disease duration < 1 year) with a median follow-up of 4 years (range 1-6 years), 25% 
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achieved modified ARA remission at one visit and only 15% on two consecutive 
visits (279).       
  
A prospective, longitudinal study of 142 early RA patients (< 2years) with a mean 
follow-up of 6 years, treated according to „saw tooth‟ strategy using traditional 





 year and at last visit respectively. However, only 19% were 
in remission both at 2
nd
 year and at last visit (238). In another prospective study of 
191 early RA patients (< 1 year) with a maximum follow-up of 5 years, remission 
rates based on DAS (<1.6) were 25% and 20% at 3 and 5 years respectively. 
Nonetheless, only 15.7% maintained remission at both time points (223).  
 
Makinen et al, reported 39% and 37% of clinical remission at 2 and 5 years 
respectively in their inception cohort of 111 early RA (median disease duration 5 
months). Nevertheless, only 21% achieved remission at both 2 and 5 years (119).  
In another multicenter, observational study of early RA patients (< 1 year) with a 
maximum follow-up of 5 years, frequency of point and period remission was assessed 
using DAS 28 criteria (< 2.6). Although, 34 to 38% of patients in this cohort achieved 
remission at individual time points (18, 24 and 60 months), only around 20 % 
maintained remission at all time points (285).  
 
Mierau et al analysed frequency or remission using modified ACR, DAS 28, 
simplified disease activity index (SDAI ≤ 3.3) and clinical disease activity index 
(CDAI ≤ 2.8) in 621 RA patients with established disease (mean disease duration 10 
years) in a routine clinical practice. In that study, frequency of point remission was 
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43% and 34% based on DAS 28 and SDAI & CDAI respectively. However, only 20% 
(DAS 28) and 17% (SDAI & CDAI) achieved sustained remission (297). In a similar 
clinical cohort of 115 patients, but with early disease (< 2 years), although 34 patients 
achieved DAS 28 remission at one time point, only 5 patients maintained remission at 
multiple study points (287).  
 
This thesis has shown that, although about one fourth of the study patients fulfilled 
DAS remission criteria at individual time points (21 to 26%), only around 10% were 
in sustained remission for at least three consecutive annual visits. Among those 
patients who were in DAS remission at any given time point (point remission), 
disease inactivity persisted (period remission) for 12 months in around 60% and for 
24 months in 40% of patients. These findings confirm previous reports that period 
remission is less frequent than point remission in RA.  
 
A number of early RA studies have analysed prognostic factors for remission and they 
showed that the predictive value of baseline disease variables for subsequent 
remission could be variable and inconsistent. However, some baseline features such 
as male sex, low joint count or disease activity and low HAQ have consistently shown 
good prognostic value for remission in many observational cohorts 
(12;80;223;279;281;285;287).  
 
Studies have shown that male patients with RA have less severe disease and higher 
chances of remission. This gender difference in RA can partly be explained by 
hormonal differences as the disease activity usually improves during pregnancy and in 
a majority of patients it can flare up after delivery (298).  Studies have also shown the 
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beneficial effects of oral contraceptives and hormone replacement therapy on disease 
activity (299;300) and oestrogen seems to have a positive impact on the immune 
system by down-regulating inflammatory immune responses and up-regulating 
immunoglobulin production (301).  
 
It has been argued recently that the positive predictive value of male sex for remission 
may in fact be due to a possible gender difference in reporting tender joint count 
(TJC) and global health (GH), as women apparently tend to report these symptoms 
more (302;303). This is supported by findings from Makinen et al, that the difference 
in disease activity in relation to sex difference was more pronounced in patients with 
0 or 1 swollen joint count (SJC) compared to patients with > 1 SJC and this was 
because of relatively higher TJC and GH scores in women compared to men, 
particularly in patients with low disease activity (302).  
 
It has also been suggested that the type of remission criteria used may influence the 
frequency of remission, in relation to gender difference (302;303). This is because 
DAS and DAS28 do not have separate ESR values for men and women like ARA 
criteria, and the normal range for ESR tends to be higher in women. Also, ESR and 
GH may have more influence on the total disease activity score based on DAS and 
DAS28, because of the weighting in the formulae. 
 
Makinen and colleagues have recently reported that women had higher mean ESR 
values compared to men in their cohort, although CRP levels were the same in both 
sexes. Although men appeared to have higher frequency of DAS28 remission in their 
study, ARA criteria did not show any gender difference in the remission rate (302).   
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In this thesis a subgroup analysis was carried out of prognostic factors in patients with 
0 or 1 SJC compared to patients with > 1 SJC. The predictive value of male sex for 
sustained DAS remission remained the same in the ERAS cohort despite different 
subgroup analyses. In a previous analysis of the ERAS cohort (n=732) using more 
stringent ARA criteria, remission was reported as 13% at 5 years and male sex and 
low HAQ at baseline showed predictive value for ARA remission (12). It is likely that 
the good prognostic value of male sex for DAS remission reported in this thesis is due 
to true disease characteristics rather than any reporting difference between men and 
women.  
 
Remission rates and prognostic factors for remission were comparable in ERAS 
despite using two different remission criteria. Analysis of the ERAS patients, using 
sustained DMARD-free remission criteria (no current use of DMARDS or steroids, no 
swollen joints and clinical diagnosis of DMARD-free remission by the treating 
physician) also showed frequencies (9.4%) similar to that of sustained DAS remission 
(11%).  
Baseline features such as duration of symptoms, RAI and HAQ showed prognostic 
value for subsequent remission irrespective of the remission criteria used. 
Interestingly, baseline variables such as age, acute onset of symptoms, absence of RF 
and shared epitope (SE) showed predictive value for DMARD-free remission, but 
they were not of any prognostic significance for remission based on DAS. This may 
be due to difference in the remission criteria used and/or difference in total number of 
patients (704 vs 895) between the analyses (293). 
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Although, a number of early RA studies have reported on RF and SE as prognostic 
factors for remission, the positive predictive value of these prognostic markers, 
particularly of SE, have not been consistent and reliable (80;118;223;281;285;287).  
 
Radiographic progression in RA, particularly during the early stages (< 5 years) can 
be highly variable and unpredictable and different models of x-ray progression have 
been proposed (90;100). Quantification of structural damage, using Larsen method in 
random order in ERAS has showed that radiographic progression at group level was 
essentially linear over the first 5 years of disease presentation, except between year 2 
and 3, where it was accelerated. However, in contrast to x-ray progression, clinical 
and laboratory measures such as, DAS, HAQ and ESR improved from baseline, 
stabilised, and then gradually deteriorated between 4 and 5 years. This accelerated x-
ray damage between 2 and 3 years follow-up was considerably different from x-ray 
progression at any other time points and there was no significant correlation between 
x-ray scores and any of the clinical or laboratory disease measures throughout the 
study period to explain this unexpected finding.  
 
This thesis has attempted to explore other possible reasons for this disproportionate 
increase in x-ray progression between 2 and 3 years such as, higher clinical disease 
activity preceding the x-ray assessment, treatment effect and scoring methodology. As 
described earlier, the results showed that the accelerated radiographic progression was 
not related to any difference in clinical disease activity both before and during the x-
ray assessments or to treatment. However, a small subgroup analysis of x-ray 
progression using the same Larsen method, but in chronological order (reading with 
known sequence) showed that radiological progression was constant and linear 
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between baseline and 5 years, and did not show the accelerated phase using random 
Larsen scoring. Possible weaknesses in the argument that the scoring order of films 
influenced the nature of x-ray progression in this study include the smaller number of 
films in the subgroup analysis.  
 
The influence of scoring methodology on longitudinal x-ray progression was explored 
further in this thesis by comparing different scoring methods (Larsen, SvdH and 
SENS) and scoring sequence (random and chronological) in subgroups of patients. 
Larsen‟s method used in this study was a global scoring system, which incorporates 
soft tissue swelling, joint space narrowing (JSN) and erosions together and gives a 
unified score (172). Inclusion of soft tissue swelling in the Larsen‟s score may lead to 
a relatively high score at baseline, decreasing with response to treatment. This may 
reduce the total possible increased score due to progressive damage, contributing to 
low sensitivity to change (149). Also, scoring JSN and erosions separately may give 
more valuable information on disease heterogeneity and progression (189).  
 
Each scoring method has its own strengths and limitations in terms of scoring 
technique, time and reliability. SvdH method has shown to be superior to others in 
relation to its sensitivity to change, smallest detectable difference and in detecting 
minimal clinically important difference (181;182). SENS, a simplification of the 
SvdH method, has shown to be quick and easily reproducible in the research as well 
as in the routine clinical setting (170).  
 
For the above reasons, these three commonly used scoring methods were compared in 
this thesis. As described in chapter 5, the results showed that radiographic progression 
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at group level, based on all three (Larsen, SvdH and SENS) scoring methods was 
essentially linear and similar, provided the films were read in chronological order. 
However at individual level, SvdH method was more sensitive in detecting x-ray 
progression above measurement error i.e. clinically meaningful x-ray progression.   
 
Scoring order of the films is more important in RA studies with radiographic outcome 
as one of the main objectives. In clinical trials studying treatment interventions, the 
films should ideally be read in paired order (reading films without known sequence) in 
order to assess the real difference in treatment outcome without introducing any bias 
(158). However, in longitudinal studies and observational clinical cohorts, 
chronological reading of x-rays is more useful to detect clinically meaningful x-ray 
progression above measurement error (160).   
 
In this observational cohort of early RA, chronological reading of x-rays was more 
sensitive in assessing longitudinal x-ray progression than random reading. However, it 
is difficult to draw a definite conclusion as the films were read in random (observer CS) 
and chronological order (observer KJ) by two different observers, although reliability 
between the observers was very good. Chronological scoring of x-rays using SvdH 
method in these patients has been shown to be more reliable and meaningful in 
measuring significant x-ray progression, both at group and at individual level, 
particularly in patients with low disease activity or remission.  
 
As described in the earlier chapters, another interesting and important finding from the 
radiographic analysis of the ERAS cohort was that a small proportion of patients (8%) 
showed marked progression in their x-ray (Larsen) scores despite low or minimal 
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clinical disease activity. This unexpected finding has prompted a study of radiographic 
progression in detail in patients in sustained DAS remission, as there is only limited 
information on this in early RA patients treated with conventional DMARDs in routine 
clinical setting. Although, x-ray damage is relatively less in patients with minimal or no 
clinical disease activity (80;239), it has also been shown to progress despite clinical 
improvement or remission (243;288;289).  
 
Radiographic progression during sustained periods of clinical disease inactivity was 
analysed in detail for this thesis, both at group and at individual level, using absolute 
scores as well as smallest detectable difference (SDD). Two separate analyses of x-ray 
progression in the ERAS cohort during sustained DAS remission were analysed.  
 
The first analysis was radiographic progression over 3 years, using Larsen scoring 







follow up assessments and with serial x-rays (n=78). In this group, 22% showed 
significant or clinically meaningful x-ray progression and in a majority of them (82%), 




 year assessments. Nearly one quarter of 
the patients in sustained DAS remission (24%) developed new erosions during the 
study period, most of them (89%) at year 3.  
 
A separate analysis of the ERAS patients, who were in sustained DAS remission from 
year 1 to 5 and had serial x-rays (n=35), revealed significant radiographic progression 
despite remission. The SvdH method was used in chronological order for this analysis, 
as previous studies including this thesis, have shown that this scoring methodology is 
more sensitive in detecting x-ray progression that is clinically important (160;182). 
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Although, 80% of patients in this group showed an increase in their total x-ray (SvdH) 
scores between year 1 and 5, only half of them (43%) showed clinically meaningful 
progression i.e. progression above measurement error. However in a majority of 
patients, JSN rather than erosions appeared to be the main reason for increase in total x-
ray scores, and only in 13% of them the x-ray progression was due to new erosions.       
 
Various hypotheses have been put forward over the years to explain radiological 
deterioration in spite of clinical improvement or disease inactivity. Disease 
heterogeneity including a difference in pathogenesis between synovial inflammation 
and joint damage has been proposed as one of the main reasons  (251;254;255). Other 
causes such as, residual inflammation in the joints despite fulfilling the remission 
criteria, time lag between clinical disease activity and appearance of erosions on x-rays 
and presence of subclinical synovitis detectable only on US or MRI have also been 
suggested as possible underlying reasons for progressive x-ray damage despite 
remission (266;268;269;289).  
 
Disease heterogeneity is the most likely explanation for the paradoxical relationship 
between clinical disease activity and radiological damage in the ERAS cohort, as 
attempts to test various other hypotheses have not revealed any positive results.  
ERAS used more stringent remission criteria than described in recent publications. The 
original DAS assesses more joints for swelling (44) and tenderness (68), involving both 
hands and feet, compared to DAS28 which assesses only 28 joints and does not include 
the feet (264-266). DAS of < 1.6 correlates with the more rigorous ARA remission 
criteria (279) and this DAS cut-off value was used to define remission in this thesis. 
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Therefore, residual inflammation in the joints despite achieving DAS remission is less 
likely in this study cohort, although it is a possibility. 
 
Conventional radiography, using x-rays, may be relatively insensitive in detecting early 
radiological changes due to RA and there may be a significant time lag between clinical 
disease activity and appearance of erosions on x-rays. Although, this time lag can be 
quite variable and unpredictable, it is usually up to 12 months (268;269).  
Among patients showing significant x-ray progression despite DAS remission in this 
thesis, a majority progressed to develop radiological damage including new erosions 
after being in remission for at least 12 to 24 months. Therefore, time lag as a possible 
reason for progressive x-ray damage is less likely in this cohort.  
 
New imaging techniques such as US and MRI are more sensitive in detecting 
subclinical inflammation in apparently „normal looking joints‟ and there may be a 
significant time delay between appearance of erosions on MRI and on x-rays (101-
104). Therefore, it is possible that some ERAS patients could have had subclinical 
inflammation and/or early radiological changes, detectable only on US and MRI, in 
spite of DAS remission. However, radiographic analysis in this thesis was in early RA 
patients in sustained DAS remission for up to 5 years and so the results from previous 
short-term studies in patients with established or active disease should be carefully 
interpreted in the right context.    
 
Scoring methodology as a potential reason for unexplained x-ray progression in 
patients with sustained remission was also explored. This showed that a significant 
proportion of patients in sustained DAS remission developed progressive x-ray damage 
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irrespective of scoring methods or reading sequence of films. No significant difference 
between patients in sustained DAS remission with and without x-ray progression in 
terms of DMARD treatment was seen. Therefore, scoring methodology and treatment 
effects are unlikely explanations for progressive structural damage seen in patients with 
low or no clinical disease activity.   
 
Although, several studies have reported on prognostic factors for radiological 
progression in RA (68;69;138), there is not much information on predictive value of 
standard disease measures in determining subsequent x-ray progression in patients with 
clinically inactive disease. In a recent imaging study by Brown et al in RA patients in 
clinical remission, positive power Doppler signal and synovial hypertrophy on US and 
synovitis on MRI showed predictive value for x-ray progression at 12 months (289).  
 
In a subgroup analysis of this thesis, male sex, RF, erosions and x-ray scores at baseline 
have shown prognostic value for x-ray progression in patients in sustained DAS 
remission. However, only male sex showed independent predictive value in 
multivariate analysis and other studies have not reported on this. This is an interesting 
and unexpected finding as men in general have shown to be in good prognostic group 
in relation to their disease activity and progression (303). On the other hand, oestrogen 
may have a favourable influence on the immune system in women with protective 
effect on the bone (301;303).  
 
Nevertheless, previous studies have not shown any significant difference in 
radiographic outcome between men and women, and gender was not of any prognostic 
value in predicting x-ray progression (7;283;304).  
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Patient numbers in this group reported for this thesis were small, so caution is needed 
for these conclusions. Future long-term studies of patients with persistently inactive 
disease should elucidate this further. 
 
The results of this thesis are consistent with previous reports that RA patients with 
active disease have worse outcomes (55;57). In a previous analysis of ERAS patients 
(n=732), functional disability (Steinbrocker‟s functional grade FG III & IV) had 
progressed from 7% at study entry to 16% at 5 years and female sex, age of onset > 60 
years and baseline HAQ >1 were associated with worse functional outcomes (12).   
 
Although, several studies have reported on various disease and non-disease specific 
outcomes in RA (9;12;56;57), there is only limited information on long-term outcomes 
such as work disability, orthopaedic surgery and mortality in early RA patients with 
sustained low disease activity or remission, treated with traditional DMARDS in 
routine outpatient clinics. As far as is known, long-term functional outcomes in relation 
to x-ray progression in early RA patients in sustained DAS remission have not been 
reported before.  
 
Patients in sustained DAS remission had better outcomes including reduced functional 
& work disability, less radiographic damage and fewer requirements for supportive aids 
and orthopaedic surgeries compared to patients with disease activity.  
Although, patients in sustained DAS remission had relatively fewer deaths (15% vs 
23%), the difference was not statistically significant (p=0.14). It was reassuring to see 
that patients in sustained DAS remission had better functional and other outcomes, 
although a significant proportion of them showed progressive x-ray damage.           
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Also, it was encouraging to note that there was no significant difference in 3 & 5-year 
outcomes between patients in sustained DAS remission with and without x-ray 
progression.   
 
A separate analysis was carried out to study 5-year outcomes in relation to cumulative 
clinical disease activity (from initial disease presentation up to 5 years) in the ERAS 
cohort. The main objective was to analyse long-term outcomes in patients with 
persistently low or no disease activity (DAS ≤ 2.4) from year 1 to 5, compared to other 
patients with either persistently high or fluctuating (relapsing-remitting) disease 
activity. This showed that patients with persistent clinical disease inactivity had better 
radiographic and functional outcomes compared to patients with active or fluctuating 
disease.  
 
Also, other outcomes such as, work disability, orthopaedic surgery and mortality were 
significantly less in the low or inactive disease group. It is important to note that 
patients with fluctuating or relapsing-remitting disease also had poor outcomes, 
although it was relatively better compared to patients with persistent disease activity. 
Previous studies have also shown that fluctuating clinical disease activity could have an 
independent effect on x-ray damage with worse radiographic outcome (243;245).  
 
The strength of ERAS includes large number of early RA patients with long-term 
follow up in a „real-life setting‟. Longitudinal analyses of this traditional pre-biologic 
cohort provide valuable information on natural disease course, outcomes and 
prognostic factors in RA. Furthermore, no previous studies have reported on 
 248 
radiographic progression, outcomes and prognostic factors in detail in early RA 
patients with sustained remission or low disease activity for up to 5 years. 
 
However, there are some limitations. There is a possibility of bias in this type of 
hospital-based observational studies, as they may not include patients who go into 
remission early and not attend hospital (left censoring) and also it may not include 
patients who either die or become too unwell to attend (right censoring). The other 
common and unavoidable problem with such longitudinal studies is the missing data. 
Nonetheless, on separate analyses, there was no significant difference between the 
study patients and those with missing data in relation to most of the disease 
characteristics.  
 
A further limitation, particularly with regard to sustained DAS remission is that the 
DAS were recorded only at yearly intervals and so there was a possibility of disease 
exacerbations between the study assessments. However, study patients were assessed 
by their treating physicians every 3 to 6 months and no treatment change was noted to 
suggest any flare ups.   
 
In conclusion, sustained DAS remission is less frequent than point remission in this 
early RA cohort and baseline variables such as, gender, duration of symptoms, disease 
activity and HAQ showed prognostic value for sustained DAS remission.  
The link between clinical disease activity and radiological damage may be variable and 
unpredictable and structural damage on x-rays can progress despite clinical disease 
inactivity or remission in early RA.  
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Male sex, RF, erosions and x-ray scores at baseline have shown modest prognostic 
value in predicting radiographic progression during sustained DAS remission in this 
study. Therefore, x-rays at regular intervals, even during clinical disease inactivity, may 
give valuable information on true disease progression in early RA.  
Scoring methodology may have an influence on radiographic disease progression in 
RA, particularly at individual patient level, and so it is important to choose the 
appropriate method depending upon the type and purpose of the study.   
 
Patients with persistently inactive disease had better outcomes compared to patients 
with relapsing-remitting or persistent disease activity. No significant difference was 
seen in functional and other outcomes between patients in DAS remission with x-ray 
progression and those in DAS remission without x-ray progression. Therefore, 
maintaining a state of disease inactivity is probably as important as achieving remission 















The findings reported in this thesis has strengthened the resolve for a detailed analysis 
of ERAS patients who have completed at least 10-year follow up in order to study 
disease progression over a longer period. ERAS recruited patients in the pre-biologic 
era between 1988 and 1998 and management of RA has been revolutionized by the 
introduction of biological agents over the last decade.  
 
Current evidence supports the use of targeted treatment strategy involving DMARDs, 
high dose steroids and/or biological agents as early as possible in the disease course to 
have a positive impact on disease progression and outcomes. Therefore, it will be 
interesting to see how these newer agents or other forms of intensive treatment 
influence long-term disease progression, particularly in relation to their effect on the 
link between clinical disease activity and radiological progression and other outcomes.  
 
Future randomised studies of patients with different levels of clinical disease activity 
including low disease or remission and with long-term follow up may provide valuable 
information on the treatment effect, which is difficult to explore in detail without any 
bias in observational studies like ERAS.    
 
Use of conventional radiography to assess disease progression in RA has several 
advantages, because performing x-rays of hands and feet is readily available, rapid, 
relatively cheap, and scoring methods are reproducible and validated. However, newer 
musculoskeletal imaging techniques such as US and MRI have shown to be excellent 
diagnostic as well as prognostic tools in the management of RA, both in the research 
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and clinical setting. X-rays can be relatively insensitive, particularly in the early disease 
and in patients with low or no clinical disease activity, whereas US and MRI can be 
very sensitive in detecting subclinical inflammation as well as early radiological 
damage in RA.  
 
In addition, US and MRI findings appear to correlate with structural damage on x-rays 
and these imaging modalities have been shown to have good predictive value for 
subsequent development of erosive changes on x-rays. Therefore, future studies, using 
these newer imaging techniques, particularly in patients with inactive disease, may 
provide some vital information on the link between clinical disease activity and 







































NO Study title Objectives Methodology Results Strengths Limitations 
   1 
Progression of 
radiological changes in 
RA. Scott D L, et al. Ann 
Rheum Dis 1984;43:8-17 







variables in RA, 
in relation to 
treatment with 
second line drugs 
Prospective study of pts with active RA. 
Two different F/U periods – short term study = 1 yr F/U   long term study = 
10 yrs F/U 
Short term study = 64 pts with established RA and mean disease duration – 6 
yrs. 
Clinical and lab variables used – grip strength, RAI, pain score, ESR/CRP, 
Hb, RF & Igs 
X-rays were scored using Larsen‟s (mean score of 2 observers were used) 
DMARDs used – IM Gold, auranofin, penicillamine, clobuzarit and no 
steroids. 
Long term study = 112 pts with established RA and mean disease duration – 
5 yrs. 
Clinical and lab variables were same as above. 
Functional ability and x-rays were reported using steinbrocker grading (2 
observers) 
DMARDs used – HCQ, IM Gold, penicillamine, AZA, chlorambucil, CYC and 





damage and clinical 
and lab variables 
(radiological damage 
occurred in all 
cases). 
Good correlation 
between clinical and 
lab variables  
  
Prospective study using 
conventional DMARDs 
Analysis of clinical, lab 










Feet not included in 
Larsen‟s scoring. 
X-ray progression 
criteria not clearly 
stated. 
Radiological 
progression before the 
study entry was 
considered as linear, 
which is not true in 
all cases ( as in ERAS 
study)  
 
      
2 Remission in rheumatoid  
arthritis. Wolfe F et al.  J 
Rheumatol 1985;12:245-
252 
To assess the 




a) database with details prospectively entered was analysed – 458 pts with 
atleast 3 clinic visits were included & only 27% of pts had < 1 yr disease at the 
initial visit 
b) parallel chart review by an independent observer was also done. 
F/U – up to 30 months (1131 pt year) 
ARA remission criteria used – either 5 /6 or 4/5 (excluding 
Remission rate - 
18.1%(ARA) & 
18.8%(chart) 
Only 15% of these 
remissions lasted for 
more than 24 months. 
Median duration of 
remission 10 months.  
Female sex, onset < 
60 yrs & early 
erosions –reduced rate 
of remission  
Prospective analysis. 
Large no of pts. 
All pts met ARA 
criteria for RA. 
Spontaneous Vs drug 
induced remission was 
also analysed 
Too many subgroup 
analysis. 
Chart review was 
not validated for 
assessing remission. 
Small no of pts (16) 





duration >7 yrs).  
1. Critical Appraisal 
Clinical and radiological disease progression in RA 
   
 




Chart review – clinical remission or inactive disease noted by the clinician 
F/U visits were not 
standardised 
       
3 Remission of 
rheumatoid arthritis – 
myth or reality?  
Piai et al. Revmatologira 
(Mosk) 1990 Apr-
Jun;(2):68-72 
To study different 
types of remission 
ie. Drug induced 
Vs spontaneous 
Observational (5 yrs) 
956 pts 
Lengthy remission 
(1-5 yrs) was 
attained in 14% of 
pts 
Long term observational 
data with a large no of pts 
Frequency of F/U 








      
4 Frequency and prognostic 
features of rheumatoid 
patients with remission 
inducing agents – a 
comparison of different 
kinds of medication. 
Kutsuma et al. Ryumachi 
1990 Oct;30(5): 336-42 
To study the 
frequency of  
complete remission 
in RA & their 
special features  
with different 
treatment  
Observational (2 yrs) 
466 pts (90 male, 376 female) 
ARA remission criteria used 
7.1% achieved 
remission. 
High remission rates 
in pts who had no 
F/H of RA, no 
rheumatoid nodules 
or hip contracture 
Observational data with a 
large no of pts   




       
5 Radiologic progression 
during intramuscular 
methotrexate treatment 
of rheumatoid arthritis.  
Sany J et al.  J 
Rheumatol 
1990;17:1636-41  
To study whether 
treatment with IM 
MTX in patients 
with established 
RA could reduce 
the radiological 
progression 
Prospective controlled study 
41 pts with established RA (mean disease duration 13 yrs) 
F/U – 2 years (mean 31 months) 
Mean MTX dose:10 mg 
Clinical remission criteria – not stated 
Radiological remission – Larsen‟s index of <5 over the 2 yrs study period 
Clinical 
improvement  in all 




in >83% of 
pts(hands& wrists), 
>76% of pts(hands, 
wrists & feet). 
No predictive factor 
for radiographic 
Prospective study. 
Validated x-ray scoring 
method used and read 
by two independent 
observers in random 
order. 
Patients with 
established RA and 
radiological 
damage (baseline 
Larsen score was  
high-mean 84). 
Clinical remission 
criteria not stated. 
Small no of pts and 
low dose of MTX. 
No control group. 
All the x-ray films 
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evolution were available in 
only 25 pts. 
 
      
6 Studies on clinical 
remission of rheumatoid 
arthritis. Itoh I et al. 
Ryumachi 1992 
Feb;32(1):47-51 
To study the 
frequency of 
remission 
276 pts and duration of F/U – 17 months 19 out of 276 pts 
were in clinical 
remission. 
All 19 pts remained 
in remission for 17 
months. 
Remission rate 
higher in male pts. 
Erosive changes 
developed even after 
clinical remission. 
Looked at both clinical 








used and x-ray 
scoring methods. 
No details on 
statistical analysis. 
       




Evidence that the 
pathogenesis of synovial 
inflammation and 
articular erosions may 
differ. Mulherin D et al. 
Br J Rheumatol 
1996;35:1263-1268 








course in a cohort 
of RA pts. 
Patients with active RA entered a prospective study. 1958 diagnostic criteria 
for RA used. 
No previous DMARDs or steroids. 
40 pts included and the mean duration of F/U 6yrs. 
Clinical assessment – EMS, pain (VAS), grip strength, RAI, Hb, ESR 
Radiological - Larsen 
Significant 
improvement in  
clinical & lab 
measures of disease 
activity (RAI, Hb, 
ESR) but  marked 
radiological 
deterioration. 
Measures of disease 
activity at enrolment 
did not predict the 
radiological course. 
Correlation between 
RAI, Hb, ESR and x-
rays at review was 
found. 
Prospective study. 
Validated x-ray scoring 
method. Duration of 
F/U 6 yrs. Correlation 
between clinical, 
laboratory variables and 
radiological course & 
outcome were analysed. 
Small no of pts and 
no details of  
F/U(frequency, no 
of study points). All 
pts had established 
RA with active 
disease.  
 SJC not included in 
the analysis and 
HAQ not available. 
Radiological 
deterioration  may 
be due to the active 
disease at the study 
entry rather than at 
the study point. 
       
8 Remission in a 
prospective study of 
To evaluate the 
prevalence of 
Observational study with an inception cohort of  early RA pts (<1 yr disease 
duration since diagnosis) with a maximum F/U of 6 yrs and no previous 
69 pts(37%) fulfilled 
the remission criteria 
Prospective study with 
a long F/U. 
Variable F/U 





remission criteria in 
relation to the disease 
activity score(DAS). 





according to the 
ARA criteria and 
to investigate the 
relationship of the 
ARA remission 
criteria  with the 
DAS 
DMARDs.  
227 patients were included, median age – 55 yrs and median duration of F/U 
3.9 yrs. 
F/U visits were every 3 months. 
Modified ARA remission criteria was used –4/5  
at least once and 39 
pts(21%) on at least 
two consecutive visits.  
Because of variable 
F/U duration pts 
fulfilling remission 
criteria/ follow up yr 
was calculated: 
25%  at one visit & 
15% on  two 
consecutive visits. 
DAS of 1.6 
correlated with ARA 
criteria for remission.  
Validated remission 
criteria used. 
Standardised F/U system. 
DAS was compared with 
ARA remission criteria 
for the first time to get a 
cut-off point for 
remission using DAS. 
SJC was the most 
influential and EMS, 
ESR were the least 
influential factors in 
deciding remission 
assessed in only 53 
joints and SJC was 
assessed in only 44 
joints and so the 
remission rate 
could have been 




       
9 Evaluation of the ARA 
preliminary remission 
criteria in rheumatoid 
arthritis: a prospective 
study. Alarcon G, et al. J 
Rheumatol 1987;14:93-6 





Cross sectional study, which included two different populations of patients 
with established RA from two different countries. 
ARA remission criteria used. 
Prevalence of 
remission –1% and 
30% at one visit in 
two populations 
respectively 
 Pts with 
established RA and 
pts were selected 
during a visit at the 
clinic. 
 
      
10 Outcome in patients 
with early rheumatoid 
arthritis treated 
according to the 
„sawtooth‟ strategy. 
Mottonen T, et al. 
Arthritis & rheumatism 
June 1996;39(6): 996-
1005 
To investigate the 
outcome of early 
RA when treated 
according to the 
„sawtooth‟ 
strategy 
Prospective, longitudinal study including 2 cohorts of patients from 2 
centres with early RA (<2 yrs) and no previous DMARDs. All pts met the 
1987 ACR diagnostic criteria at some point of the study. 
Total no of pts –142, mean disease duration 7.9 months and mean time from 
the onset of symptoms and start of DMARDs was 7.9 months. Most 
common first DMARD was IM gold (82%) followed by SZZ (10%) and 
HCQ (7%). 92% of pts were symptomatic for <12 months at study entry. 
F/U every 3-6/12 for 3 yrs and then yearly. Mean duration of F/U 6.2 yrs 
(range 18-111 months).  
ARA remission criteria used. 
x-rays – Larsen‟s(0,1,2 & at last visit) 
Outcome measure- functional grade (Steinbrocker & MHAQ) 
All pts had atleast 1 
DMARD. Mean ± 
SD cumulative time 
of DMARD 
treatment was 60 ± 
24 months (or 81% 
of the mean F/U) and 
mean cumulative no 
of DMARDs used by 
all pts was 3.3 (1-8).  
49 pts received 
steroids (<10 mg)  
Prospective study with 
early RA pts. Low drop 
out rate-only 3 pts. Long 
duration of F/U. 
Inefficacy was the most 
frequent cause for 
discontinuing DMARDs 




status was reported 
only for year 0, 1, 2 
& last visits. 
Radiological 
progression despite 
clinical remission at 
the last visit could 
be due to fluctuating 
disease in the 
preceding years and 
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Remission –20% 
(year 1), 27% (2
nd
 yr) 
and 32% (last visit). 
Only 19% of pts 
were  in remission 
both at 2 yrs  and at 
the last visit. 
94% of pts who were 
in remission at their 
last visit had erosive 
disease. 
Only 24% progressed 
to functional grade III-
IV  
it was not the 
primary outcome 
measure. Absolute 
Larsen‟s scores in 
pts in remission Vs 
non-remission were 
not reported, so 
difficult to comment 





not studied.  































Clinical course and 
remission rate in patients 
with early rheumatoid 
arthritis: Relationship to 
outcome after 5 years. 
Eberhardt K, et al. Br J 
Rheumatol 
1998;37:1324-1329 
To investigate the 
clinical course in 
early RA pts and 
to assess the 
outcome after 5 
yrs and to identify 
prognostic 
factors. 
Prospective study of definite RA pts with disease duration of <24 months. 
Total no of pts-183, mean age-51.4 yrs and mean duration of symptoms-11.1 
months. 
F/U – every 6months for 5 yrs. 
1.Modified ARA remission criteria  - 4/5 on at least two consecutive visits 
(6 months apart) 
2.Clinical remission criteria -„no arthritis at least at one F/U visit‟ 
X-rays – Larsen‟s at baseline & then yearly. Patients with active disease 
received DMARDs and 62% of pts received DMARD some time during 
F/U. Most common DMARD was HCQ. 29 pts (16%) had oral steroids.  
 
37 pts (20%) achieved 
ARA remission 
periods of at least 6 
months duration. 21 
were spontaneous and 
18 drug induced. 
Mean duration of 
remission = 20.5 
months. 
36% of pts were in 
remission according to 
the clinical remission 
criteria. 
56% had a relapsing-
remitting disease and 
44% had a persistent 
disease  
Prospective study with a 
F/U of 5 yrs. Low drop 
out rate-only 7 pts(4%). 
Standardised F/U. 
Remission assessed at 
two study points  
Radiological 
progression not 
analysed / reported 
at regular intervals 























       
12 The relationship 
between synovitis and 
erosions in rheumatoid 
arthritis. Kirwan J, et 
al. Br J Rheumatol 
To study the 
correlation 
between synovitis 
and erosions in 
individual joints 
Analysis of data from a prospective multi-centre study of low-dose 
prednisolone. 
Total no of pts - 93 
Clinical assessment every 3 months and the duration of F/U-2 yrs 
Clinical disease – soft tissue swelling + tenderness=synovitis. 
216 joints (out of 
2064) showed 
progressive x-ray 
damage and 44% of 
these had little or no 
Prospective, multicentre 
study. 
X-ray scoring done by 
two observers. 
Pts with early RA 
Clinical assessment 
not accurate. All 
pts had active 
disease. 
No details on 
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1997;36:225-228 in hands X-ray – Larsen‟s (change in score over 2 yr period)  synovitis. Of the 12% 
of joints that were 
synovitic, 63% show 
no x-ray progression. 
In contrast to placebo, 
steroid treated pts did 
not have any increase 
in correlation between 
synovitis and erosions 
as progressively larger 





Absolute change in 
Larsen score not 
mentioned and feet 





Duration of F/U (2 
yrs) probably not 
enough to assess 
structural damage 
on x-rays. Inter & 
intrarater reliability 
not reported  
       
13 Utility of disease 
modifying antirheumatic 
drugs in „sawtooth‟ 
strategy. A prospective 
study of early 
rheumatoid arthritis 
patients up to 15 years. 
Sokka T, Hannonen P. 
Ann Rheum Dis 
1999;58:618-622  
To study long 
term utility of 
early, continual, 
and serial use of 
DMARDs in early 
RA in clinical 
setting 
Two cohorts (total=135 pts) of early RA pts who met the 1958 ARA criteria 
for RA. 
Cohort 1(1983) – 58 pts (observational)  
Cohort 2(1988) – 77 pts (case-control – SSZ vs placebo) 
Subsequently both cohorts were enrolled into this prospective study 
F/U every 3/12 for the first 2 years and at least yearly thereafter  Maximum 
F/U duration- 15 yrs from disease onset. 
ARA remission criteria used. 
Criteria for early RA not reported. 
All pts were treated with DMARDs except one (self-limiting) 
Most commonly 
used  DMARD – 
GST & SSZ 
Median duration of 
DMARD period = 10 
months (range 6-18) 
Reason for stopping 
DMARDs = inefficacy 
(51%), adverse 
reactions (28%), other 
reasons (15%), 
remission (n=32, 6%) 
Prospective study with 
a maximum F/U of 15 
yrs. 
Standardised F/U at 
regular intervals. 
Validated clinical 
remission criteria used 
Small no of pts and 
some pts in cohort 2 
had placebo before 
this study. 
Clinical remission 
was not studied as a 
primary outcome 
and it was rather   
reported as a reason 
for DMARD 
discontinuation So, 
patients in remission 
but staying on 
DMARDs were 
missed and so the 
actual  remission 




assessment   not 
explained  
 
      
14 How does functional 
disability in early RA 
affect patients and their 
lives? Results of 5 yrs of 
follow up in 732 pts from 
the ERAS. Young A, et 
al. Rheumatology 
2000;39:603-611  
To assess the 
impact of RA on 
function and how 
this affects 
patients‟ lives 
Inception cohort of early RA pts (disease duration < 2 yrs and no prior 
DMARD use). 
732 patients who fulfilled the 1987 ACR criteria for RA and with a 
maximum F/U of 5 yrs were included. 
Clinical  assessments at 0, 3, 6 months and then yearly. X-rays at 0,1,2,3,5 & 
9 yrs and scored using Larsen‟s. 
ARA remission criteria used.  
Functional assessment using steinbrocker‟s functional grade and HAQ. 
 
84% of pts received 
atleast one DMARD. 
NSAIDs and/or 
steroids were used in 
16% 
Most commonly used 
first DMARD SSZ 
(73%) followed by Gold 
inj(10%). 
Remission by 5 yrs –
n=94, 13% 
Predictive factors for 
remission – male sex 
& baseline HAQ of < 
1 
FG III,IV has 
increased from 
7%(baseline) to 16% 
by 5 yrs- bad 
prognostic factors = 
female sex, age of 
onset >60 & baseline 
HAQ of >1 
 
Large no of early RA 
pts with a F/U of 5 yrs. 
Regular F/U 
assessments were made 
and validated clinical 
remission criteria and x-
ray scoring methods 
were used 
Remission was not 
assessed as a 
primary outcome 
and the ARA 
remission criteria 
was probably not 
strictly followed 
(no report of either 
5/6 or 4/5 ARA 
remission criteria 









    
 
 
15 Early inflammatory 
polyarthritis: results from 
the Norfolk Arthritis 
Register with a review of 
To examine 
disease outcome 
and predictors of 
prognosis among 
All pts with a new onset of IP, who presented to primary care were recruited 
to NOAR. 
Median age – 55 yrs 
No of pts who completed 3 yrs F/U – 486 out of 579(84%) 
6% fulfilled the 
remission criteria at 
3 yrs and 11% 
fulfilled the criteria 
Primary care based 
study with a large no of 
pts.   
Left censorship, which 
Results of the 




the literature. II. Outcome 




pts with new 
onset of IP/RA, 
referred to NOAR 
Outcomes assessed = remission of synovitis, functional disability (HAQ) 
and radiological damage (Larsen) 
A subset of 231 pts (47%), who satisfied the 1987 ACR criteria for RA were 
also assessed separately 
Clinical assessments & HAQ at 0, 1, 2 ,& 3 yrs. 
 X-rays were done only in pts ,who satisfied the study criteria(total no=390, 
x-rays available-only 335 pts) 
Median time from symptom onset to the latest available x-ray was 22 
months 
Remission – 4/6 ARA criteria excluding ESR & fatigue 
Acute phase reactants were not measured in this study. 
Over the 3 yr F/U period, 357 pts (73%) were referred to hospital for 
arthritis. 
cross-sectionally at 





younger age at 
disease onset(16-25 
yrs) and male sex. 
The median HAQ 
score was higher in 
RA subset at 3 yrs. 
Linear relationship 
between HAQ and 
age at disease onset. 
Women had higher 
HAQ scores. 
Baseline HAQ was 
the most important 
predictor of future 
disability 
Out of 335 pts ,who had 
x-ays, 61% fulfilled the 
criteria for RA and 38% 
had seropositive 
disease. Median Larsen 
score 4 (RA subset). 
Significant relationship 
was found between 
erosive disease and 
older age at disease 
onset, RF positivity and 
longer symptom 
duration before initial 
presentation. HLA-
DRB1 was associated 
is a major problem in 
hospital based studies 
can be minimised in 
this type of studies. 
Multiple logistic 
regression analysis was 
used to predict 
outcomes. 
Other related studies 
were compared in the 
discussion. 
The proportion of 
true „RA‟ pts is 
lower in NOAR 
than hospital based 
studies. 
X-rays were not 
taken in all pts and 
pts who did not 
meet the x-ray 
criteria initially 
went on to develop 
erosions at 5 yrs. 
Acute phase 
reactants were not 
measured. 
ARA remission 
criteria was not 
strictly applied. No 
details of  
remission rate in 
the subset of RA 
pts. 
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with the development of  
erosions(only in 
seronegative pts). No 
positive correlation 
between erosive disease 
and disability. 
       
16 Remission and 
response to early 
treatment of RA 
assessed by the DAS. 
Svensson B, et al. 
Rheumatology 
2000;39:1031-1036 




on the DAS in RA 
pts participating 
in a long-term 
observational 
study 
Open, controlled study within the observational study. 
Early RA pts (<1 yr) who fulfilled 1987 ACR criteria. 
Mean disease duration – 6/12.  
All pts had active disease with a mean DAS >4 (90% of pts had DAS > 2.4) 
No of pts – 90, duration of F/U – 2 yrs. 
Pts randomised to 2 strategy  1) Pred ± MTX      2) SZP/Gold ± Pred 
Clinical remission – DAS 
X-ray scoring – Larsen‟s (mean of the two independent observers values 
used) 
No difference in the 
two treatment groups 
for responders and 
remission 
36% (n=32) were in 







progression in good 
responders (DAS 
<2.4) and remission. 
Prospective study of 
early RA pts. 
Validated clinical 
remission  and x-ray 
scoring criteria used. 
Small no of pts.  
All pts had active 
disease and all 
were on DMARDs 
and so no 









F/U not long 
enough to study the 
predictive factors, 
x-ray changes and 
other outcomes. 








seropositive RA. A 20-
year follow-up study. 




To study the 
frequency of 
radiographic 
remission in pts 
with seropositive 
RA over 20 yrs of 
F/U 
Prospective study of  
117 pts with recent onset RA (< 6 months) 
Mean age 45 yrs  
F/U at 1,3,8,15 & 20 yrs. 
For this study 102 pts(out of 117)  with seropositive and erosive RA who 
were seen at 8 and 20 yr check-ups were included. 
82 out of 102 pts attended 15 yr F/U and 67 pts attended 20 yr F/U. 
Larsen‟s method was used to assess x-ray progression  
Radiographic remission criteria - no change or a change in score of ≤ 1 point 
between two study points 
Radiographic 
remission = 27 out of 
102 pts (26%) 
(at 1 yr - 3 pts, at 3yrs 
– 5 pts, at 8 yrs – 6 pts,  
at 15 yrs – 13 ). 
ESR and CRP at year 
8 & year 20 F/Us were 
low in pts in 
remission. 
SJC at year 8 F/U was 
low in pts in 
remission. 
More pts in remission 
group had less 




Prospective study with 
a long duration of F/U.  
First study to look at 
radiographic remission 
prospectively and to 
some extent clinical and 
lab measures of disease 
activity were compared 
with radiographic 
progression. 
Small no of pts and 
the frequency of 
F/U was too long. 
Clinical & lab 
assessments were 
made only at 0, 8 
& 20 yrs. Only pts 
with seropositive 
and erosive disease 
were included and 
so no comparison 
can be made. 
Intra/inter observer 
variability not 
reported and  
scoring 
methodology was 
not reported in 
detail.  
       
18 How to diagnose RA 
early.  A prediction 
Model for Persistent 
(Erosive)ArthritisVisser 
H, et al. Arthritis & 
Rheumatism. Feb 
2002;46(2):357-365 
To develop a 
clinical  model for 
the prediction, at 
the first visit, of 3 





Prospective study of pts with early arthritis (presence of arthritis in at least 1 
joint and if the symptoms lasted <2 years) 
Total no of pts – 524 (23% were seropositive for RF) Median age – 49, 
median symptom duration – 2.7 months  
Clinical, lab and radiographic details were recorded at  0, 1 & 2 yrs. 
At 2 yrs F/U the pts were divided into 3 groups: 1.Self-limiting – no arthritis 
and no DMARDs or steroids in the last 3/12. 
2.Persistent arthritis- arthritis in at least 1 joint and/or treatment with 
DMARDs or steroids in the last 3/12. 
At 2 years – 156 pts 
(30%) fulfilled the 
criteria for RA and 137 
pts (26%) had 
undifferentiated 
arthritis. 
5% of these pts with RA 
had self-limiting 
arthritis (natural 
Prospective study with 
large no of pts. 
Predictive value of the 
discriminative factors to 
identify different 
outcomes at 2 yrs were 
reported and it can be 
applied to day to day 
clinical practice. 
Some of the pts 
were treated with 




The remission rate 
was lower in pts 





3.Erosive arthritis- erosions  remission)and it was 
33% in undifferentiated 
arthritis. 
Criteria  to discriminate  
3 types of arthritis , at 
the first visit –1) 
symptom duration,  2) 
EMS of at least 1 hr, 3) 
arthritis in ≥ 3 joints, 4) 
bilateral compression 
pain MTP joints, 5) RF, 
6) anti CCPabs, 7) 
erosions  
Duration of symptoms, 
RF & anti CCP 





pain in MTPs, RF and 
anti CCP positivity 
were strongly 




and not drug 
induced remission. 
This study result 
(remission rate) 
may not be 
generalisable to the 
other early RA 
studies as the 
inclusion criteria 
and study design 
were completely 
different. 
       
19 Ten year outcome in a 
cohort of patients with 
early RA: health status, 
disease process and 
damage. Lindqvist, et al. 




measured by health 
status, disease 
process, damage in 
an unselected group 
of pts with early RA 
and search for 
prognostic features 
Observational study of pts with early RA 
Total no of pts – 183   
Duration of F/U - 10 yrs 
Modified ARA remission criteria used 
Remission rate – 
18% 
Health status was the 
only predictable 
outcome using HAQ 
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20 Functional disability in 
relation to radiological 
damage and disease 
activity in patients with 
RA in remission. 
Molenaar E, et al. J 
Rheumatol 2002;29:267-
70 







of disease activity 
and co-morbidity 
in patients with 
RA in remission 
This study was part of a larger cohort observational study. 
Total no of pts-186  
Median disease duration – 7 yrs 
Assessment was made at one study point 
Co-morbidity was considered to be present when the pt was medically 
treated for a disease. 
Clinical remission – modified ACR criteria - 4/5 (omitting fatigue) & DAS 
X-rays – SvdH method (mean of two observer scores were used) 
 
Only 82% of pts (out of 
186) fulfilling modified 
ACR remission criteria  
were in remission using 
DAS. 
Female = 65%, 
Ever RF + = 69% 
92% of pts had joint 
erosions 
SvdH score = 52 
(mean), 21 (median) – 
only few had significant 
joint damage. 
70% of pts were on 
DMARDs. 
Significant correlation 
between HAQ and 
VAS, DAS, SvdH and 
disease duration. 
In pts with  <7 yrs 
disease duration , 
significant correlation 
between HAQ & DAS 
and in pts with > 7 yrs 
disease, significant 
correlation between 
HAQ, DAS and SvdH. 
Large no of pts and  
the inclusion criteria 
was that the pts should 
be in remission for the 
last 6/12. 
Validated remission 
criteria and x-ray 
scoring method used. 
First of it‟s kind to 






disease activity and 
radiological 
damage. 





factors were not 
studied in detail.  
No details on effect 





       
21 Progression of radiologic 
damage in pts with RA in 
remission. Molenaar E, et 
al. Arthritis & 
Rheumatism vol 50(1); 
Jan 2004:36-42 





in pts with RA 
Prospective study of pts with established RA (median disease duration –  7 
yrs) 
Only pts in clinical remission (should be in remission for 6/12 before the 
study entry) were included 
Pts on steroids were excluded 
Total no of pts – 187 
Persistent remission = 
59%  (preliminary 
ACR), 52% (modified 
ACR) and 42% (DAS ) 
Radiological 
progression was more in 
Prospective study with 
large no of pts 
Frequent clinical 
assessment was done. 
Remission was assessed 
using 3 main types of 
All pts with 
established RA. 
Pts on steroids 
were excluded, 
which could have 
influenced the 
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Duration of F/U – 2 yrs 
Clinical assessment every 3/12 and x-rays were done at baseline, 1 & 2 yrs 
Clinical remission was based on preliminary ACR, modified ACR 
4/5(omitting fatigue) and DAS 
X-rays were scored using SvdH method (progression of <5 after 2 yrs was 
considered not significant) 
pts with disease 
exacerbation although a 
slight but statistically 
significant progression 
was also seen in pts in 
clinical remission 
DAS AUC (area under 
the curve) was a 
stronger predictor of 
radiologic progression 
than was the absence of 
persistent remission 
validated criteria. 
X-ray progression was 
correlated with clinical 
disease progression. 
results. 
X-rays were read 







       
22 Value of DAS 28 and 
DAS 28-3 compared to 
ACR defined remission 
in RA. Balsa A, et al. J 
Rheumatol 2004 
Jan;31(1):1-4 
To assess criteria 
for remission based 
on DAS 28 and DAS 
28-3 (excluding pt‟s 
global assessment of 
disease activity 
Random sample of 788 pts with RA were selected from 34 Spanish centres.  
Clinical remission was based on both preliminary ACR and modified ACR 
(omitting fatigue) 
Remission - 4% (7.9% 
if fatigue excluded) 
Positive predictive 
value for remission: 
ESR-6.5%, EMS <15 
mins-8.4%, no tender 
joints -13%, no 
swollen joints-
15.8%, no joint pain-
27.7%, no fatigue-
8.7% 
DAS 28 cut off  value 
for ARA remission-
2.81% and  DAS 28-3 
cut off value was 2.95% 
(if fatigue excluded) 
Multi centre study with 
a large no of pts. 
 
       
23  Predictive factors in 
early arthritis: long term 
follow up. Schumacher et 
al. Semin Arthritis 
Rheum. Feb 
To predict which pts 
with undifferentiated 
arthritis are likely to 
have a poor outcome 
(remission vs 
Observational study of pts with early arthritis (symptom duration of <1 yr). 
Total no of pts – 121 and frequency of F/U was variable but at least once a 
year. 
Mean  disease duration to the first evaluation was 3 months and median  F/U 
was 5 yrs. 
Remission rate    – 52 %  
Pts meeting criteria for 
RA or spondylo  
arthropathies had more 
persistent disease and 
Observational study of 
pts with recent onset 
arthritis and  long 
duration of F/U. 
Prognostic factors were 
Remission rate in 
this study can not 
be generalised to 
other RA studies 
because of 
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had better prognosis. 
Pts with poly articular 
and /or hand 
involvement had poor 
prognosis (less chances 
of achieving remission) 
Hand involvement was 
the strongest predictor 





criteria and study 
design. 







       
24  Prognostic factors for 
remission in early RA: a 
multiparameter 
prospective study. Gossec 




for remission in 
early RA.  
Prospective study of pts with early RA (disease duration of <1 yr and no 
prior DMARDs) 
Total no of pts – 191, mean age at diagnosis 50.5 and mean disease duration 
was 3.3 months 
80% at baseline had seropositive disease and 45% had at least one SE. 
Six months after inclusion: 93% were on DMARDs ( 69% - monotherapy 
(mainly MTX/SZP) and 25%  combination therapy (MTX+SZP) 
Mean DMARDs at 5 yrs – 1.95 
33% received steroids at least once during F/U (5-15 mg/day) 
Duration of study – 5 yrs 
Clinical assessment by the same investigator at baseline,  6 months, 1 yr, 3 yrs 
and 5 yrs. 
X-rays of hands & feet were done at baseline, 3 & 5 yrs and scored using 
SvdH (films were read by 2 observers in chronological order and mean of two 
scores were used) 
Clinical remission based on DAS (<1.6) 
Remission was assessed at 3 yrs and both at 3 and 5 yrs (persistent remission) 
Drop out rate - 7.3% (3 
yrs) & 13.6%(5 yrs).  
Missing data at 5 yrs -
16% 
Remission rate at 3 yrs 
– 48 (25%), at 5 yrs – 
38 (20%) and both at 
year 3 & 5 - 30 (15.7%) 
79% of pts in remission 
at 3 yrs were also in 
remission at 5 yrs 
Univariate analysis: 
baseline DAS score of 
<4 ( OR 3.2), HAQ 
<1.25, Ritchie <17 and 
CRP <14.5 were 
significantly correlated 
with remission at 3 yrs 
All the above variables 
and  total Sharp score of 
<4, EMS <60 mins and 
RF negativity were 
Prospective study with 
long duration of F/U. 
Pts were treated early 
with DMARDs. 
Standardised F/Us and 
detailed clinical, lab 
and radiological data 
were collected. 
Validated remission 
criteria and x-ray 
scoring method were 
used.   
Radiographic scores at 
baseline were assessed 
in relation to their 
predictive value for 
remission.  
 
Clinical and lab 
variables were 
recorded only at 0, 6 
months, 1, 3 & 5yrs 
and x-rays were only 
done at 0, 3 & 5 yrs. 
Role of DMARDs 
were not analysed in 
detail. 
Correlation between  
clinical disease 
activity/ remission  
and  radiological 
disease progression 
and functional 




persistent remission at 3 
& 5 yrs  
Multivariate logistic 
regression :  low DAS, 
baseline total 
radiographic score and 
Ritchie score were 
important predictors for 
both remission at  3 yr 
& persistent remission 
at year 3 & 5.  
Low HAQ and short 
duration of morning 
stiffness were predictive 
of remission at 3 years. 
Low baseline CRP was 
predictive of persistent 
remission 
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25 The influence of sex on 
RA: A prospective study 
of onset and outcome 
after 2 yrs. Tengstrand B 
et al.                    J 
Rheumatol 2004;31:214-
22 
To analyse the 
influence of 
patient‟s sex on 
early RA within 1 
yr of disease 
onset and after 2 
yrs F/U 
Prospective, multicenter observational study of early RA pts (disease 
duration of <12 months) 
Total no of pts - 844 (1987 ACR criteria for RA) 
Mainly 3 outcome variables were analysed in relation to sex: DAS28, HAQ 
and radiological damage/Larsen‟s score. 
Clinical disease activity was assessed using DAS 28 (remission <2.6). 
 DAS 28 and x-rays were recorded at baseline and at 2 yrs. 
In a subgroup of pts (n=329) Larsen‟s method was used to quantify damage 
and the drop out rate at 2 yrs was 30%, mainly due to lost films. 
x-ray films were read by 1 or 2 observers and the mean score was used. 
  
At study entry: 
significant difference 
in mean age of 
disease onset (men-
62, women-54) and 
age  distribution 
(incidence of RA = 
1:5 M/F for age 
between 20 and 30 
yrs and 1:1 for age 
between 60 and 70 
yrs). 
Women had more hands 
& feet involvement with 
high DAS 28 and HAQ 
scores at presentation. 
More men with younger 
age of disease onset had 
seropositive disease and 
positive family history 
of RA. 
In women, CRP, DAS 
28, radiological changes 
and Larsen‟s score were 
all correlated 
significantly with 
higher age at disease 
onset. 
Remission at 2 yrs-40% 
(men) & 28% (women). 
In men, significant 
correlation was found 
between disease 
duration before study 
entry, RF positivity, 
DAS 28 at baseline , 
HAQ and DAS 28 at 2 
yrs. In men, presence of 
SE, initial DAS28 
Prospective, multicenter 
study with a large no of 
pts with early RA. 
More detailed analysis 
of clinical, functional, 
lab and radiological 
disease status between 
men and women. 
Validated remission 
criteria was used. 
 
Larsen‟s score was 
used only in a 
subgroup of pts. 
Duration of F/U (2 
yrs) was probably 
too short to assess 
the functional and 
radiological 
outcome. 
Subgroup of pts in 
remission were not 
analysed in detail in 





 and HAQ correlated 
with HAQ at 2 yrs. 
No significant 
difference in Larsen‟s 
score at 2 yrs  between 
men and women. 
In men, RF and Larsen 
score at baseline 
correlated with Larsen 
score at 2 yrs. In 
women apart from 
above variables, age, 
CRP and DAS28 at 
baseline also correlated 




showed that in men, RF 
and DAS28 at baseline 
correlated with DAS28 
at 2yrs , whereas in 
women, age, HAQ, and 
DAS28 at baseline 
correlated with DAS28 
at 2 yrs. 
Significant correlation 
between RF at baseline 
and Larsen score at 2 
yrs in men and between 
RF,CRP at baseline and 
Larsen score at 2 yrs in 
women. 
 Women switched 
DMARD more 
frequently than men 
during the first study 
year (42% vs 31%) 
Start of steroids at 
study entry – 53% 





       
 
26 Comparison of 
combination therapy with 
single-drug therapy in 
early rheumatoid arthritis: 
a randomised trial. FIN-
RACo trial group.    
Mottonen T, et al. Lancet 
1999;353:1568-73  
 









Multicenter, randomised controlled trial. 
Patients with active RA (n=195)were randomised either to combination 
therapy (SZP=500 mg bd, MTX=7.5 mg/wk, HCQ=300 mg od, Pred=5 mg 
od) or monotherapy (SZP=2 gm od ± Pred ≤ 10 mg od) for 2 yrs and then 
they were treated according to the physician‟s choice. 
In the combination therapy arm, prednisolone could be tapered and stopped 
after 9 months if patients remained in remission. 
Clinical assessments were done at 1,3,4,5,6,9,12,18 and 24 months.  
Clinical remission (primary outcome measure) was  assessed using modified 
ACR criteria (5/5 excluding fatigue) 
ACR 20, 50 and 70% responses were also analysed. 
X-rays of hands & feet at baseline, 6, 12 and 24 months and scored using 
Larsen method 
97 pts received 
combination therapy 
and 98  received 
monotherapy in 
which MTX was 
substituted in 51 pts. 
At 2 yrs, 178 pts 
(combi-87, mono-91) 
completed the trial. 
At 2 years, more pts 
in monotherapy 
group used steroids 
than combination 
group (50 vs. 43) and 
cumulative no of 
steroid injections 
were higher in the 
monotherapy group. 
ACR remission was: 
25%(yr 1) and  
37%(y 2) in the 
combi group 
compared to 11% (yr 
1) and 18% (yr 2) in 
the mono group. 
Early institution of 
DMARDs(< 4 
months from disease 
onset) showed 
increase in remission 
rate in the mono 
group but not in the 
combi group. 
ACR 50% response 
Randomised, controlled 
trial with standardised 
assessments and 
frequent F/Us.  
Good sample size with 
long duration of F/U 
(up to 5 yrs). 
First clinical trial to use 






analysed and was 
related to functional 
outcome after 5 years in 
another study from the 
same group. 
Radiological disease 
progression was studied 
prospectively in pts in 
persistent remission at 
6, 12 and 24 months 
Usual weaknesses 
of randomised 
trials as it does not 
reflect the „real 
life‟ pts and 
clinical 
management. 
Relatively more pts 
received steroids 
both at study start 
(all in combi group 
and 64% in mono 
group) and after 2 
years (49% in 
combi group and 






was 75% (yr 1) and 
71% (yr 2) in the 
combi group 
compared to 60%(yr 
1) and 58% (yr 2) in 
the mono group. 
Frequency of adverse 
events were similar 
in both groups. 
Mean Larsen score 
did not increase 
significantly in pts in 
sustained remission 




      
27 Retardation of joint 
damage in pts with early 
RA by initial aggressive 
treatment with DMARDs. 
Korpela M et al. Arthritis 
& Rheumatism. July 
2004; vol50 (7):2072-
2081 
To evaluate the 
long-term frequency 
of disease 
remissions and the 
progression of joint 
damage in pts with 





(3 DMARD) for 2 
yrs. 
Frequency of 
remissions and the 
extent of 
radiological damage 
are the primary 
Multicenter, randomised study of early RA pts (symptom duration of < 2 yrs; 
median 6 months) comparing the efficacy and tolerability of combination 
therapy (MTX+SZP+HCQ+Pred) with monotherapy (SZP ± Pred). 
IA steroids were allowed in all pts if necessary. 
A total of 199 pts (1987 ACR criteria) with active disease were included. 
After 2 years, the choice of DMARDs and Pred dose was unrestricted, but the 
aim was still to achieve remission. 
After the initial 2 yrs, clinical assessments were done at 30, 36, 42, 48, 54, and 
60 months. 
Median no of DMARDs at 5 yr F/U in both groups was 3     (range 1-8 in 
monotherapy and 3-6 in combination therapy) 
Clinical remission was based on no swollen or tender joints and low ESR/CRP. 
X-rays were taken at baseline and then annually for 5 yrs (Larsen‟s method) 
At 2 yrs, the frequency 
of remission was 37% 
(combi) & 18% (mono). 
At 3 yrs – 29% vs 21%, 
at 4 yrs – 34% vs 21% 
and at 5 yrs – 28% vs 
22%. 
Radiologic progression 
was significantly low in 
combination therapy 
compared to 
monotherapy at both 2 
and 5 yrs F/U (5yr 
median Larsen score 11 
vs. 24). 
Logistic regression 
analysis showed that the 
extent of radiologic 
Randomised study with 
long duration of F/U 
and standardised F/U 
assessments . 




Primary outcomes were 




trials as it does not 
reflect the „real 







damage at 5 yrs was 
predicted by the 
presence of RF at 
baseline, single 
treatment strategy for 
the first 2 yrs, disease 
duration before 
diagnosis and ESR at 
baseline. 
Rate of permanent work 
disability at 5 yrs was 
nil in pts in remission at 
6 months and pts in the 
initial combi group 
were more likely to 
maintain their capacity 
to continue in paid work 
over 5 yrs compared to 
mono group. 
 
       
28 The relationship between 
disease activity and 
radiologic progression in 
patients with RA. 
Welsing P, et al. Arthritis 
& Rheumatism. July 
2004; 50(7):2082-2093 




disease activity and 
subsequent 
radiologic 
progression and to 
determine whether a 
change in disease 
activity is related to 
a change in 
radiologic 
progression in 
Two prospective cohorts of early RA pts 
 
1) UMCN inception cohort :  disease duration of <1 yr and no prior 
DMARDs.  For this study pts with at least 3 yrs F/U were included.             
A total of 185 pts with a maximum F/U of 9 yrs. Clinical assessment (DAS) 
was done every 3/12 and x-rays (SvdH-one observer) every 3 yrs. 
 
2) COBRA cohort: 56-week, multicenter, randomised, double-blind, controlled 
trial to test the efficacy of SZP+MTX+Pred vs SZP alone 
(disease duration of < 2yrs and no prior DMARDs except HCQ or steroids).                   
A total of 152 pts with active disease and a maximum F/U of 6 yrs. Clinical 
assessment (DAS28) at 0, 16, 28, 40 and 56 weeks and then at least once a yr 
and x-rays (SvdH-mean score of 2 observers) 6 monthly first yr and then 
annually. 
Pts in the COBRA 
cohort had relatively 
high DAS and  HAQ 
but less Sharp score 
(median) compared to 
UMCN cohort at study 
entry.  
In the UMCN cohort, 
RF positivity and Sharp 
score at baseline 
correlated significantly 
with radiologic damage. 
In the COBRA cohort, 
treatment allocation, RF 
Prospective study of 
early RA pts with 
standardised and long 
duration of F/U. 
Longitudinal regression 
analysis (GEE) was 
used in this study  to 
assess the relationship 
between clinical and 
radiologic disease 
progression. In other 
studies looking at 
relationship between 
disease activity and 
Missing data. For 
14 pts in UMCN 







variability and ceiling 
effect) could have 
introduced 
measurement error 
rather than true 
 274 
individual pts. positivity and Sharp 
score at baseline were 
significantly related to 
radiologic damage. 
Fluctuations in disease 
activity had an 
independent effect on 
radiologic progrerssion 
and the strength of this 
association was 
dependent on RF status 
and/or baseline disease 
activity. 
Statistically a change in 
the mean interval DAS 
and/or SD of the mean 
interval DAS over time 
in the UMCN cohort or 
a change in the DAS28 
over time in the 
COBRA cohort results 
in corresponding 
change in radiologic 
progression and this 
was only found in RF 
positive pts.  
The finding of  RF 
positivity and baseline 
x-ray damage having  
an independent effect 
on radiologic 
progression in this study 
might explain the 
radiographic 
progression in pts in  
clinical remission, seen 
radiologic progression,  
time- independent 
linear regression 
analysis  were used , 
where within-patient 
variation in disease 
activity is not accounted 
for by AUC analysis 
and the correlation was 
only judged within one 
time interval. 
This study/statistical 
methods  addressed the 
problems with other 
studies based on time-
averaged estimates for 
disease activity to assess 
the interrelationship 
between disease activity 
and radiologic progression 
– time averaged estimates 
do not reflect the high 
variability of disease 
activity within pts and the 
ordinary regression 
methods used in these 
analyses assume a linear 
course of radiologic 
progression over time. 











allocation,  clinical 
assessment (DAS 
vs DAS28) and  
frequency & 
duration of  F/U 
between two 
cohorts. X-rays 
were also done at 
different intervals 
in these two 
cohorts. 
.    
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in other studies.  
       
29 A good response to early 
DMARD treatment of pts 
with RA in the first yr 
predicts remission during 
follow up. Verstappen S, 
et al. Ann Rheum Dis. 
Jan 2005;64(1):38-43 
To describe the 
frequency and 
duration of 
remission in a cohort 
of pts with RA and 
to describe clinical 
and treatment 
characteristics of pts 
with remission vs pts 
without remission. 
Randomised, prospective clinical trial of early RA pts (disease duration < 1 
yr), who fulfilled 1987 ACR criteria. 
Pts were randomised into 4 treatment strategy groups: 1) HCQ, 2) IM Gold, 
3) MTX, 4) pyramid (NSAIDs for at least a yr and then DMARDs if no 
response) 
After 2 yrs, the clinicians were allowed to use any other DMARDs. 
Total no of pts – 562 and the mean F/U duration was 62 months. 
Clinical assessment at baseline and every 3 months for the first 2 yrs and 
then 6monthly. For missing clinical data, the mean of the previous and next 
score was imputed. 
X-yays were taken at baseline and then yearly (SvdH). For missing data at 
the last visit, the slope of radiological progression of the previous yrs was 
used) 
Remission was defined as – EMS ≤ 15 mins, VAS pain sscore ≤ 10, 
Thompson joint score (a weighted joint score including both swollen and 
tender joint counts) ≤  10 and ESR ≤ 30 for at least 6 months. 
Good response to initial DMARD ( ≥ 50% improvement from baseline on at 
least 3 of the following 4 parameters; VAS, Thompson joint score, EMS or 
ESR)was assessed at 1 yr after study entry 
Baseline disease 
characteristics of the 4 
treatment groups were 
similar. 
In the study cohort, 
22% used oral steroids 
and 57% received IA 
steroids during F/U. 
A total of 144 pts 
dropped out during F/U 
(42 died, 13 in 
remission). 
205 pts (36%) 
achieved at least one 
period of remission 
during F/U(57 pts had a 
second and 8 pts had a 
third period of 
remission). Of the 270 
remission periods, 158 
remission periods were 
followed by a flare up. 
Mean cumulative 
duration of all remission 
periods was 25 months , 
comprising 39% of total 
F/U time. 
Mean duration from 
study start until the first 
period of remission was 
24 months.  
16 pts (8%) did not 
receive any DMARDs 
Prospective study of pts 
with early RA and long 
duration of F/U. More 
frequent clinical 
assessment. Effect of 
treatment on subsequent 
remission was analysed 
and predictive factors 
were looked at. Effect of 
different DMARDs on 
subsequent disease 
activity/ remission was 
analysed in detail. 
Both the frequency and 
duration of remission 
was looked at. 
Missing data and 
large drop out rate. 
The results of this 
randomised, 
clinical trial may 
not be 
generalisable to the 









used in this study 
was not widely 





was not correlated 





during the 6 months 
prior to first period of 
remission. 
At 4 yrs F/U, 142 out 
of 425 pts (33%) had at 
least one period of 
remission. 
Good responders at 1 
yr F/U were found to 
achieve remission more 
likely in the subsequent 
yrs despite similar 
baseline characteristics 
and similar treatment. 
Baseline predictors of 
remission were good 
response to treatment, 
less pain, negative RF 
and lower joint score. 
 
       
30 Frequency of remissions 
in early RA defined by 3 
sets of criteria. A 5 yr 
follow up study. Makinen 
H, et al. J Rheumatol 
2005;32:796-800)  
To study the 
frequency of 
remission using 3 
sets of criteria in 
pts with RA at 5 
yrs after the 
diagnosis. 
Inception cohort of pts with early RA  
Inclusion criteria - pts > 16 yrs old with recent onset inflammatory arthritis 
who did not meet criteria or show clinical signs of other specific arthritides. 
Total no of pts – 127 at study entry and 111 pts completed the 5 yr F/U. 
Mean age – 56 yrs and median duration of symptoms before diagnosis was 5 
months 
Clinical, lab measures of disease activity and x-ray findings (Larsen‟s – one 
observer) were recorded at baseline, 2 & 5 yrs. 
All pts but one had DMARDs. 
 SZP followed by MTX were the two most commonly used first line 
DMARDs.  
During F/U 59% took MTX. 
54% of pts used steroids at some time during F/U  
3 types of remission criteria: 
95 pts (75%) met 
ACR classification 
criteria for RA at 
baseline. 
 cumulatively 96 out 
of 111 pts (87%) met 
ACR criteria for RA 
at 5 yrs and 9 pts 
fulfilled the ACR 
criteria for RA 
during the 5 yr F/U 
period. 
Clinical remission:  
39% at 2 yrs, 37% at 5 
Prospective study of pts 
with early RA and the 
aim of treatment was to 
achieve remission. 
Validated clinical 
remission criteria used 
and validated x-ray 
scoring method used. 
Both clinical and 
radiographic remission 
was studied. 
Other similar studies 
were discussed. 
Relatively small no 
of pts. 
Classification 
criteria for RA was 
not met in all pts. 
Frequency of 
clinical and x-ray 
assessment was too 
long (0,2,5 yrs) 
X-ray scoring 
methodology was 




1) ACR remission criteria – fatigue excluded, 5/5 
2) Clinical remission – no tender and no swollen joints and normal ESR 
3) Radiographic remission – no worsening of erosions and/or no new erosions 
from baseline to 5 yrs. 
 
yrs and 21% at both 2 
& 5 yrs. 
ACR remission: 17% at 
5 yrs 
Radiographic 
remission: 55% at 5 yrs. 
Only 13% met all 3 sets 
of remission criteria 
Less than 50 % of pts 
who were in clinical 
remission at 2 yrs were 
in remission also at 5 
yrs. 
22 pts with no swollen 
and no tender joints and 
normal ESR did not 
meet ACR criteria 





was not correlated 
with function and/or 
other outcomes. 
 
       
31 Comparison of different 
definitions to classify 
remission and sustained 
remission: 1 year 
TEMPO results. van der 
Heijde D, et al. Ann 
Rheum Dis 
2005;64:1582-1587  
To assess methods 
to calculate 
achieving remission 
in a double blind 
randomised trial in 
pts with RA who 
received etanercept, 
MTX or the 
combination of both 
TEMPO trial – multicenter, double blind, parallel design study active RA pts 
randomised to one of the 3 treatment groups. 
Total of 682 pts (MTX-228, Eta –223 & both – 231) 
Mean age – 52 yrs 
Duration of this study analysis – 1 yr. 
Clinical assessment using DAS, DAS28 and ACR 70. 
 
DAS remission:  
37%(eta+MTX), 18% 
(eta) & 14% (MTX). 
DAS28 remission 
38% (eta+MTX) 18% 
(eta) & 17% (MTX) 
Concordance was 
greater between DAS 
and DAS28 but not 
between either of these 
and ACR70.  
Prospective, 
randomised trial with 
large no of pts. 
Validated remission 
criteria used .  Detailed  
statistical analysis to 
study sustained 
remission and to 
incorporate time factor. 
(ConRew scoring 
system and GEE) 
Results of this 
study may not be 
generalisable to 
other remission 





Short duration of 






       
32 Impact of age and co-
morbidities on the criteria 
for remission and 
response in RA. Krishnan 
E, et al. Ann Rheum Dis 
2005;64:1350-1352 
To determine to 
what extent health 
status impairment 
in RA measured 





attributable to age 
and other co-
morbid conditions 
as opposed to the 
disease itself 
Questionnaire survey  of random sample of 1530 adults    As the no of co-
morbidities increase, 
the no of subjects 




When there are 3 or 
more co-morbidities 
1 in 5 (20%) of the 
general population 




regressions, the only 
predictors of pain 
and global general 
health were age and 
co-morbidities. 
  
       
33 Is DAS28 an appropriate 
tool to assess remission in 
RA. Makinen H, et al. 
Ann Rheum Dis. June 
2005;64:1410-1413 
To study which 
cut off point of 
DAS28 
corresponds to 




criteria in patients 
with RA 
Observational study of pts with RA. 
One off study point at 5 yr F/U. 
Remission at 5 yr was based on ARA remission (fatigue excluded, 5/5) and 
clinical remission (no swollen and no tender joints and normal ESR) 
Total no of pts – 161,   
mean age – 61 yrs 
61% had seropositive disease and 32% had erosive disease.  
12% met ACR 
remission criteria, 
25% met the less 
vigorous ACR 
criteria (4/5) and 
34% met clinical 
remission criteria. 
Cut off value of 
DAS28 was 2.32 for 
ACR remission 
criteria and 2.6 for 
the less vigorous 
ACR criteria. 
Prospective study. 
ROC curve analysis 
was performed to 
calculate a cut off point 
of DAS28 that best 
corresponds to the  









Cut off value of 
DAS28 was 2.68 for  
clinical remission 
criteria. 
In pts with DAS28 
<2.32, 19% had tender 
joints, 11% had swollen 
joints and 7% had both 
swollen and tender 
joints. 
ESR had lowest 
positive predictive 




       
34 Most patients receiving 
routine care for RA in 
2001 did not meet 
inclusion criteria for most 
recent clinical trials or 
ACR criteria for 
remission. Sokka T, et al.                
J Rheumatol 2003 
Jun;30(6):1135-7 
To determine the 
proportion of 2 
cohorts of pts with 
RA who met 4 
common criteria for 
inclusion in clinical 
trials (SJC ≥ 6, TJC 
≥ 6, ESR ≥ 28, EMS 
≥ 45 mins)  
Two cohorts of pts who met 1987 criteria for RA 
Cohort L (late): 146 pts with a mean disease duration of 14 yrs and a mean 
F/U of 6.2 yrs 
Cohort E (early): 232 pts with a mean disease duration of 1.8 yrs 
Overall, 15.3% of 
cohort L and 34.1% 
of cohort E pts had ≥ 
6 swollen and tender 
joints as well as an 
ESR of  ≥ 28 or EMS 
of  ≥ 45 mins. 
Only 4.1% of pts in 
cohort L and no pt in 
cohort E met ARA 
criteria for remission 
Clinically relevant as it 
shows the „real pts‟ that 
we see in clinics and the 
difficulty in recruiting 
pts for clinical trials 
with strict inclusion 
criteria 
 
       
35 The longitudinal 
evaluation of RA pts in 
clinical remission: 
Frequency of persistent 
remission, disease flare, 
structural and functional 
To assess the 
longitudinal 
outcome of a 
cohort of pts in 
clinical remission 
and test the 
Longitudinal study of 107 pts with RA, who were in clinical remission 
(absence of clinically significant synovitis with no disease flare or change in 
treatment for at least 6 months) 
Clinical, lab and imaging assessments at baseline and 12 months (MRI & 
US of the dominant hand and wrist) 
At baseline, 55% pts 
satisfied criteria for 
ACR remission and 
57% DAS28 
remission. 
79% had evidence of 
Prospective study using 
x-rays, US and MRI to 
detect early radiological 
changes. 
Correlation between 
clinical,  radiological 
Pts with 
established RA. 
No details on 
DMARDs. 
Predictive value of 
baseline clinical 
 280 
status. Brown A, et al. 









inflammation on US 
and 81% on MRI. 
By 12 months, 56% 
remained in ACR 
remission and 74% 
DAS28 remission. 
79% had evidence of 
persistent inflammation 
on US and 77% on 
MRI. 
28 out of 107 (26%) 
had a flare up, which 
required treatment 
change. 
Deterioration in erosion 
score in at least one 
joint was observed in 
25% on x-rays, 34% on 
MRI and 38% on US. 
MRI total synovitis 
score at baseline was 
the best predictor of 
subsequent change in 
erosion score. 
Overall, 1 in 4 pts in 
clinical remission 
experienced disease 





and lab variables 
for remission not 
reported. 
Short duration of 
F/U to assess long 
term outcomes.  
These imaging 
techniques may not 
be easily accessible 
to many clinicians 
and difficult to 




       
36 MRI and US may 
improve the accuracy of 
RA clinical remission 
assessment by identifying 
To test the 
hypothesis that 
MRI and US 
would improve 
Cross sectional study of 107 pts with RA who were in clinical remission (no 
swollen and no tender joints and normal ESR for at least 6 months) 
Clinical, lab and imaging (US & MRI) assessments. 
Mean age – 56 yrs and mean disease duration – 9 yrs 
92% were on DMARDs 
64% had seropositive 
disease and 83% had 
erosions. 
This study revealed the 
problems with clinical 
remission criteria in 
assessing remission 
Cross sectional 




a high frequency of sub-
clinical inflammation. 
Brown A, et al. [Abstract 
- ACR] 
the precision of 
clinical remission 
assessment 
Mean CRP – 5, mean 
duration of remission – 
28 months.  
55% of pts satisfied 
ACR remission criteria 
and 57% DAS28 
remisssion. 
However, only 15% 
were in remission on 
US and 6.5% on MRI. 
31% of joints on US 
and 44% of joints on 
MRI had evidence of 





US and MRI were used 
to supplement the 
clinical parameters in 
assessing remission. 






for remission not 
reported. 
These imaging 
techniques may not 
be easily accessible 
to many clinicians 
and difficult to 




       
37 
 
Clinical and radiographic 
outcomes of four 
different treatment 
strategies in patients with 
early RA (the BeSt 
Study). Goekoop-
Ruiterman YPM, et al. 
Arthritis & Rheumatism 










monitoring in pts 
with early RA. 
Multicenter, randomised, controlled clinical trial with 4 different treatment 
arms: Group 1. sequential monotherapy (MTX→SZP →Lef→combi); 
Group 2. step-up combination therapy 
(MTX→MTX+SZP→MTX+SZP+HCQ→MTX+SZP+HCQ+Pred→other 
combi); Group 3. initial combination therapy (MTX+SZP+Pred 60 
mg→other combi); Group 4. initial combination therapy with infliximab (up 
to 10 mg/kg every 8 wks) 
Patients with active RA and disease durarion of < 2yrs were included. 
Pts were assessed every 3 months for a year by a trained nurse who was 
blinded to treatment arm and therapy adjusted to keep DAS <=2.4.  
If DAS remained <2.4 for 6 months, drugs were tapered to monotherapy 
maintanence dose. 
Primary end points: functional (HAQ) and radiographic outcome (SvdH) 
from baseline upto yr 1. 
Secondary end points: ACR 20%, 50% and 70% response criteria and DAS 
remission (<1.6) 
x-rays of hands and feet were done at baseline and at yr 1 and scored by two 
Total no of pts-508 
(Group 1=126, 
Group 2=121, Group 
3=133, and Group 
4=128). 
 32% of all pts had 
DAS clinical 
remission at year 1.  
Low-disease activity 
(DAS <=2.4) at 1 
year was 53%, 64%, 
71%, 74% in Groups 
1-4 respectively. 
78% in group. 3 had 
stopped prednisolone 
and 50% in group.4 
had stopped 
Randomised clinical 
trial with large no of 
early RA pts.  
Validated clinical 
remission criteria and x-




clinical and  
radiological disease 
progression was 
analysed and related to 
functional ability. 
Detailed radiological 
assessments were done 
and the x-ray 
All pts had active 
disease and the 
aggressive 
treatment strategy 
in this study makes 
it difficult to 
compare it with 
other remission 
studies. 
Short duration of 








trained assessors and mean of the two scores were used. Radiographic 
progression was reported using mean, median and SDD 
infliximab because 
of DAS persistently 
<=2.4.  
Mean HAQ scores 
were lower in groups 
3 and 4 compared to 
groups 1 and 2 at 3 
months but the 
difference was 
smaller at 1 yr. 
Radiographic 
progression was less 
in groups 3 and 4 
compared to other 
groups and the 
median increase in 
total Sharp scores 
were 2.0, 2.5, 1.0 and 
0.5 in groups 1-4 
respectively. 
No progression of 
total Sharp scores 
were noted in 67%, 
73%, 87% and 93% 
in groups 1-4 
respectively. 
Of all pts with 
nonerosive disease at 
baseline, 29%, 53%, 
38% and 15% of pts in 
groups 1-4 respectively 
progressed to erosive 
disease after 1 yr. 
Adverse events of 
>=1 was noted in 
43%, 47%, 37% and 
progression was 
reported both at group 
and individual level 
using SDD. 
used in this study 
which have its own 
implications on 
cost and long term 
side effects. 
Still > 40% of pts 
in group 1 and 2 
had a DAS of <= 
2.4 at 1 yr and the 




between groups 3, 
4 and 1, 2 was not 
very impressive at 





39% of pts in groups 
1-4 respectively 
No of serious AEs 
were, 8, 9, 17 and 6 
in groups 1-4 
respectively. No 
cases of TB or 
opportunistic 
infections.  
       
38 Clinical improvement in 
Early RA: Association 
with joint damage and 
benefit of initial 
combination therapy. De 
Vries-Bouwstra J, et al    
[Abstract - ACR] 





joint damage for 
different 
treatment 
strategies in pts 
with early RA 
BeSt-study – randomised clinical trial of 508 pts with early, active RA 
comparing 4 treatment strategies – 1. sequential monotherapy, 2. step-up 
therapy (both starting with MTX for 6 months) and  initial combination 
therapy with 3. high dose prednisolone or 4. infliximab. 
Clinical assessment (DAS)every 3 months. 
For this study, all pts with continuous DAS <1.6 (remission) and pts with 
continuous DAS >2.4 (failure) between 6 and 24 months of F/U. 
Joint damage progression (SvdH) and functional ability for the subgroups of 
remission and failure between initial monotherapy (Groups 1+2) and initial 
combination therapy (Groups 3+4) were compared in this study. 
61 pts (15, 6, 19 and 21 
in Groups 1-4, 
respectively) achieved 
remission and 54 pts 
(19, 12, 12 and 11 in 




was twice as frequent 
with initial combination 
therapy and was 
significantly associated 
with less radiographic 
progression and good 
functional ability. 
Within the remission 
group, the percentage of 
pts with radiographic 
progression was ten 
times higher with initial 
monotherapy as 
compared to initial 
combination therapy. 
For the failure group, 
Randomised clinical 
trial with large no of 
early RA pts.  
Validated clinical 
remission criteria and x-




clinical and  radiological 
disease progression was 
analysed and related to 
functional ability. 
All pts had active 
disease and the 
aggressive 
treatment strategy 
in this study makes 
it difficult to 
compare it with 
other remission 
studies. 
Short duration of 





for this study could 
have influenced the 
results. 
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the percentage of pts 
with radiographic 
progression did not 
differ significantly 
between treatment 
groups; however for 
this group, the mean 
cumulative HAQ scores 
were significantly lower 
with initial combination 
therapy.  
       
39 Defining remission in RA 
using different 
instruments. Mierau M, et 
al. 
[Abstract - ACR] 




care and to 
identify the 
potential remnant 





Observational study of 757 RA pts. 
Clinical assessment every 3 months 
Mean age – 60.2 yrs 
Mean disease duration – 9 yrs. 
Remission criteria used were  1) modified ACR criteria    (4/5, excluding 
fatigue),                 2) DAS28 < 2.6,                     3) DAS28≤ 2.4,                      
4) clinical disease activity index (CDAI) ≤ 2.8, and                  5) simplified 
disease activity index (SDAI) ≤ 3.3 
31% fulfilled 
modified ACR 
remission criteria at 
least once and 17% 
at least at 2 
consecutive visits. 
88 % of the visits in 
ACR remission 
criteria also fulfilled 
the DAS28 remission 
criteria (77% for 
modified DAS28, 
64% for SDAI and 
61% for CDAI). 
Modified ACR and 
DAS28 remission 
criteria allowed for 
higher joint counts 
and HAQ indices 
than SDAI and 
CDAI 
Large no of pts. 
Comparison of different 
remission criteria and 
they are more easy to 




criteria was assessed. 






was not reported. 
Individual 
parameters of these 
remission criteria 




       
40 Presence of significant To test the Prospective controlled cohort study Study cohort was Prospective cohort with RA pts with 
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synovitis in RA patients 
with DMARD induced 
clinical remission. Brown 
AK, et al. Arthritis & 
Rheumatism, vol.54, 




imaging (US & 
MRI) improves 




No of pts included – 107 RA pts with established disease (median disease 
duration = 7 yrs (2-38) 
No of controls – 17 (sex matched normal subjects) 
Inclusion criteria: physician determined remission, age > 18 yrs, at least 12 
months disease duration, no disease flare or treatment change in the last 6 
months. 
3 different remission criteria were applied to the study cohort. 1) ACR 
remission  at 0 & 2 months;  2) DAS 28 of  <2.6; 3) Complete clinical 
remission ie,asymptomatic patients with no painful, tender, and swollen 
joints.  
Median duration of remission at study entry – 22 months (6-144) 
 
X-rays were scored using Genant method by one observer.  
US and MRI of the dominant hand & wrist ( 8 joint regions) were performed 
by a single observer.  
 
predominantly 
female (66%) and the 
mean age was 56 yrs. 
81% of pts had 
erosive disease. 
99% of the study 
cohort had received 
DMARDs at some 
point during the 
course of their 
disease but only  
92%  were taking 
DMARDs at the 
study time and  2% 
were on steroids (<5 
mg). 
68% of pts were on 
monotherapy(most 
common – MTX, 
SZP), 24% were on 
combination therapy 
and 4 pts  on 
biologics. 
Only 55% of study 
cohort fulfilled ACR 
remission and 57% 
fulfilled DAS 28 
remission. 




fulfilled ACR and 
DAS 28 remission. 
 
85% of study cohort 
sex matched controls. 
Sample size was good 





criteria were used as 
well as complete 
clinical remission. 
More sensitive imaging 
modalities with 
validated scoring 
systems were used to 
define the true disease 
status. 
Demonstrated that  the 
day to day clinical 
assessment is 
insensitive  in defining 
true disease inactivity 
and may explain the 
discrepancy between 
clinical and radiological 
disease progression in 
some cases. 
Appropriate  statistical 












There were still 
significant  no of 
pts with some form 
of disease activity 
(painful or tender 
joints and  high 
CRP/ESR) which 
might explain 
some of the US or 










particularly in a 
DGH setting. 
Very time 
consuming ( US – 
30 mins , MRI – 70 
mins) and 
accessibility is a 
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showed evidence of 
synovial hypertrophy 
(SH) on US and 60% 
had increased power 
Doppler signal.  
36% of total joints 
examined (263 out of 
725) on US showed 
SH despite normal 
clinical findings and 
increased power 
doppler signal was 
seen in one third of 
these joints. 
92% of study cohort 
showed evidence of 
synovitis on MRI 
and 55% showed 
bone marrow edema. 
52% of total joints 
examined (327 out of 
627) showed 
synovitis on MRI 
despite normal 
clinical findings. 
3 controls (18%) had 
evidence of synovitis 
on MRI but no bone 
marrow edema. 
96% of pts in clinical 
remission according 
to all three remission 
criteria have  infact 
showed synovitis on 
MRI.  
SH on US was seen 
problem. 
Cost effectiveness 
of such approach is 
yet to be proven. 
Only long term 
studies of pts in 
clinical remission 
can  show whether 
such expensive 
modalities have 







based on US or 
MRI findings.  
3 out of 17 normal 
subjects (controls) 
had synovitis on 
MRI – Is it 
expected? 
Practically it is 
difficult to rely on 
US or MRI to 
define true 
remission and  to 
justify any 
treatment change 






in 81%  (ACR 
remission); 84% 
(DAS 28 remission) 
and  73% (complete 
clinical remission) of 
pts respectively.  
  
       
41 Sex: a major predictor of 
remission in early 
rheumatoid arthritis? 
Forslind K, et al. Ann 
Rheum Dis Jan 2007; 
66:46-52 
To determine the 
frequency of 
remission in early 
RA. 
Also to analyse 
predictive factors 
for remission with 
a detailed analysis 
on the influence 
of sex on future 
disease 
course/remission 
BARFOT Study Group – multicentre, observational study of early RA pts 
(<= 12 months) 
No of pts at study entry and at 2 yrs – 698 
No of pts at 5 yrs - 608 
F/U visits at  – 3 ,6, 12, 18, 24 and 60 months. 
Remission was assessed using DAS 28 ( <2.6) and clinical remission criteria 
(no swollen or tender joints and normal ESR). 
Frequency of both point remission (at 18, 24 and 60 months) and period 
remission (18-24, 24-60, 18-24-60) were assessed.  
At baseline, > 80% received DMARD monotherapy (most common – MTX, 
SZP). 
After 2 years, 30% of pts were off DMARDS and some more after 5 years. 
 
At baseline, 42% of women and 41% of men were given prednisolone and at 
2 years the corresponding figures were  35% and 33% and at 5 yrs- 23% and 
17% respectively 
Mean age of pts at 
baseline was 58 yrs, 
64% were women 
and mean disease 
duration was 6.2 
months. 
Most pts had 
moderate or severe 
disease activity at 
baseline (mean DAS 
28– 5.27, mean 
HAQ- 1) 
60% had seropositive 
disease and anti CCP 
was positive in 56% 
of pts. 
Remission rates: 
DAS 28 criteria – 
Point remission: 
34.5% (at 18 
months), 37.9% (at 
24 months), 38.5% 
(at 60 months); 
Period remission:  
26.3% (18 &24 
months, 24 & 60 
months) and 19.6% 
(18, 24 & 60 
Multicentre inception 
cohort of early RA with 
large number of pts. 
Validated remission 
criteria used at specified 
time points. 
Low drop out rate. 
Both point and period 
remission rates were 
studied. 
Appropriate statistical 
methods were used. 
Detailed analysis of 
women and men 
separately and their 













which time the 
disease could have 
fluctuated a lot and 





assessment did not 
find higher 
baseline disease 
activity in women, 
the DAS28 scores 
were significantly 





course and results. 
Relatively more 
patients were on 
steroids at baseline 
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months). 
For women the 
frequency of point 
remission at 18, 24 
and 60 months were 
30.4%, 32.1% and 
30.8% respectively 
(42%, 48% and 52% 
for men) 
In women, frequency 
of period remission 
were 22%, 19% and 









17.8% of women and 
26.8% of men 
achieved remission 
at 24 months and the 
corresponding 
figures at 60 months 
were 21% and 28.5% 
respectively. 
Period remission (at 
24+60 months) using 
above criteria was 
9.5% in women and 
16.4% in men. 
Univariate analysis 
showed sex, duration 
and subsequently 
which may explain 
higher remission 
rate in this study 
Also it  may be 
because the 
DAS28 is not as 
stringent as 




and long term 
outcome not 
reported. 
Odds ratio from 
univariate analysis 
were not reported 
and odds ratios 
from multivariate 




of disease at 
baseline, anti-CCP, 
RF, DAS 28 and 
HAQ showing 
predictive value for 
remission. CRP did 




showed that male 
sex, short disease 
duration, low 
baseline DAS 28, 
low baseline HAQ 





Sex (male) seemed to 
be the major 
independent 
predictor of 
remission which was 
not influenced by age 




was more noted in 
women at both 2 and 
5 years compared to 
men.  
No difference in 
DMARD or steroid 
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treatment between 
women and men in 
relation to rate of 
remission 
       
42 Bone oedema predicts 
erosive progression on 
wrist MRI in early RA-a 
2 yr observational MRI 
and NC scintigraphy 
study. Palosaari K, et al. 
Rheumatology 
2006;45:1542-1548 











27 (21 women & 7 men) 
 pts with early RA (<= 12 months) were prospectively assessed at baseline , 
1 yr (1 pt dropped out) and at 2 yrs (further 3 pts dropped out). 
Median age – 51 yrs and median duration of symptoms - 5 months. 
 
Clinical (TJC, SJC, ESR/CRP) and  functional assessment (HAQ) and MRI 
(wrist) & scintigraphy (hands) were done at 0, 1 & 2 yrs. 
Patients were classified as treatment responders if there was >= 50% 
improvement in the TJC, SJC, HAQ, with normal CRP/ESR at 1 or 2 yr 
F/U. 
Primary outcome measure was the progression of erosion score on wrist 
MRI. 
9 out of 24 pts (38%) 
showed persistent 
clinical response 
throughout 2 yrs of 
F/U. 
At baseline, MRI 
detectable bone 
erosions were found 
in 21 pts (75%) and 
the corresponding 
figures at 1 yr and at 
2 yrs were 81% and 
83% respectively. 
4 pts had no erosions 
in their baseline and 
F/U scans. 
 
Only 1 out of 9 
responders 
developed new 
erosion during F/U. 




from baseline to 1 yr 
F/U.  
From 1 to 2 yrs F/U, 9 
out of 15 non-
responders (60%) had 
Prospective, 
observational  study of 
early RA pts. 
Sensitive and specific 





variables and erosive 
changes on MRI. 
Positive correlation 
between increased 
isotope uptake and  
development of new 
erosions on MRI as 
shown in this study  
was not reported before. 
  
Small no of pts. 
X-rays of hands 
and feet were not 
done at any time 
point and so no 
information on 
correlation 
between x-ray and 
MRI findings and  
interrelationship 
between clinical, x-
ray and MRI 
disease progression  
was not studied. 
Poor ICC (0.71) 
value for inter 
observer variability 
for reading 
erosions at 1 yr. 
Issues such as 
accessibility and 
cost effectiveness  
in relation to long 
term outcomes 








damage, while the 
remaining 6 pts (40%) 
had stopped erosive 
progression.  
Baseline variables 
such as bone oedema 
score, synovitis 
score, ESR, CRP and 
isotope uptake 
correlated with 
development of new 
erosions on MRI 
from baseline to 2 
yrs and no 
correlation was 
found for age, sex, 
DMARDs, TJC, SJC, 
HAQ and RF. 
On multivariate 
analysis, bone 
marrow oedema was 
the only baseline 
variable, which 
showed predictive 
value (OR 4.2) for 
progression of  
erosions at 2 yrs F/U. 
 





       
43 Low dose prednisolone in 
addition to the initial 
DMARDs in patients 
with early active RA 
reduces joint destruction 
To assess the 
efficacy of low-
dose prednisolone 
on joint damage 
and disease 
Multicenter, open randomized trial comparing pred 7.5 mg + DMARD 
(n=119) vs DMARD (n=131) alone. 
Primary end point – difference in changes in radiographic damage scores 
after 2years. 
Secondary end points – remission rates and differences in disease activity 
Remission rate after 1 
yr:  51.3% ( 
prednisolone ) vs 
39.2% (non- 
prednisolone) and after 
Multicenter, 
randomized study. 
Patients were selected 
from a large 
observational cohort 
Not‟ real life‟ pts 
as only pts with 
active disease were 
included and lot of 
pts were excluded 
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and increases remission 
rate. Svensson B, et al. 
Arthritis& Rheumatism. 
Vol.52,No.11, Nov 2005, 
pp 3360-3370 
activity in patients 
with early RA 
and function. 
Inclusion criteria: early RA (<= 1 year), active disease (DAS 28 > 3.0) 
Exclusion criteria: earlier use of steroids,  DMARDs or contraindication to 
steroids, patients with previous fragility fractures, pts aged < 65 years with a  
T score of  < -2.5 and pts aged >= 65 years with  a     Z score of  < -1 
250 pts (all on DMARDs) were included and clinical & functional 
assessments at 0, 3, 6, 12, 18 and 24 months. 
X-rays of hands and feet at baseline, 1 yr and 2 yrs (SvdH). 
BMD (DEXA) was measured at baseline and after 2 yrs. 
Remission criteria – DAS 28 of < 2.6 
2 yrs  55.5% and 32.8% 
respectively.  group 
achieved remission. 
HAQ and SOFI index 
decreased significantly 
in the pred group than 
in the non-pred group. 
CRP fell rapidly in 
both treatment groups. 
Radiographic 
progression (change in 
total SvdH score) was 
less (erosion score more 
than JSN) after 1 and 2 
yrs in the pred group 
compared to non-pred 
group. 
X-ray progression 
(total and erosion score) 
was less in pts in 
clinical remission at 2 
yrs in the pred group 
but not in the non-pred 
group despite almost 
identical DAS 28. 
No of new erosions 
were also less in the 
pred than in the non-
pred group. 
BMD at lum.spine and 
fem.neck did not differ 
significantly at baseline 
and after 2 yrs between 
the  two treatment 
groups 
(BARFOT). 
Large no of early RA 




Clearly shown that 
prednisolone reduces 
disease activity and 
radiographic 
progression over 2 yrs 
as there were no 
difference in DMARDs 
between two treatment 
groups and the baseline 
disease activity and 
radiographic scores 
were similar in both 
groups. 
Low drop out rates and 
90% of randomized 





because of various 
exclusion criteria. 
Not a double blind, 
placebo controlled 
study. 
Long term follow 
up needed to look 
for steroid induced 











as one of the risk 
factors for 
rheumatoid c.spine 
disease was  not 
addressed and it 
will require long 
term F/U. 
 293 
       
44 Very low-dose 
prednisolone in early RA 
retards radiographic 
progression over 2 years. 
Wassenberg S, et al. 
Arthritis & Rheumatism. 
Vol.52, No.11, Nov.2005, 
pp 3371-3380 
To assess the 








Double-blind, randomized, placebo-controlled trial. 
Inclusion criteria: disease duration < 2 yrs, at least 3 of 4 disease activity 
indices (6 tender joints, 3 swollen joints, EMS > 60 mins, ESR >= 28) 
Exclusion criteria: pts with steroid dependent disease, previous steroid use, 
previous use of or contraindications for  MTX or IM Gold. 
192 patients were enrolled but only 76 patients have completed the study 
after 2 yrs. 
Clinical and functional assessments at 0, 6, 12, 18 and 24 months.  
X-rays of hands and feet at 0, 6, 12 and 24 months (Ratingen and SvdH 
scoring). 
Lumbar spine x-rays at baseline and at 24 months.  
Primary outcome measure – changes in Ratingen score at 24 months 
compared with baseline. 
Secondary outcome measure – changes at 6 and 12 months, no of eroded joints, 
and changes in SvdH scores at each F/U visit compared with baseline  
Remission was assessed using ACR criteria at 2 yrs  
Patients in the pred 
group were slightly 
older and more 
women. 
Clinical and functional 
improvement were 
only temporary in the 
pred group and failed 
to reach significance. 
Radiographic 
progression and no of 
new erosions were  
less in the pred group 
than in the non-pred 
group and this 
difference was less 
marked in the second 
year. Erosion scores 
showed more 
difference than JSN in 
assessing x-ray 
progression. 
ACR remission rate in 
pred group was 16% 







assessment and adverse 
events were recorded in 
detail 
 
High drop out rate. 
BMD (DEXA) was 
not assessed for all 
the pts. 
Only MTX and IM 
Gold were used 
which might have 
influenced the 
results. 
Need long term 





       
45 Effect of a treatment 
strategy of tight control 
for rheumatoid arthritis 
(the TICORA study): a 
single-blind randomised 
controlled trial. Grigor C, 
To test the 
hypothesis that an 
improved 
outcome can be 
achieved by  
intensive  
Single-blind, randomised controlled trial. 
Inclusion criteria: RA pts with DAS of > 2.4 and with disease duration of < 
5 yrs. 
Exclusion criteria: previous use of combination therapy with DMARDs, 
abnormal LFTs, FBC & creatinine. 
110 pts were included and duration of study was 18 months. 
Total no of pts – 110 
(intensive-55, routine-





randomised controlled trial 
with standardised 
assessments. Treatment 
regime (step-up) is more 






in this study could 
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et al. Lancet 
2004;364:263-69 
management of 
RA pts in the out-
patients compared 
with routine care  
Intensive group: monthly F/U & DAS. In the first 3 months of starting a 
DMARD, if DAS remains > 2.4, IA/IM steroid were used. After 3 months of 
DMARD, if DAS remains > 2.4, then  escalation of treatment with 
combination therapy including Pred 7.5 mg od (step-up) as per protocol were 
used. 
Routine group: 3 monthly F/U and no formal disease activity assessment. 
DMARD mono or combination therapy ± IA/IM steroids were used at the 
discretion of the treating physicians. 
Both groups had 3 monthly F/U with a metrologist (masked assessment) and 
had their clinical (EULAR, ACR) and functional (HAQ, SF 12) assessments 
done. 
Remission criteria - DAS < 1.6 
X-rays of hands & feet done at 0 and 18 months and were scored (SvdH) by 
two radiologists in known order (Inter observer ICC= .84)  
Primary outcome: mean fall in DAS and proportion of pts with EULAR good 
response criteria. 
Secondary outcome: frequency of remission (EULAR), ACR response rates, 
EULAR core measures of disease activity and outcome including HAQ and SF 
12. 
Cost benefits were also analysed. 
characteristics were 
similar, although 
intensive group had 
slightly higher ESR (45 
vs. 34) and CRP (44 vs. 
38) but slightly less 
radiological 
damage/Sharp score (28 
vs. 32) compared to 
routine group. 
Mean fall in DAS was 
significantly greater in 
the intensive group and 
this effect was seen 
within the first 3 
months of study start 
and this effect lasted 
through out the study 
period. 
DAS remission at 18 
months  was 65% 
(n=36) in the intensive 
group and 16% (n=9) in 
the routine group. 
Significant 
improvement in all 
disease variables 
(except CRP), physical 
function (HAQ)and 
quality of life (SF 12) 
in the intensive group. 
Intensive group 
showed less 
progression of erosion 
and total sharp scores 
but not in joint space 
many in a „real life‟ 
situation. 
Low drop out rates and 
intention to treat analysis. 
Cost effective analysis 
was carried out 
be attributed to 
increased use of 
steroids in the 
intensive group 
and long term F/U 
is needed to look 
for steroid induced 
side effects and to 
analyse the risk, 
benefit ratio. 
Study duration is 









shown that the 
benefits might be 
lost after stopping 
steroids. 
Monthly 
assessment of pts 




In the intensive group, 
combination DMARDs 
were more frequent  
(67% vs. 11%) and 
mean MTX was higher. 
Drug related toxic 
effects were less 
frequent and  fewer pts 
stopped DMARDs due 
to side effects in the 
intensive group. 
IA/IM steroid use 
(mean triamcinolone 
dose/month)  was more 
in the intensive group 
(28 mg vs. 8 mg). 
Costs were lower in 
the intensive group  but 
no significant 
difference in total 
hospital or community 
cost per patient between 
two groups  
   
       
46 Combination therapy 
with sulfasalazine and 
methotrexate is more 
effective than either drug 
alone in patients with 
rheumatoid arthritis with 
a suboptimal response to 
sulfasalazine: results 




SSZ and MTX is 
superior to either 
drug alone in pts 
with RA with a 
suboptimal 
responseto SSZ 
Randomised, controlled study with active RA (DAS> 2.4) without prior 
MTX or SSZ. 
Phase I – 687 pts started on SSZ and assessed 6 months later. 
165 pts entered phase II as suboptimal response to SSZ (MTX+SSZ=56 vs 
MTX=54 vs SSZ=55). 
Duration of F/U- 18 months and assessments were made at 6, 9, 12, 15 and 
18 months. 
X-rays of hands and feet done at 6 and 18 months (scored by two observers 
in known order-SvdH). 
Mean age – 55 yrs 
and mean duration of 
symptoms – 20 
months. 
77% female, 65% had 
sero positive disease. 
Mean DAS at 
baseline=4.0 





and most pts had early 
disease (70% < 1 yr). 
 
 
24% of pts after 
phase I did not 
enter phase II even 
though eligible. 
Relatively large 






MASCOT study. Capell 
H, et al. Ann Rheum Dis 
2007; 66: 235-241 
(DAS > 2.4 after 6 
months on SSZ) 
Primary outcome: reduction in DAS 




Improvement in DAS, 
ACR & EULAR 
response were 
 better in combination 




MTX and SSZ arms. 
DAS remission = 
10%(combi), 5%(SSZ), 
3%(MTX) 
Study was not 




response in combi 
arm was not 
statistically 
significant.  
       
47 Radiological damage in 
patients with RA on 
sustained remission. 
Cohen G, et al. Ann 
Rheum Dis 2007;66:358-
363 





recent RA in 
sustained 
remission 
Prospective study of early RA pts (< 1 yr), some of whom already 
participated in a 52 week randomised controlled trial (SSZ vs,. MTX vs. 
SSZ+MTX). 
 
Clinical assessment at 0, 6, 12, 36 and 60 months by same observer. 
Remission – DAS < 1.6 and sustained remission – DAS < 1.6 at 3 and 5 yrs. 
Radiographic progression both at individual level (no of new erosions & 
progression above SDD) and at group level (mean & median) -rays of hands 
and feet at baseline, 3 and 5 yrs and were scored by two observers in 
chronological order (mean of the two scores were used; inter and intra 
observer ICC=>.85) 
Functional progression – HAQ at baseline, 3 and 5 yrs 
 
Total no of pts = 
191( women-140, 
men-51) 78.5% of 
these pts were 
already involved in a 
clinical trial. 
Mean age at 
diagnosis-50.5  yrs  
and mean duration of 
symptoms – 3.3 
months. 
81% were 
seropositive and 86% 
had atleast one 
shared epitope at 
baseline. 
93% of pts were on 
DMARDs (68.6%-
mono; 24.6%-combi) 
6 months after 
inclusion. During the 
5 yr FU, a mean of 
Prospective, multicenter  
study with early RA. 










individual and group 
level were analysed as 
recommended by 
OMERACT committee. 




assessed at only 3 
and 5 years and pts 
could have had a 
disease flare in 
between, which 
might have 
accounted for new 






noted between 3 




(range 1-5) were 
used. 33% of pts 
received steroids 
atleast once during 
FU. 
Remission rate: 
35.8%(n=48) at 3 
yrs, 28.4%(38) at 5 
yrs and 22.4% 
(n=30) at both visits.  
80% of pts in 
remission at yr3 were 
also in remission at 
yr 5. 
Remission group had 
low baseline DAS, 
CRP, RF positivity, 
HAQ and a trend for 





higher in pts with 
persistent disease 
activity. 5 pts 
(16.7%) in sustained 
remission had 
progression above 
SDD between 3 and 
5 yrs (3 pts were not 
on treatment). 
Although no of pts 
with erosions 
remained the same 
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(n=16) at both 3 and 
5 years in the 
remission group, 6 
pts (20%) developed 
erosions in a 
previously 
unaffected joint 




was a significant 
difference between 
the two groups at 3 
and 5 years but no 
difference between 3 
and 5 years 
(progression in 











      
48 Assessing remission in 
clinical practice. Mierau 






practice and to 
compare different 
621 RA patients with complete data set for two consecutive visits over 12 
months were included. 
Clinical remission criteria used: modified ACR (4 out of 5 excluding 
fatigue); DAS 28 (<2.6); SDAI ( 3.3); CDAI ( 2.8) 
 
Mean age 61.4; mean 
disease duration 10 
yrs and only 10% of 
pts with early RA ( 2 
yrs). 
78% female and 64% 
Included large no of pts 
in a routine clinical 
setting. 
Validated remission 
criteria used and kappa 





Median joint count 
was 0 at baseline. 
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remission criteria were seropositive. 
93% were treated 
with DMARDs and 
11% had biologics. 
At baseline: Median 
joint counts 0  (both 
SJC, TJC) and 
median ESR 22; 
median CRP 6. 
Remission at any one 
visit : 43% (DAS 
28); 39% (mACR); 






was best for CDAI 
and SDAI (=0.89) 
and good for DAS28 
and SDAI or CDAI 
(=0.63 & 0.58) but 
only moderate 
between mACR and 
others (  0.40). 
Residual swollen 
joints were seen in 
13% of pts in DAS28 
remission, 7% of pts 
in mACR remission 
and only 5% of pts in 












observer error on 
assessing remission 
(it was not clear 
whether joints 




assessed and too 
short follow-up to 
report x-ray and 
HAQ details   
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drugs in early rheumatoid 
arthritis. Makinen H, et 
al.               J Rheumatol 
2007;34:316-21  
To study frequency 
of sustained 
remission and good 
treatment response 
and the association 
of both with 
radiographic 
progression in early 
RA –   FIN-RACo 
trial 
195 pts with early RA (< 2 yrs duration) and with active disease  were 
randomised to either combi (n=97) or monotherapy (n=98). Previous 
DMARD use or steroids 2 weeks before recruitment were excluded. 
COMBI ARM: SSZ+MTX+HCQ+Pred. 
MONO ARM:  SSZMTX or other  Pred. 
Clinical remission at 0, 6, 12 & 24 months (ACR -all 5 excluding fatigue,  
DAS28  < 2.6) and radiographs at 0, 6 & 24 months (Larsen score 0-200). 
Sustained remission – remission at 6, 12  & 24 months.  
Good treatment response – DAS28 < 3.2 and a decrease of > 1.2 from 
baseline  
 
Total of 169 pts with 
complete data were 





erosions at baseline 
49%. 
Mean DAS28 at 
baseline=5.6. 
ACR remission at 6 
months :  
 25% (combi), 12% 
(mono). 
Sustained ACR 
remission at 6,12 & 24 
months: 
14% (combi), 3% 
(mono). 
DAS28 remission at 6 
months:  
66% (combi), 37% 
(mono). 
Sustained DAS28 
remission at 6,12 & 24 
months: 
51% (combi), 16% 
(mono). 
Good treatment 
response (EULAR) at 6 
months: 75% (combi), 
52% (mono). 
Sustained good 
response at 6,12 & 24 
months:  
Prospective study of 
early RA pts with 2 yrs 
follow-up and analysed 
frequency of sustained 
remission. Also 
analysed EULAR 





analysed. Mono and 
Combi DMARD 
therapy were compared 
in relation to clinical 
efficacy. X-ray 
progression over 2 yrs 
in pts in sustained  
clinical remission was 
studied.  
All pts had active 
disease and a large 
proportion of pts 
received steroids 
(100% in combi 




assessed only at 6, 
12 & 24 months 
and pts could have 
had disease flare in 
between. Duration 
of follow-up was 




in combi and mono 
groups separately 










Change of Larsen score 
from baseline to 24 
months:  0 (sustained 
ACR remission), 1 
(sustained DAS28 
remission), 1 (sustained 
good response) 





      
50 Prognostic markers of 
clinical remission in early 
rheumatoid arthritis after 
2 years of DMARDs in a 
clinical setting. 




To analyse the 
frequency of 
clinical remission 




Open-label study of 115 pts with early RA (< 2 yrs duration) who were 
treated with standard treatment strategy using step-up approach (gold + 
MTX + Pred) for the first year and then according to clinician‟s discretion. 
No prior DMARDs but if pts were taking < 10 mg of pred, they were 
included for the study 
Clinical assessments were done at 0, 6, 12, 18 & 24 months (DAS28) and 
radiographs at 0, 12 & 24 months (Larsen score). 
Primary outcome: clinical remission = DAS28 < 2.6 
Significant radiographic progression =  4 Larsen score between baseline 
and 24 months. 
ACR20 and 50 response criteria  and EULAR response criteria were also 
analysed. 
Total of 105 pts 




CCP=70% and mean 
DAS28 at 
baseline=5.7 
No DMARD in 13 
and 15 pts at 1 and 2 
yrs respectively and 
63% of pts were still 
on steroids after 2 
yrs. 
DAS28 remission: 
34 pts (32%) at 2 yrs 
but only 5 pts had 
sustained remission 
at 6, 12, 18 & 24 
Study was conducted in 
a real out pt setting. 
Early RA pts with 
frequent follow-ups and 
standard treatment 
regime. 
Predictive factors for 
remission analysed and 
frequency of sustained 
remission reported.  
Small no of pts and 
pts and some of 
them may have 
been on steroids 
already when they 




properly and a cut 
off  point was 




explanation of how 
it was chosen. 
Follow-up not long 
enough for x-ray 
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months and 15 pts 
had sustained 
remission at 3 out of 
4 study points. 
X-ray progression 
was not statistically 
different between pts 
in remission and  not 
in remission. 
DAS28 < 5.1, high 
Hb levels and male 
gender were baseline 
predictors for 










ACR50 response and 
a good EULAR 
response emerged as 
independent factors 
associated with 






       
51 An explanation for the 
apparent dissociation 
between clinical 
remission and continued 




Prospective study of 102 RA patients who were considered to be in 
remission by their treating physicians whilst on conventional DMARDs. 
Inclusion criteria: ACR criteria for RA, disease duration of atleast 12 
months, no disease flare within the preceding 6 months, stable therapy for 6 
90 patients with 
complete set of x-
rays were included 
for final analysis. 
Prospective study with 
standard follow-ups and 
assessments. Validated 




structural deterioration in 
rheumatoid arthritis. 
Brown AK et al. arthritis 
& Rheum vol. 58, No.10, 
Oct 2008, p 2958-2967 




months and no clinical indication for a change in treatment. 
A control group of 17 sex-matched normal subjects was also studied. 
Clinical remission: no joint pain, swelling and tenderness 
Modified ACR remission criteria: 5 out of 6 criteria at 0 & 2 months 
DAS28 remission criteria: DAS28 < 2.6 
Clinical assessments and blood tests were done at 0, 3, 6, 9 and 12 months 
x-rays of hands and feet were done at baseline and at 12 months and were 
scored by one observer (paired reading) using Genant-modified Sharp 
method. SDC was used to assess significant x-ray progression. 
US [for synovial hypertrophy(SH) and power Doppler (PD), erosions] and 
MRI [for bone marrow edema (BME) , synovitis and erosions] of the 
dominant hand and wrist was done at baseline and at 12 months 
67% women; 64% 
RF positive; median 
disease duration 7 
years. Median 
duration of remission 
at baseline was 2 
years. 99% had 
DMARDs during the 
disease course ( 21% 
on combination 
therapy, 2 received 
biologics before). 
54% fulfilled ACR 
remission criteria 
and 56% satisfied 
DAS28 remission 
criteria. 
At baseline, 60% had 
erosions on x-rays. 
On US, 68% had 
erosions, 89% had 
SH, 63% had 
increased PD signal. 
On MRI, 96% had 
erosions, 92% had 
synovitis and 53% 
had BME. 
3 control subjects 
(18%) had synovitis 
on MRI but none had 
BME. 
At 12 months, 45% 
of pts fulfilled ACR 
remission criteria 





x-rays with US and 
MRI and assessed the 
predictive ability of 




First to demonstrate a 
direct association 
between synovitis and 
radiographic 
progression in 
individual joints and 
first to assess the 
predictive ability of 
subclinical 
inflammation on US 





In total, 19% of pts 
showed radiographic 
damage > SDC at 12 
months. In the 
clinical remission 
group, 16% showed 
x-ray progression 
above SDC and the 
corresponding 
figures for ACR 
remission and DAS 
28 remission groups 
were 11% and 12% 
respectively. 
Baseline predictive 
factors for x-ray 
progression: positive 
PD signal (OR 12.2), 
SH (OR 2.3) on US 
and synovitis (OR 

































HEALTH  ASSESSMENT  QUESTIONNAIRE (HAQ) 
 
 
Name: ………………………………………………………….         Date: …………………………. 
 
We are interested in learning how your illness affects your ability to function in daily life. 
Please feel free to add any comments at the end of this form. 
 
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES OVER 



















1.   DRESSING & GROOMING 
Are you able to: 
 
Dress yourself, including tying 
shoelaces and doing buttons? 






















2.   RISING 
Are you able to: 
 
Stand up from an armless straight 
chair? 






















3.   EATING 
Are you able to: 
 
Cut your meat? 
Lift a full cup or glass to your mouth? 




























4.  WALKING 
Are you able to: 
 
Walk outdoors on flat ground?   
























PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES : 
 
   Cane    Walking frame     Crutches    Wheelchair   
 
   Built up or special utensils     Special or built-up chair                      
  
   Other (specify) ………………...  
 
 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM 
ANOTHER PERSON : 
 





PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES OVER 

















4. 5.   HYGIENE 
Are you able to: 
 
Wash and dry entire body? 
Take a bath? 


























5. 6.   REACH 
Are you able to: 
 
Reach and get down a 5 lb object (e.g. 
a bag of 
potatoes) from just above your head? 



























6. 7.   GRIP 
Are you able to: 
 
Open a car door? 
Open jars which have been previously 
opened? 



























7. 8.   ACTIVITIES 
Are you able to: 
 
Run errands and shop?   
      Get in and out of the car? 
      Do chores such as vacuuming,                                           
housework or  




























PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES : 
 
   Raised toilet seat    Bath rail    Bath seat    Jar opener  (for jars previously 
opened) 
   Long handled appliances for reach     Other (specify) ……………….…………. 
 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM 
ANOTHER PERSON : 
 
   Hygiene     Gripping and opening things    Reach     Errands 
and housework 
 
We are also interested in learning whether or not you are affected by pain because of your 
illness. 
 
HOW MUCH PAIN HAVE YOU HAD BECAUSE OF YOUR ILLNESS IN THE PAST WEEK ? 
 
Place a mark on the line to indicate the severity of the pain 
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